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We work in the dark – we do what we can – we give what we have. 
Our doubt is our passion and our passion is our task. 
The rest is the madness of art.
Henry James (1843-1916)
4Abstract
Multiple Sclerosis (MS) is considered an autoimmune disease of the central nervous 
system (CNS). It usually starts with a relapsing remitting (RR) course that eventu-
ally transforms into progressive (P)MS, showing neurodegenerative features. The 
pathogenesis behind the transition from RRMS to PMS is essentially unknown.
The aim of this thesis was to investigate if biomarkers in the cerebrospinal fluid 
(CSF) of MS patients could provide new insights into the pathophysiology of MS 
progression, and if biomarker levels could reflect disease activity, disability progres-
sion, or therapeutic efficacy.
Three study designs were established. The first was cross sectional and comprised 
MS patients, healthy controls (HC) and control subjects with another inflammato-
ry disease. The second used a long-term follow-up setting in which RRMS, PMS 
and HC were assessed twice 8-10 years apart. The third used immunomodulatory 
or immunosuppressive intervention (natalizumab, mitoxantrone or rituximab) and 
assessed MS patients pre- and 12-24 months post-treatment. CSF biomarkers were 
analyzed for i) axonal damage (neurofilament light, NFL), ii) astrogliosis (glial 
fibrillary acidic protein, GFAP), iii) amyloid precursor protein metabolism (BACE1 
activity, and sAPP/Aβ metabolites) iv) B-cell regulation (CXCL13) and v) intrathe-
cal IgG synthesis (IgG index, oligoclonal IgG bands (OCB)).
Increased mean GFAP levels were found in all courses of MS with the highest levels 
in PMS, whereas the mean NFL level of this MS population was not different from 
that of HC (Paper I). At long-term follow-up GFAP levels correlated with disability 
and had prognostic value. In contrast, increased NFL levels were found in another 
MS population compared to HC (Paper IV). This discrepancy might be explained 
by differences in disease activities between the investigated populations and due 
to improved sensitivity of the NFL immunoassay. We found signs of downregula-
tion of BACE1 activity (Paper II) and sAPP/Aβ metabolism (Paper III) in MS. The 
levels of sAPP/Aβ in MS were generally decreased compared to HC suggestive of 
impaired neuronal function in MS. Mass spectrometry studies indicated that the 
sAPP/Aβ metabolism was changed in PMS compared to HC by formation of other 
decomposition products.
We demonstrated, in opposite to the general view, changed number and pattern of 
OCB in CSF over time, which correlated to CXCL13 levels (Paper V). Natali zumab 
treatment increased sAPP Aβ metabolites towards HC levels. Immunosuppressive 
treatment (mitoxantrone, rituximab) reduced NFL and CXCL13 in PMS. Interest-
ingly, significantly lower NFL levels were found prior to immunosuppression in 
PMS patients previously treated with interferon beta or glatiramer acetate, suggest-
5ing an impact on axonal damage also with first line MS therapies. Immunosuppres-
sive treatment did not influence the number or pattern of OCB (Paper V).
In conclusion, our studies present evidence that increased immune activity plays 
a critical role in PMS for axonal damage and seemed to influence sAPP/Aβ me-
tabolism. In PMS, the reduced NFL level following immunosuppressive treatment 
clearly supports a relationship between CNS inflammation and neurodegene ration. 
Biomarkers in CSF provide unique information about the pathophysiology in PMS, 
and may serve as complement to clinical and MRI measures for assessment of dis-
ease activity, progression, severity and therapeutic efficacy.
Key words: multiple sclerosis, cerebrospinal fluid, biomarker, disease progression, 
NFL, GFAP, CXCL13, BACE1, sAPP/Aβ, IgG, oligoclonal IgG bands, IgG index
6Populärvetenskaplig sammanfattning
Multipel Skleros (MS) är en av de vanligaste orsakerna till neurologiskt handikapp 
bland unga vuxna i västvärlden. I Sverige lever 17 500 personer med sjukdomen. 
Minst två tredjedelar av de drabbade är kvinnor. MS är en autoimmun sjukdom som 
drabbar det centrala nervsystemet (CNS). Vanligtvis debuterar sjukdomen med re-
lapsing remitting (RR) MS där återkommande försämringsepisoder (skov) följs av 
hel eller delvis återhämtning (remission). Efter i genomsnitt 15-20 år övergår sjuk-
domen i sekundär progressiv (SP) MS där en gradvis försämring inträder. Vid MS 
föreligger inflammatoriska cellinfiltrat i avgränsade områden (plaque) i hjärna och 
ryggmärg. Där skadas nervfibrernas isolering (myelin), myelinbildande celler (oli-
godendrocyter), stödjeceller (astrocyter) och nervcellernas utskott (axon). I SPMS 
sjunker eller upphör skovfrekvensen och den neuro-axonala förstörelsen är utbredd 
med förtvining (atrofi) av både vit och grå substans i CNS. Man vet idag att det är 
förstörelsen av axon som framförallt orsakar sjukdomssymptomen och den progres-
siva neurologiska funktionsförlusten.
Sista decenniernas genombrott vad gäller behandling av MS har ingivit hopp om att 
kunna förbättra prognosen för många MS patienter. Framgångarna har dock i prin-
cip gällt RRMS och förståelsen för vilka mekanismer som är speciella för progressiv 
(P) MS är fortfarande bristfällig.
Tanken bakom avhandlingens studier var att med hjälp av biomarkörer i rygg-
märgsvätska (CSF), hitta samband för att öka förståelsen av dessa mekanismer. Vi 
ville också karaktärisera biomarkörerna för att bestämma deras förmåga att avspegla 
sjukdomsaktivitet, progression och terapeutiska effekter vid PMS.
I CSF undersöktes nivåer av i) neurofilament (NFL), en axonskademarkör, ii) gli-
afibrillärt surt protein (GFAP), en markör för astrocytaktivering, iii) BACE1 akti-
vitet och amyloid precursor protein/betamyloid (sAPP/Aβ) metabolismen och iv) 
tecken på B-cells reglering av inflammation (CXCL13) och en ökad produktion av 
immunoglobuliner.
Studierna har byggts upp kring tre studiedesigner med tillhörande patient- och kon-
troll populationer. I den första användes en tvärsnittsanalys, i den andra gjordes 
en långtidsuppföljning, och i den tredje studerades effekten på biomarkörer under 
immunomodulerande eller immunosuppressiv terapi (natalizumab, mitoxantrone 
eller rituximab). Patienterna som långtidsuppföljdes och de som behandlades un-
dersöktes vid två tillfällen med intervall på 8-10 år respektive 1-2 år.
CSF biomarkörerna visar att inflammation utgör en betydande del av sjukdomsme-
kanismen också vid PMS och att den går att påverka med läkemedel som dämpar 
immunaktiviteten. NFL nivåerna var stegrade vid PMS. Behandling med cellgiftet 
7mitoxantrone och det immundämpande medlet rituximab sänkte NFL nivåerna. Vi 
såg en tydlig koppling mellan immunrespons (CXCL13 nivåer och inflammation 
synlig på magnetkamera(MRI)) och axonskada (NFL).
Under hela MS förloppet sågs tecken på aktivering av hjärnans stödjeceller med 
ökat läckage av GFAP till CSF. Detta var mest uttalat vid hög sjukdomsaktivitet som 
ett tecken på ett akut astrocytsvar men sågs också vid långvarig sjukdom som ett 
troligt mått på den sammanlagda spridda plaque bildningen i CNS. GFAP nivåerna 
visade ett samband med klinisk funktionsnedsättning och visade prognostiskt värde 
men påverkades inte av terapi.
BACE1 aktivitet och sAPP/Aβ metabolismen har tidigare framförallt studerats vid 
Alzheimer’s sjukdom, men har sista åren också studeras vid inflammatoriska sjuk-
domar. I våra studier fann vi att BACE1 aktivitet och sAPP/Aβ nivåerna sjönk vid 
MS generellt, sannolikt som tecken på pågående inflammation och möjligen störd 
nerv funktion. Vid RRMS ökade nivåerna mot de normala efter natalizumab behan-
dling vilket inte skedde efter mitoxantronebehandling av SPMS. Genom utvidgade 
studier med mass spectrometri sågs tecken på att metabolismen inte bara är sänkt 
utan också ändrad vid PMS genom att andra nedbrytningsprodukter bildas.
En generell uppfattning är att immunglobolinproduktionen av oligoklonala IgG 
band i CSF är oförändrade över tid. Våra observationer motsäger detta och visar en 
koppling till att OCB bildningen är relaterad till B-cells aktiviteten. Antalet band 
och mönstret av OCB ändrades över tid men inte av behandling med mitoxantrone.
Våra studier av biomarkörer i CSF talar för att inflammatorisk aktivitet har be-
tydelse för degenerativa processer såsom axonal skada och ändrad sAPP/Aβ me-
tabolism. Vi visar att detta samband även finns vid PMS och att immunhämmande 
behandling kan påverka dessa processer. Några av dessa biomarkörer kan komma 
att få betydelse för värdering av sjukdomsaktivitet (NFL, CXCL13), progression 
och svårighetsgrad (GFAP) och monitorering av terapi (NFL, CXCL13, sAPP/Aβ 
metaboliter) vid progressiv MS.
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1. Introduction
1.1 General background
Multiple Sclerosis (MS) is an organ-specific autoimmune disease of the central ner-
vous system (CNS). The aetiology and pathogenesis of MS remain largely unk-
nown. There is evidence that it may begin as a primarily inflammatory disorder 
that subsequently takes on degenerative features; however the inflammation activity 
seems to vary widely between patients (1).
MS is initially dominated by focal white matter inflammatory infiltrates, with de-
myelinating lesions also appearing in the cortex and deep grey matter of the brain. 
Additionally, the CNS tissue shows diffuse and global changes, including signs of 
widespread inflammation (2), microglial activation (3), neuron and axon damage 
(4), oligodendrocyte depletion (5), and astrogliosis (6). Irreversible degeneration 
appears early in the disease process (7), and brain atrophy may already be observa-
ble at the clinical onset of MS (clinically isolated syndrome; CIS).
The initial clinical course is usually relapsing-remitting (RR) with transient episo-
des of neurological symptoms. In most cases, this eventually changes into a secon-
dary progressive (SP) course characterized by continuous accumulation of neurolo-
gical disability with or without superimposed relapses. Over time, the inflammatory 
activity decreases and CNS degeneration becomes more prominent. The role of 
inflammation in neurodegeneration and the pathophysiology behind secondary pro-
gression are essentially unknown. Further investigations are required to determine 
whether they are independent from each other, or if inflammation is responsible for 
secondary degeneration.
Magnetic resonance imaging (MRI) has become the dominant method for diagnosis, 
monitoring disease activity, and evaluating treatment effects. Although, MRI may 
differentiate between inflammatory activity and degenerative processes to some ex-
tent, this technique cannot be used to identify different pathophysiological proces-
ses of MS. Moreover, during the progressive phase of MS, the appearance of new 
lesions may be undetectable due to confluent lesion formation, and the methods for 
determining lesion volume and atrophy are laborious and commonly unavailable.
Biochemical biomarkers of body fluids, especially cerebrospinal fluid (CSF), have 
increasingly gained attention in studies of MS. For decades, selective detection of 
oligoclonal IgG bands in CSF has been used for diagnostic purposes (8). More re-
cently, it has been found that several inflammatory and CNS parenchymal biomar-
kers seem to reflect important pathological processes in MS, with some being rela-
ted to disease activity, disease severity, and clinical course (9).
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As patients change from RRMS to SPMS, they exhibit several features that resem-
ble those of known neurodegenerative diseases. They develop irreversible disabi-
lity, are relatively unresponsive to immune modulatory or immunosuppressive tre-
atment, and show brain and spinal cord atrophy. In the present thesis, we explored 
the pathophysiology behind this transformation by measuring the levels of different 
biomarkers in CSF. Our major objectives were to find biomarkers that are associated 
with clinical course, predict disease severity, and reflect the effects of therapeutic 
intervention.
1.2 MS epidemiology
MS is the main non-traumatic cause of neurological disability among young 
adults in Sweden. The Swedish MS prevalence is among the highest in the world 
(189/100 000), with approximately 17 500 diagnosed cases as of the end of 2008 
(10). Previous calculations show a Swedish yearly MS incidence of between 3.9-
5.2/100 000 (11, 12), but a recent nationwide study estimates this incidence to be 
twice as high (Ahlgren et al., unpublished data). MS distribution varies widely in 
different parts of the world; temperate climate zones are considered high-risk areas 
(13), and the risk seems to increase with the distance from the equator (14). There 
are exceptions to this latitude gradient, with prevalence being lower in northern 
Norway (73/100 000) (15) and higher on Sardinia (152/100 000) (16) than in sur-
rounding areas at the same latitude. In Sweden, the MS prevalence increases by 1% 
for women and 1.5% for men per degree of latitude increase (10). Studies of popu-
lations with mixed genetic background at the same latitude have suggested that the 
risk of MS development depends on ethnicity (16). In the 1970s, it was found that 
people with African and Asian backgrounds, respectively, had 50% and 20% lower 
MS risks compared to Caucasians. However, a recent investigation showed reversed 
numbers, with an increased MS risk among African Americans compared to other 
groups (17).
MS with relapse onset affects women twice as often as men, while this female pre-
ponderance is less obvious in primary progressive MS (PPMS). The female/male 
ratio in Sweden is 2.35 (10). Several studies have found that RRMS occurs with 
an increased female/male ratio (18). The increased MS risk for women seems to be 
dependent of the year of birth and geographic location (19), with the highest female/
male ratio (4.55) observed among patients born in 1980-1989 in northern Europe. 
Socioeconomic factors (20) or migration from low- to high-risk areas (21) might af-
fect the gender ratio. These observations appear to suggest on-going changes in MS 
incidence, but this has not been confirmed (10).
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1.3 Aetiology of MS
Although the aetiology of MS is essentially unknown, there is accumulating evi-
dence that both genetic and environmental factors influence MS risk.
1.3.1 Genes and MS
An increased risk is found in genetic relatives of MS patients, but the heredity of MS 
is complex. The background risk of MS is about 0.2% in Sweden (10). For a person 
with an affected relative, the risk of MS development is estimated to be 25-30% for 
a monozygotic twin, 3-5% for a dizygotic twin or sibling, 2% for a parent or child, 
and 1% for other second and third degree relatives (22, 23).
The search for MS risk genes was initially focused on genes regulating the immune 
system. Among all genes, the strongest association has been found with the HLA 
class II genotype DRB1*15:03 (on the short arm of chromosome 6); this genotype is 
carried by 28-33% of northern Caucasian MS patients compared to 9-15% of heal-
thy controls, having an OR of 3.08 (24). Protective genes have also been isolated 
among MS patients. HLA A*02 is the most potent independent risk reducer, with 
an OR of 0.73 (25). HLA-C*05 and HLA B*44 have also been found to reduce MS 
risk, both independently and in combination with each other (26, 27).
Genome-wide association studies in vast multinational MS and matching control 
populations have detected at least 57 risk loci, the majority with OR in the range of 
1.1-1.3 (28, 29). Notably, the majority of identified non-HLA genes have also been 
located in or near immune system-regulating genes. One-third of the MS-associated 
genes are also associated with other autoimmune diseases (30, 31).
1.3.2 Environmental and lifestyle factors and MS risk
Among the environmental and lifestyle factors that have been suspected to influence 
MS risk and prognosis, few have been convincingly associated with MS in repeated 
studies.
1.3.2.1 Infections and MS
Many infectious agents have been suspected to either trigger MS or maintain the 
disease as a chronic CNS infection. The proposal that infections are involved in 
MS aetiology and pathogenesis is based on the observation that people who migrate 
during adulthood from low to high MS prevalence areas or vice versa retain their 
original risk, but their children are at the risk determined by their new location (32, 
33). It has been suggested that MS incidence rose after increased migration from 
high MS prevalence areas to isolated environments (Faroe, Sardinia, etc.), leading 
to “MS epidemics” (34-36).
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1.3.2.2 Epstein-Barr virus
Epstein-Barr virus (EBV) is one of several human herpesviridae that, after an initial 
infection, hibernate in humans; EBV predominantly hibernates in B lymphocytes. 
Among adult humans, 90-95% are seropositive, compared to almost 100% of MS 
patients (37, 38). Individuals who are seronegative for EBV have an OR of only 
0.06 for developing MS compared to EBV-seropositive persons (39). Furthermore, 
previous clinical mononucleosis increases the risk of developing MS by 2-3 times 
(40). An intriguing but unconfirmed finding is the detection of EBV-infected B cells 
in germ-like follicle structures of the meninges in SPMS patients (41).
1.3.2.3 Tobacco smoke
Tobacco smoke seems to influence the risk and prognosis of MS. The relative risk 
of MS development is higher among current smokers compared to individuals who 
have never smoked (OR, 1.6) (42). MS risk is also increased among children of 
smokers (OR, 2.12) (43) and for non-smoking adults who are exposed to tobacco 
smoke (OR, 1.3) (44). Compared to non-smokers, smokers have a higher risk of de-
veloping MS from CIS (HR, 1.8) (45), and have a higher lesion load and increased 
atrophy development seen on MRI (46).
1.3.2.4 Vitamin D and sun exposure
It is well documented that MS prevalence increases with higher latitude (14), and 
this association has been connected to low sunlight exposure and less endogenous 
vitamin D production (47). It has been suggested that UVB radiation has an in-
dependent protective effect on MS risk (48, 49). High serum level of 25-hydroxy 
vitamin D is a risk reducer for MS (OR, 0.59) (50), and vitamin D seems to suppress 
disease activity. It has been demonstrated that peroral vitamin D treatment leads to a 
lower relapse rate compared to in a placebo-treated group (51, 52), and supplemen-
tal vitamin D therapy has been suggested as a potential MS treatment.
1.3.3 Combination of genes and environmental or lifestyle factors
Like many other diseases, MS seems to emerge due to a combination of genetic 
vulnerability and harmful environment. Recent studies have shown that >80% of 
the isolated MS risk genes are regulated by vitamin D (53, 54), including HLA 
DRB1*15:01. Among smokers, presence of the HLA DRB1* 15:01 genotype and 
absence of the protective HLA A*02 genotype gives an OR of 13.5 for MS devel-
opment (55), compared to an OR of 4.9 in non-smokers with the same gene set. 
The current knowledge of risk genes is an important resource to promote better 
understanding and identification of pathological processes. This information may 
also be useful in establishing risk profiles for individual environmental factors and 
predicting treatment effects.
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1.4 Clinical course of MS
In 80-90% of cases, the clinical onset of MS is transient and followed by complete 
or partial recovery from symptoms (23) (Figure 1). The symptoms may have mono- 
or multifocal origin in the CNS, most commonly involving the optic nerve, the spi-
nal cord, or the brain stem. New relapses usually occur with an annual rate of 0.5-1. 
Over time, the recovery from each relapse becomes less complete, and persistent 
symptoms accumulate. In an untreated MS population, a majority of RRMS cases 
turn into SPMS after a median time of approximately 15-20 years from disease on-
set (23, 56). SPMS patients may initially have relapses that are superimposed over 
the on-going clinically progressive process. In most cases, clinical progression con-
sists of spastic para- or tetraparesis, cerebellar ataxia, or spastic hemiparesis, and the 
symptoms gradually become more complex and severe with increasing decline of 
neurological functions. In 10-15% of patients, the course is progressive from onset; 
these patients are designated PPMS.
After clinical onset and before there is evidence for the chronic and disseminat-
ed disease of MS, the term CIS is used (57). A majority of patients with CIS will 
eventually be diagnosed with definitive MS once dissemination in space and time is 
fulfilled (Figure 2).
The term benign MS is often defined as a case with an EDSS of ≤2.0-3.0 after a dis-
ease duration of 10-15 years (58). Studies of benign MS show the frequent presence 
of non-motor symptoms, like fatigue, pain, and cognitive impairment (59). The term 
is retrospective and it is not possible to predict the individual clinical course in MS; 
it has been proposed that a better definition is needed (60).
It is debated whether different MS disease courses reflect different pathogenic 
mechanisms. RRMS and SPMS are per definition parts of the same disease, and the 
majority of untreated RRMS patients will proceed to develop SPMS. On the other 
hand, PPMS has a different clinical presentation and gender distribution; however, 
little evidence supports different mechanisms behind this process. PPMS and SPMS 
involve the same age of onset and similar disability development (61). The set of 
risk genes (HLA and non-HLA genes) also seems to be the same for both subtypes 
(28).
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Figure 1
Clinical subtypes of MS. The figure shows the two main types of onset, relapsing or progres-
sive, and totally four subgroups depending on the further course of disease. (Adapted from (64) 
reprinted with permission from with permission from Wolters Kluwer Health.)
1.5 Diagnostic criteria in MS
The diagnostic workup of MS is currently based on MRI results rather than clinical 
measurements; however, MS diagnosis still requires evidence of CNS white matter 
lesions that are disseminated in time (DIT) and space (DIS) and not better explained 
by any other diagnosis. In parallel with improved radiological and biochemical met-
hods and the unification of clinical evaluations among neurologists, the MS diag-
nostic criteria have been repeatedly modified and revised. The progression from the 
criteria of Schumacher (8) and Poser (62) to the current revised criteria of McDo-
nald (63) represents an on-going process of simplifying the diagnostic workup to al-
low early diagnosis without losing diagnostic sensitivity and specificity. This evolu-
tion has included almost complete elimination of the influence of other paraclinical 
methods, such as visual evoked potentials or detection of oligoclonal IgG bands in 
CSF. Evidence of DIT and DIS can be obtained by a single or repeated MRI, or by 
observation of new clinical attacks.
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Figure 2
Localization of lesions and demonstration of dissemination in space (different locations in CNS) 
and time have been core concepts in diagnosing MS. Clinical and paraclinical investigations are 
usually applied. (From (23), reprinted with permission from Elsevier).
In contrast with previous MS diagnostic criteria, the criteria of McDonald include 
PPMS. The diagnosis of PPMS requires continuous worsening of CNS symptoms 
over at least one year combined with paraclinical signs on MRI, or signs of inflam-
mation in CSF, such as increased IgG index and/or selective formation of oligoclo-
nal IgG bands (OCB). SPMS diagnosis is based on evidence of continued worsening 
for at least six months, without being associated with relapses (64), although some 
SPMS patients have relapses superimposed on their progression. The transition 
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from RRMS to SPMS can be difficult to assess, especially in RRMS patients with 
remaining disability following severe relapses and in SPMS patients who continue 
to have relapses.
1.6 Disease-modifying MS treatment
1.6.1 Interferon beta
In the mid-1990s, interferon beta-1b (IFNB-1b) and interferon beta 1a (INFB-1a) 
were approved as the first disease-modifying therapies for MS. INFB-1a is identical 
to endogenous synthesized interferon beta, while INFB-1b lacks glycosylation and 
differs by one amino acid substitution and one amino acid deletion. These IFNBs 
are now available as different products that are administered either subcutaneously 
or as intramuscular injections, with a frequency ranging from every other day to 
once weekly.
IFNBs belong to a group of cytokines that acts on target cells through the IFN-alpha/
beta receptor (65). They activate a cascade of genes that induce the synthesis of pro-
teins with immunomodulatory properties, but the exact function remains obscure. 
IFNBs agonize the production of anti-inflammatory cytokines (e.g. IL-4 and 10), 
promoting a shift toward a Th2 response (66); they also seem to inhibit production 
of pro-inflammatory cytokines (e.g. IL-12, IL-17, IL-23, osteopontin, IFN-gamma, 
and TNF-alpha) (67, 68). IFNB also appears to stimulate T-cell apoptosis by down-
regulating anti-apoptotic proteins (69). The mechanisms are complex and far from 
completely understood.
IFNB treatment of RRMS reduces the relapse rate by 30%, and reduces MRI lesions 
and disability development. In CIS, trials have demonstrated benefits of early tre-
atment, although the long-term effect is uncertain (70). IFNB treatment of progres-
sive MS, with few exceptions, has failed to reduce neurological disability (71, 72); 
however, it significantly affects relapse rate and lesion development (71, 73, 74).
The most common adverse effects include flu-like symptoms and skin reactions 
(75), which are the major causes of treatment discontinuation. Neutralizing antibo-
dies (NAB) against IFNB may develop in 5-35% of patients, depending on the INFB 
product (76), and a high NAB titre can reduce or completely eliminate the effects 
of the drug (77).
1.6.2 Glatiramer acetate
Glatiramer acetate (GA) is a combination of four amino acids (L-alanine, L-glutamic 
acid, L-lysine, and L-tyrosine) that are randomly polymerized into peptides. These 
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peptides have immunomodulatory effects that are poorly understood. GA attaches to 
the MHC II complex and seems to disrupt antigen presentation, which might block 
MBP-reactive T cells causing a shift to an anti-inflammatory Th2 state (78, 79). 
Since GA does not pass the blood-brain barrier (BBB), this process occurs in the 
periphery and activated T cells migrate into the CNS and induce anti-inflammatory 
effects (80). GA has been shown to affect the antigen-presenting properties of B-
cells. Although anti-GA antibodies are frequently seen, they do not seem to have an 
inhibitory effect (81, 82).
Treatment of RRMS patients with GA seems to have a clinical effect of the same 
magnitude as INFB treatment; head-to-head studies have not shown IFNB to be 
superior to GA (83-85). In progressive MS, GA treatment induced no significant 
clinical effects but on MRI lesion development (86, 87).
GA is generally well tolerated, but injection reactions occur in a majority of patients 
(75). One specific injection-related adverse effect is the immediate post-injection 
systemic reaction (IPISR) that includes dyspnoea, palpitation, flushing, and anxiety 
occurring for between 30 seconds and 30 minutes (88).
1.6.3 Natalizumab
Natalizumab (Nz) is a humanized monoclonal antibody directed against the α4β1-
integrin molecule on mononuclear leukocytes. By blocking the interaction of α4β1-
integrin with the endothelial vascular cell adhesion molecule-1 (VCAM-1) ligand, 
Nz inhibits leukocyte migration across the BBB. Pivotal clinical trials have shown 
that Nz treatment decreases relapse rates by approximately 70% versus placebo, 
and clinical and MRI measurements showed that 37% of Nz-treated patients were 
disease free, compared to 8% of placebo-treated patients (89). No randomized pla-
cebo-controlled clinical trial has yet been performed in progressive MS patients.
The major problem with Nz treatment in MS is the appearance of progressive mul-
tifocal leukoencephalopathy (PML), which is caused by an opportunistic polyoma 
virus (JC virus) infection colonizing the kidneys and bone marrow. In the absence of 
appropriate immune defence of the CNS, mutated JC virus has the ability to cause a 
massive CNS infection. Although the effect of Nz can be reversed, PML often cau-
ses lasting neurological disability and, in about 20% of cases, death (90, 91). Stra-
tegies to minimize the risks of PML include selection of patients without previous 
immune suppressive treatment and those that are negative for JC virus antibodies.
1.6.4 Mitoxantrone
Mitoxantrone (Mx) is a synthetic DNA-intercalating anthracenedione derivate that 
affects B cells, T helper cells, and cytotoxic T cells, and can both suppress and mo-
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dulate the immune system (92). Mx does not cross an intact BBB. It is the only drug 
approved for use in SPMS (in the USA, but not Europe). Two randomized controlled 
studies have shown efficacy in all stages of MS, except PPMS, with effects on both 
relapse rate and EDSS progression (93, 94).
However, Mx exerts dose-dependent toxicity on many organs, leading to increased 
risk of acute myeloid leukaemia, cardiac dysfunction in about 1% (95), and in-
creased risk of serious infections. The cumulative lifetime dose should not exceed 
100 mg/m2 for MS treatment (96).
1.6.5 Rituximab
Rituximab is a chimeric human/mouse anti-CD20 antibody. The Fab domain binds 
to the CD20 antigen on B lymphocytes, and the Fc domain recruits the immune 
system to mediate cell death (97). This antibody-dependent cytotoxicity is induced 
by either apoptosis or complement-dependent cytotoxicity (98-100). Because CD20 
expression is unique to B cells, the beneficial effects of rituximab in MS support a 
role of B cells in MS pathogenesis. It is unclear how much of the effect of rituximab 
is generated outside the CNS, but determination of the BBB penetration shows a 
CSF/plasma ratio of 1/1000, which might be sufficient to also eliminate B cells from 
the CSF compartment (101).
Although rituximab is not registered for MS treatment, a number of open-label stu-
dies and case reports have shown clinical and radiological beneficial effects (102); 
it is used off-label and considered a potent agent for MS therapy. One phase II study 
of rituximab treatment in patients with RRMS showed significantly reduced relapse 
rate and lesion formation (103). In contrast, a phase III study in patients with PPMS 
showed non-significant differences; however, reduced disease progression was ob-
served in a subgroup of patients younger than 51 years with Gd-enhancing (Gd+) 
lesions (104).
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2. Immunopathogenesis and pathology of MS
2.1 General considerations
MS is considered to be an autoimmune disease characterized by focal lesions disse-
minated throughout all parts of the CNS, and involving both grey and white matter. 
Widespread diffuse pathology is also seen in normal-appearing tissue. In the early 
phase of MS, inflammatory activity dominates, with a high rate of lesion formation; 
subsequently, this activity declines and neurodegeneration takes over (2). However, 
there is accumulating evidence that signs of neurodegeneration—including neuro-
axonal loss, astrogliosis, and CNS atrophy—are already evident at disease onset 
(105). It remains to be determined whether neurodegeneration in MS is secondary to 
destructive immune activity or essentially a parallel and primary event.
2.1.1 MS lesion (plaque) formation
MS lesion or plaque formation typically involves focal inflammation with blood-
brain barrier (BBB) breakdown and immune cell infiltration. Inflammation seems to 
be initiated in two steps. CD8+ T cells and activated microglia initially dominate, 
causing myelin destruction (106, 107). This destruction is followed by infiltration of 
activated macrophages, B cells, and T cells, and local secretion of pro- inflammatory 
cytokines and chemokines and their receptors (108, 109). Active lesions often give 
rise to BBB disruption, which can be detected by Gd+ enhancement on MRI (110, 
111). As inflammation declines, MS lesions may either progress to a chronic inacti-
ve stage that is characterized by astrogliosis and insufficient remyelination, or show 
sufficiently remyelinated axons that appear as “shadow plaques” on MRI. Some 
lesions, designated as chronic active plaques, show preserved immune activity of 
lower intensity (Figure 3); these lesions slowly expand at the border, while activity 
ceases at the centre (3). MS progression involves decreased active lesion formation, 
along with increased expanding chronic lesions. In progressive MS, inflammation 
seems to become more compartmentalized and the integrity of the BBB is maintai-
ned, allowing only low levels of protein exchange (111) (Figure 4).
26
Figure 3
Schematic, MRI and microscopic images of MS lesions in different stages.
Reprinted with permission from http://multiple-sclerosis-research.blogspot.se/
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2.1.2 Axonal degeneration
Axonal damage occurs in both early and late stages of MS, predominantly in active 
plaques (early and chronic), and correlates to the activity of lymphocytes and activa-
ted microglia (112). Ferguson et al. described accumulation of amyloid precursor 
protein (APP; a marker for axonal dysfunction or injury) all over active lesions and 
at the border of chronic active lesions (113). Axonal degeneration is also seen in 
non-lesion matter. Diffuse axonal injury and destruction are associated with wide-
spread and diffuse low-grade inflammation, microglial activation, astrocytic gliosis, 
and mild demyelination (114), illustrating an active neurodegenerative process. The 
quantity of diffuse injury increases over time, and is more pronounced in progres-
sive MS. Axonal loss outside of plaques could also be due to Wallerian degenera-
tion, in which proximal axonal damage causes distal axonal degeneration. However, 
the extent of diffuse white matter injury does not correlate with the amount of focal 
white matter lesions, and only weakly correlates with cortical demyelination (2, 
115).
2.1.3 Astrogliosis
Reactive gliosis with or without scar formation is a general feature of any kind of 
CNS damage and is a prominent feature in MS pathology (6). In areas outside of the 
plaques, the picture is diffuse with widespread areas of hypertrophic astrocytes with 
up regulated GFAP expression (116). In more severely affected areas, the astrocy-
tes proliferate outside of their normal tissue architecture. In plaques, in addition to 
astroglial activation, dense and compact glial scars are formed (117); recent studies 
suggest that these scars act as neuroprotective barriers that stop inflammatory cells 
and predominantly form along the plaque borders (118). Glial scars interact with 
other cell types, and their extra cellular matrix contains substances that inhibit cel-
lular migration (119).
2.1.4 Suggested patterns of MS pathology (120)
Investigation of the heterogeneity of MS pathology has led to the suggestion that 
there are four different and distinct immunopathogenetic patterns; these findings 
have been considered proof that there are different types of MS that may respond 
differently to treatments (121, 122). Pattern I shows T cells and macrophages around 
blood vessels, preserving oligodendrocytes but with no complement activation. 
Pattern II is like pattern I, but with complement activation. Pattern III shows dif-
fuse inflammation, distal oligodendrogliopathy, microglial activation, and a loss 
of myelin-associated glycoprotein (MAG); contrary to patterns I and II, pattern III 
has no association with blood vessels. Pattern IV includes sharp bordered lesions, 
and oligodendrocyte degeneration with a rim of normal-appearing white matter; no 
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complement activation or MAG loss is detected. These observations are based on 
biopsy or autopsy materials from severely disabled patients, and the results have not 
been confirmed. It remains to be clarified whether these patterns represent different 
disease subgroups or different stages of the same disease.
Figure 4
Schematic presentation of the evolution of structural pathology and disease mechanisms during 
the course of MS. a) Pathological features associated with conversion of RRMS (pink) to PMS 
(green). b) Changes in disease mechanisms associated with conversion of RRMS (pink) to PMS 
(green). The bars indicate the the extent of these differences in relation to increasing age and 
disease duration. Although no pathological or mechanistic feature is exclusive either for RRMS 
or PMS, major quantitative differences in their occurrence are evident between these stages. 
Abbreviations: iNOS, inducible nitric oxide synthase, RPMS relapsing progressive MS. From 
(131). Reprinted with permission from Nature Publishing Group.
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2.2 The hallmarks of grey matter pathology
In MS, involvement of the deep grey matter and cortex is seen as either demyelina-
tion or retrograde degeneration from white matter lesions. Grey matter pathology 
and white matter pathology share many common features, but there are also funda-
mental differences. The cortex exhibits both focal and diffuse pathology, including 
atrophy (123), as is also observed in early stages of MS (124). Focal changes pre-
dominantly appear early on, and are often dominated by intense inflammation with 
perivascular infiltrates and large amounts of lymphocytes throughout the tissue, 
accompanied by activated macrophages and microglia (125). Losses of neurons, 
axons, and synapses are more pronounced in early-stage cortical plaques (2, 125). 
In general, cortical lesions are more commonly seen during the progressive phase of 
MS and in the subpial cortical layers (2), often in the vicinity of ectopic B-cell fol-
licles of the meninges (126). The distance from the white matter seems to determine 
the content of inflammatory cells in grey matter lesions, with the subpial lesions 
dominated by activated microglia, apoptosis, and neuronal atrophy (127). Similar to 
white matter pathology in MS, global tissue loss is widespread in normal-appearing 
cortex, contributing to atrophy development (128).
2.3 Meningeal pathology
Topographically associated with subpial cortical lesions, meningeal B-cell follicle-
like structures have been characterized in progressive MS (129, 130). Although it 
has not been confirmed, the B cells in these structures have been identified as immu-
ne reactive for Epstein-Barr virus (EBV) (41). These tertiary inflammatory germinal 
centres are predominantly found in SPMS (126), and are suggested to have a role in 
the pathogenesis of progressive MS. It is noteworthy that these findings indicate that 
MS can no longer be considered a disease affecting only nervous tissue.
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3. Pathophysiology of progressive MS
3.1 General considerations
There are three main hypotheses explaining the pathophysiology of progressive MS 
and its relation to RRMS (131):
1. MS is a primary neurodegenerative disease. Dysfunctional and dying cells trigger 
an early immune response. Neurodegeneration may be modified or amplified by the 
reactive inflammation.
2. MS is a primary inflammatory disease that, over progressive stages, changes in 
anatomical location and intensity, making it untreatable using existing immune th-
erapies.
3. MS develops through a combination of different pathological mechanisms, star-
ting as an inflammatory disease and subsequently involving neurodegenerative pro-
cesses. Delayed damage or neuronal death occurs when the reserve capacity is used 
and the anatomical structures are destroyed.
One general consideration is that axonal loss accumulates over the course of MS, 
eventually reaching a threshold at which the disease shifts to slow progression (132). 
It is likely that this process involves the imbalance between tissue injury and repair 
(133) and the consumption of compensatory mechanisms (132).
3.1.1 Microglial activation
Tissue injury in progressive MS is associated with chronically activated microg-
lia (3), and activated microglia are found in normal-appearing white matter (134). 
Similar microglia involvement is seen in other neuroinflammatory and neurodege-
nerative diseases (135). Microglia are known to generate oxidative bursts and to 
induce demyelination and axonal damage; however, they also have neuroprotective 
functions (135).
3.1.2 Altered ion homeostasis
In normally myelinated axons, voltage-gated Na+ channels are highly concentrated 
at the nodes of Ranvier. Loss of myelin is a major structural change during progres-
sive MS. A number of studies have reported changes of ion homeostasis in demy-
elinated neurons, and redistribution of ion channels along the axon as a functional 
compensation. Altered expressions of voltage-gated Ca2+ channels (136), glutamate 
receptor (137), and Na+ channels (138, 139) have been observed, which can lead 
to intra-axonal Ca2+ accumulation and eventually axonal death (131). This delayed 
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process can be induced by inflammation-mediated demyelination and axonal injury 
that occurred several years earlier.
3.1.3 Mitochondrial dysregulation
Mitochondrial injury is observed in the demyelinated axons of MS lesions (140, 
141). Axons have excessive energy demands when they are not supported by my-
elin, and mitochondrial function is critical during axonal injury. Increased mito-
chondrial number and size are seen in axons in active plaques, which normalize after 
remyelination (142-144). Mitochondrial damage and loss in nerve cell bodies could 
accelerate axonal death and induce a state of “virtual hypoxia” (140). Redistribution 
of mitochondria is observed within damaged nerve cells, as well as increased num-
bers of defective mitochondria (145). One major cause of mitochondrial dysfunction 
is oxidative stress induced by inflammation (145). In active MS lesions, it is likely 
due to increased production of enzymes and oxygen free radicals (146, 147). Thin-
calibre axons are more severely affected than thick ones because they have less 
mitochondria relative to their axonal surface area (140). The mitochondrial damage 
also affects oligodendrocytes and their ability to remyelinate injured axons (148, 
149). Moreover, the release of high levels of extracellular Fe2+ during inflamma-
tion and tissue damage may lead to additional oxidative stress on mitochondria and 
axons (150, 151).
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4.  Measurements of disease activity and  
 disability progression in MS
4.1 Relapse rate
Measuring the annual relapse frequency is a standard method for evaluating MS 
disease activity in clinical routine and clinical trials. A relapse is defined as a pa-
tient-reported or objectively observed event that is typical of an acute inflammatory 
demyelinating event in the CNS, current or historical, with duration of at least 24 
hours, and in the absence of fever or infection (63). The average annual relapse rate 
is about 0.5-1 in an untreated population (89). A long observation time or large pa-
tient groups are needed to confirm altered activity.
4.2 Clinical scales of neurological disability, progression  
and severity
Clinical scales are used to score the progression of neurological deficit over time in 
clinical routine and clinical trials. A number of scales have been tested, with the aim 
of finding objective measurements of disability development in MS. Such measures 
should be reliable, MS specific, validated, and easy to use and interpret in clinical 
practice as well as in clinical research. The scales we used in this thesis are widely 
accepted and validated.
4.2.1 Expanded Disability Status Scale, EDSS
The currently dominant scale for clinical scoring is the Expanded Disability Status 
Score (EDSS), which gives patients a score from 0 to 10. Derived from the DSS 
(152), the EDSS is based on the evaluation of seven functional systems (FS) by 
targeted neurological examination. A synthesis of these evaluations gives an EDSS 
of up to 3.5 for which individual FS scores (with some exceptions) count equally. 
For scores in the range 4.0 to 6.5, walking ability is weighted as just as important 
as the FS scores. Scores of over 6.5 are given as an evaluation of the patient’s in-
dependence and autonomy in ambulation. A score of 10 indicates death by MS. 
Obviously, this system leads to non-linear score development with a possibility of 
overlooking the deficit development, especially at higher scores. EDSS is an or-
dinal scale, which is only suitable for non-parametric statistics. Furthermore, the 
intra-rater repeatability is reportedly low (153), especially in mental and sensory 
FS where anamnestic information is necessary. Agreement between raters has been 
tested, and is only achieved with acceptance of differences ≤ 1.5 EDSS score (154). 
When using this scale, it should be noted that two EDSS steps are needed to confirm 
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clinical change (155), underlining the limitations of the EDSS in clinical studies or 
for therapy revisions. A major strength of the EDSS is its worldwide use and ease of 
use and interpretation.
4.2.2 Multiple Sclerosis Severity Score, MSSS
The Multiple Sclerosis Severity Score (MSSS) represents an attempt to determine 
the disability progression rate in MS; it is claimed that this scale measures MS se-
verity and has predictive properties. Individual disease duration was combined with 
EDSS in 9892 patients from 11 countries (156) to establish the general EDSS deve-
lopment over the course of MS. By combining disease duration on the y-axis and the 
EDSS score on the x-axis, the MSSS score can be found in the matrix. Scores range 
from 0.01 to 9.99. Obviously the scores are non-linear and can only be calculated 
with non-parametric statistics. Patients with EDSS 10 (death) were not included in 
the investigation, underrepresenting severe cases of MS; MSSS scores were also not 
included for patients with disease duration exceeding 30 years. Thus, MSSS is ba-
sed on a large—but in some aspects, historical—population. It could be questioned 
whether this population is still relevant for measuring MS severity.
4.2.3 Progression index
The progression index is calculated by EDSS/disease duration (157, 158). The main 
concept is the same as in MSSS, but the progression index has less predictive value. 
It has no limitations for use with patients with disease duration of above 30 years, 
but it has been scarcely used in previous studies.
4.2.4 Multiple Sclerosis Functional Composite, MSFC
The MSFC was established in 1999 as a complement to EDSS for overcoming the 
weaknesses of the widely used scale (159). The main idea was to use quantitative 
measurements and compare them with those derived from a large control popula-
tion. The MSFC is based on three specific tests that examine walking speed in a 
short range (timed 25-foot walk; T25W), fine motor function and coordination in 
the arms (nine-hole peg test; 9HPT), and cognitive function (paced serial addition 
test, 3 sec; PASAT3). The test results are converted to a z-score and normalized to 
a control population. The z-score describes the number of standard deviations of a 
patient score in comparison with a reference population. This score has relatively 
high inter-rater agreement (160). Some studies claim that, compared to the EDSS, 
the T25W part of the MSFC is a better prognostic tool (161, 162), while other stu-
dies have reported that the T25W is equal or even inferior (163-165). The MSFC is 
time consuming and requires specific tools. It is mainly used in clinical treatment 
trials as a complement to the EDSS.
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4.3 MRI
MRI has become the most important MS diagnostic tool (see MS diagnosis, page 
20). The use of MRI in MS has increased along with the growing possibilities and 
demands for accurate diagnosis, assessment of disease activity and progression, and 
evaluation of therapeutic efficacy. Much of our current knowledge concerning di-
sease activity, neurodegeneration, atrophy development, and grey matter involve-
ment has been attained using MRI research. In phase II clinical trials, MRI measure-
ments are used as surrogate markers for therapeutic outcome, and phase III clinical 
trials include several MRI-based secondary and tertiary objectives.
4.3.1 T1-weighted images
A T1 image is created by measuring the time that it takes protons to return to the 
magnetic field axis. MS lesions may appear as hypointense areas (“black holes”). 
These are preceded by Gd+ lesions, reflecting destructive inflammation. The degree 
of hypointensity correlates with the degree of pathological severity (166) and per-
sistent hypodense areas reflect irreversible tissue destruction with axonal loss (166). 
T1 lesions correlate more strongly with clinical deficits than pathology seen on other 
sequences (167).
4.3.2 Gadolinium-enhanced T1-weighted images
A T1 image with Gd+ lesions reflects a damaged BBB (168). BBB disruption ap-
pears during acute inflammation and may be detected for up to five weeks. Cont-
rast enhancement is often connected to clinical symptoms, i.e. relapses (169). This 
sequence is a fundamental part of the diagnostic criteria, as it provides evidence of 
dissemination in space and time (63).
4.3.3 T2-weighted images
A T2 image is created by measuring the proton dephasing following a transverse 
pulse, and is useful for describing the anatomy and composition of the central ner-
vous system. Lesions detected on T2-weighted images can reflect a wide diversity of 
pathological processes, such as inflammation, demyelination, and glial scar forma-
tion. This is the sequence that visualizes the expansion of MS in the CNS. T2 lesions 
appear as focal hyperdense areas with typical location (periventricular, infratento-
rial, or juxtacortical) and appearance (ovoid and >3 mm in diameter). T2 lesions are 
the main diagnostic source for establishing dissemination in time and space (63).
4.3.4. Fluid-Attenuated Inversion Recovery (FLAIR)
Fluid-Attenuated Inversion Recovery (FLAIR) produces T2-weighted images. 
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Using an inversion-recovery technique, the inversion time (TI; the time between 
inversion and excitation pulses) is carefully chosen for the CSF signal (170). In MS, 
FLAIR imaging is more sensitive for detecting lesions close to the ventricles than 
T2-weighted lesions, since these may not be distinguishable from the signal of CSF 
(171). FLAIR can also detect juxtacortical and cortical lesions (172, 173), but the 
appearance of infratentorial lesions may be false positive (174).
4.3.5. MRI as a surrogate marker for MS activity and progression
In CIS, the appearance of one or more T2 lesions predicts conversion to definitive 
MS (175), and the number of T2 lesions at disease onset may predict disability de-
velopment (176). The disease activity measured by MRI is much higher than that 
estimated clinically. Monthly MRI performance shows approximately 10-fold more 
new lesions compared with the number of new relapses (177, 178). However, in-
creasing lesion load is not a common feature of PMS. Disability progression is bet-
ter correlated with atrophy measurements, such as brain parenchymal fraction on 
T1-weighted images (179). The annual rate of whole brain atrophy is approximately 
0.5-1% in MS patients, compared to 0.2-0.5% in healthy individuals (180-182). 
Significant brain volume reduction is also evident early in the disease, involving 
both grey and white matter (183). Atrophy of the grey matter and spinal cord seem 
to predict disability progression (184, 185). Brain atrophy measurements have been 
proposed for predicting outcome following neuroprotective therapies in MS trials 
(186).
4.4 Biochemical biomarkers in MS
4.4.1 General considerations
Biomarkers are physical, functional, or biochemical indicators of physiological or 
disease processes; they can have diagnostic properties, provide information about 
the risk of disease development, reflect disease activity or disease severity, and have 
predictive or prognostic properties. They are also used to investigate responses to 
therapies, or discern adverse events and drug interactions. Additionally, biomarkers 
may be used to explore important pathophysiological mechanisms in disease pro-
gression. In clinical trials, biomarkers can act as surrogate endpoints, i.e. substitutes 
for clinical endpoints. New biomarker development involves many challenges, and 
the use of biomarkers carries the risk that a biomarker may not measure what it is 
supposed to and instead reflect other processes.
In MS, MRI measurements (discussed above) are the most frequently used biomar-
kers. However, CSF biomarkers are the most widely studied among the biochemical 
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biomarkers in diseases affecting the CNS in general, and specifically in MS. MS is 
considered a CNS-specific disease and thus CSF is topographically near the disease 
process. However, the impact on the CSF differs depending on what CNS areas are 
affected. Frontal, parietal, or occipital regions of the cortex are considered CSF-
distant, and pathological processes in these areas have less impact on CSF composi-
tion (187). The BBB creates an environment that is relatively isolated and partially 
protected from pathological processes affecting the rest of the body. However, about 
80% of the protein content and all immune cells in the lumbar CSF are blood deri-
ved, and immune cells regularly migrate across the BBB in both directions. Under 
physiological conditions, blood-derived proteins enter the CSF compartment via 
passive diffusion and show a specific CSF-to-blood ratio (188), and these conditions 
change during some pathological processes.
Lumbar puncture side effects, including perceived discomfort of the patient, post-
punctional headache, and minor risk for CNS infections or haematoma, makes CSF 
less attractive compared to blood. The development of blood-derived biomarkers 
for monitoring is therefore sought. Indeed, some serum and plasma biomarkers 
 reflecting different immune mechanisms, show association with MS course or 
 disease activity like osteopontin, LIGHT and metalloproteinases (189-192). How-
ever, structural biomarkers have been investigated in blood and the results to date 
have been inconclusive. For example, Eikelenboom et al. (2011) found no signi-
ficant correlation between neurofilament heavy in blood and in CSF (193). Other 
studies have  revealed diagnostic biomarkers for demyelinating diseases; aquaporin 
4 antibodies have been included in the diagnostic criteria for neuromyelitis optica 
(194); and recently, KIR 4.1 antibodies were discovered in 50% of MS patients 
(195).
4.4.2 Structural biomarkers
4.4.2.1 Neurofilament protein
The neurofilament protein is the major component of the axonal cytoskeleton and 
is only found in nerve cells. Its function is to maintain the axonal structure, and it is 
essential in physiological processes like axonal transport (196). The neurofilament 
protein can be divided into three subunits: the 61-kDa neurofilament light (NFL) 
protein, the 103-kDa neurofilament medium (NFM) protein, and the 111-kDa neu-
rofilament heavy (NFH) protein. The three subunits each have a common head and 
rod region, but differ in the tail region (196, 197) (Figure 5).
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Figure 5
Schematic representation of the different neurofilament subunits. NFH: neurofilament heavy 
chain, NFM : neurofilament medium chain, NFL: neurofilament light chain, N: N-terminus, C: 
C-terminus. (199) Reprinted with permission from Sagepub.
These three subunits are assembled to interfilament structures of 8-10 nm. Neurofi-
laments are highly phosphorylated and the degree determines the three-dimensional 
structure and axonal diameter (198). During axonal damage, neurofilament leaks 
out into the surrounding tissue and further disperses into the CSF and blood. The 
pathological process of how the intermediate filaments are dissolved is not fully 
understood, and the further pathways of the three different subunits are uncertain 
but are clearly not identical (199, 200). While NFM remains poorly studied, the 
other two are increasingly valued as biomarkers of axonal damage in several neu-
rological diseases. NFL levels in CSF are increased in many CNS diseases, such as 
herpes simplex virus encephalitis and tick borne encephalitis (201), cerebral vascu-
litis (202), atypical Parkinson disorders (PSP, MSA-C, MSA-P and CBD) (203), and 
ALS (204, 205). A number of studies have shown elevated neurofilament levels in 
MS. NFL levels are particularly elevated in active RRMS, early in the disease and 
during relapse but have been elevated in all courses of the disease (206-209). NFH 
is also elevated in patients with SPMS, and is related to disease progression and to 
brain atrophy on MRI (210, 211).
Neurofilament has also been experimentally measured in brain autopsy samples to 
verify axonal loss (112), and only been detected in blood (NFH) where massive 
axonal damage has occurred (212). The differing degrees of phosphorylation of the 
same protein in different situations and the similarities between the subunits in the 
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head region (213) create challenges in creating reliable assays that are free from 
cross reactions (214).
4.4.2.2 Glial fibrillary acidic protein (GFAP)
Glial fibrillary acidic protein (GFAP) is the major intermediate filament of the astro-
cyte cytoskeleton. It is thought to maintain the mechanical strength and outer shape 
of the astrocyte, and is essential for the processes of reactive astrogliosis and glial 
scar formation (215). Although GFAP has been isolated in various tissues, it is gene-
rally considered a CNS-specific protein (216, 217). GFAP consists of three domains: 
a head, rod, and tail. It can form homodimers as well as heterodimers with other 
proteins (218), it has a molecular weight of 43-49 kDa, and the proteins are arranged 
in fibre bundles of 8-9 nm (219). GFAP was originally isolated and characterized 
in MS lesions with severe astrogliosis (220). Elevated CSF GFAP levels are obser-
ved in pathological CNS conditions, such as dementia (221) and normal pressure 
 hydrocephalus (222). In MS, augmented CSF GFAP levels are related to relapse 
(223) and a correlation has been observed between GFAP levels and disability in 
SPMS patients (208). Increased serum levels of GFAP are seen in patients with 
severe head injury (224) and are related to outcome in subarachnoid haemorrhage 
(225).
4.4.2.3 Albumin ratio
Albumin ratio (CSF/plasma albumin) is used as a measure of BBB function (226). 
Albumin is a liver-produced, 67-kDa heavy plasma protein that passively diffuses 
over the BBB. The ratio is positively correlated to age, and is also elevated in  several 
pathological processes (227). Most MS patients have albumin ratio values below the 
upper reference level (228); thus, this measure is not used as an independent marker 
in MS. However, the BBB affects the measurements of other biochemical markers, 
such as intrathecal IgG production (229).
4.4.3 Inflammatory biomarkers
4.4.3.1 CXCL13
Cytokines are small proteins (~25 kDa) that function as mediators for intercellular 
communication. CXCL13 is 8-10 kDa, and is the 13th identified member of the 
cys-x-cys (CXC) motif ligand cytokine sub-family of the 17 members described 
in humans. This protein is also called ANGIE, ANGIE2, “B-cell chemoattractant”, 
BCA-1, BLC, and BLR1L.
CXCL13 is selectively chemotactic for B cells in the B1 and B2 subsets, and stimu-
lates the chemokine receptor CXCR5 (230). CXCL13 is produced by a number of 
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cell types; it seems to control the organization of B cells within follicles in lymp-
hoid tissue (231) and to indirectly influence immunoglobulin synthesis. From T-cell 
lymphomas, it is known that T cells can express CXCL13, reflecting their germinal 
centre origin (232). Elevated CXCL13 levels in CSF are seen in infectious diseases, 
such as Lyme borreliosis (233) and viral encephalitis (234). In MS, elevated levels 
of CSF CXCL13 reportedly predict conversion from CIS to definite MS (235). The 
levels are elevated during relapse, and correlate to IgG synthesis and the appearance 
of OCB (234, 236).
4.4.3.2 Oligoclonal IgG bands (OCB)
IgG in OCB produced in the CNS is characteristic of MS (237) and found in almost 
all patients (>95%) (228, 238, 239). In physiological processes, OCB are produced 
by clonally expanded plasma cells and plasma blasts (240, 241). Although target 
antigens for CSF antibodies in MS patients have been isolated, the congruence and 
pathological relevance of these antibodies remain obscure. Until recently, OCB 
were used as a diagnostic marker for all types of MS; however, the latest revision of 
the diagnostic criteria only uses OCB as a diagnostic marker for PPMS (63).
4.4.3.3 IgG Index
IgG produced in the CNS is the oldest identified biomarker in MS (242). To distin-
guish IgG produced outside the BBB, the IgG index is calculated as follows: (CSF 
IgG (mg/L)/serum IgG (mg/L))/(CSF albumin (mg/L)/serum albumin (mg/L)), thus 
compensating for the BBB function. An elevated IgG index is seen in 70-90% of MS 
patients, and is usually normal in OCB-negative patients (243-245). Use of the IgG 
index has been limited since its sensitivity is lower than that of OCB. In spite of its 
close connection to OCB, the IgG index is more closely related to immune activity 
(124, 234, 246) and treatment effects (247); therefore, the IgG index has been va-
lued as a marker of immune suppression and treatment effect (247).
4.5.4 Biomarkers of the sAPP/Aβ metabolism
Amyloid precursor protein (APP), its degradation products, and the involved en-
zymes have been most extensively studied in Alzheimer´s disease, where the CSF 
levels provide diagnostic information (248). The figure 6 below describes the three 
known APP processing pathways, which are dependent on the involvement of three 
secretases: α, β, and γ.
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Figure 6
APP processing pathways.
(a) α-Secretase cuts APP within the Aβ domain, inhibiting Aβ formation and releasing α-sAPP. 
(b) APP may be sequentially processed by BACE1 at the N-terminal portion of Aβ and by 
γ-secretase at the C-terminal. In fact, γ-secretase may cut APP at different positions, producing 
Aβ peptides with different C-terminal amino acids. Other enzymes are involved in the produc-
tion of Aβ peptides having other N-terminal amino acids (for example: AβX-42, AβX-40 and 
AβX-38). (c) APP may undergo combined α- and β-secretase processing, producing a range 
of short Aβ peptides. Aβ: amyloid beta; APP: amyloid precursor protein; BACE1: β-site APP 
cleaving enzyme 1; C-terminal: the acid end of an amino-acid molecule; CTF: C-terminal frag-
ment; N-terminal: the amino end of an amino-acid molecule. Paper III Reprinted with permis-
sion from Sagepub.
4.5.4.1 β-site APP cleaving enzyme, BACE1 (β-secretase)
As shown in the above figure, BACE1 (β-secretase ) cleaves APP, resulting in the 
release of N-terminal β-cleaved soluble APP (β-sAPP). The C-terminal fragment is 
further processed by γ-secretase to yield different Aβ peptides and the APP intracel-
lular domain (AICD), or by α-secretase to form shorter fragments. APP can also 
undergo α-secretase-mediated cleavage, resulting in α-sAPP release (249). Studies 
in BACE1-knockout mice suggest that this enzyme has various functions besides 
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its role in APP metabolism, including cell differentiation, immunoregulation, and a 
physiological role in cleaving neuregulin 1 (NRG1) (250, 251). NRG1 is an axonal-
expressed membrane-bound factor required for CNS myelination (252). BACE1-
mediated release of the soluble ectodomain of NRG1 is required for the activation 
of myelination by oligodendrocytes (250).
Increased BACE1 levels have been reported in Alzheimer’s disease and in persons 
with mild cognitive impairment (253, 254), as well as in traumatic brain injury and 
ischemic brain injury (255, 256). Little is known about BACE1 activity related to 
MS.
4.5.4.2 sAPP (α-sAPP and β-sAPP) and the Aβ peptides
In Alzheimer’s disease, the Aβ 1-42 levels are reduced, while α-sAPP and β-sAPP 
are unaffected (257). Reduced CSF levels of Aβ peptides as well as α-sAPP and 
β-sAPP are observed in inflammatory conditions of the CNS, such as Lyme di-
sease (258), opportunistic cerebral infections due to HIV (259), bacterial meningitis 
(260), and systemic lupus erythematosus (SLE) (261). Little is known about how 
APP metabolism in the CNS is affected in MS, and the CSF markers have not been 
systematically evaluated.
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5. Aims of the study
The purpose of this project was to investigate if biomarkers in the CSF of MS pa-
tients
• can differentiate between different clinical courses of MS
• are associated with disease activity
• are associated with progression of neurological disability in MS
• are useful for monitoring therapeutic efficacy in different stages of MS
• may provide new insights into the pathophysiology of MS progression.
B-cell line 
involvement 
Differentiation 
between 
disase courses 
Paper I Paper II Paper III Paper IV Paper V 
Progression of 
neurological 
disability 
Therapeutic 
impact on 
biomarkers 
Pathophysiology of progressive MS sAPP/Aβ 
metabolism 
Investigation of biomarkers in MS 
Major purposes of the papers  
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6. Subjects and methods
6.1 MS populations
This thesis includes three major cohorts of MS patients, of which the majority were 
consecutively recruited at the Department of Neurology, Sahlgrenska University 
Hospital, Gothenburg, Sweden. The first cohort consisted of patients included in 
a cross-sectional investigation of the sAPP/Aβ pathway in MS (Paper II); patients 
in this cohort were also recruited from two other MS centres: Akershus University 
Hospital, Oslo, Norway and Karolinska University Hospital, Stockholm, Sweden. 
The second cohort comprised a sub-group of patients from the first cohort, who were 
additionally examined in long-term follow-up setting (Papers I, II, III, and V). The 
third cohort consisted of patients who were assessed before and after 12-24 months 
of immunosuppressive or second-line immunomodulatory treatment (Papers III, IV, 
and V); patients in this cohort were also recruited from two other MS centres: Umeå 
University Hospital, Umeå and Örebro University Hospital, Örebro, both in Swe-
den.
All MS patients recruited before 2001 were diagnosed according to the Poser cri-
teria (62). Patients recruited thereafter were diagnosed according to the criteria of 
McDonald (262) and later revisions (63, 263). Informed consent was obtained from 
all subjects, and studies were approved by the regional ethical boards of Gothenburg 
and Uppsala.
6.1.1 Patients included in the cross-sectional study of the sAPP/Aβ 
pathway (Paper II)
This cross-sectional study included 100 patients (33 men and 67 women) from th-
ree different populations (Gothenburg, Oslo, and Stockholm). The population from 
Gothenburg consisted of 66 patients (25 men and 41 women) and has been described 
previously (208). This group comprised 23 RRMS patients who were included at 
the time of an acute relapse, 18 RRMS patients in clinical remission, and 25 SPMS 
patients. The mean age was 39.5 years (range, 17-59 years), mean disease duration 
was 14.3 (range, 1-40 years), and median EDSS was 3.0 (range, 1.0-8.0).
The population from Oslo consisted of 21 patients (3 men and 18 women) with a 
mean age of 42 years (range, 27-65 years), mean disease duration was 5 years (range, 
0.3-16 years), and median EDSS was 2.0 (range, 0-5.0). Fourteen had RRMS and 
7 had PPMS.
The population from Stockholm constituted 13 patients (4 men and 9 women) with 
a mean age of 39 years (range, 25-52 years), mean disease duration of 3.2 years 
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(range, 1-14 years), and median EDSS of 1.0 (range, 0-4.5). Eleven had RRMS and 
two had SPMS.
6.1.2 MS patients with long-term follow-up (Papers I, II, III, and V)
Twenty-six patients (18 women and 8 men) were recruited from a previous study 
population of 66 MS patients (208). At their first assessment, the mean age was 41 
years (range, 21-59 years) and mean disease duration was 11 years (range, 1-40 
years). Each patient was assessed twice with a median interval of 9 years (range, 
8-10 years). All had a clinically stable course and none had a relapse within 6 months 
prior to either assessment. At the first assessment, 16 patients were classified as 
RRMS and 10 as SPMS. At the second assessment, six additional patients were clas-
sified as SPMS. None of the patients were receiving disease-modifying treatment 
at the first assessment, but six were receiving immunomodulatory treatment at the 
second assessment (five interferon beta and one glatiramer acetate). Their median 
EDSS was 3.25 (range, 1.0-8.0) at the first assessment and 5.25 (range, 0-9.5) at the 
second. From this long-term follow-up cohort, 25 patients were examined for Paper 
I, 23 patients for Paper II, 26 patients for Paper III, and 20 patients for Paper V.
6.1.3 MS patients treated with immunosuppressive or second-line 
immunomodulatory treatment (Papers III, IV, and V)
6.1.2.1 Patients treated with immunosuppressive therapies (Papers III, IV, and V)
After publication of the OLYMPUS study (104), we modified the patient inclu-
sion criteria for mitoxantrone treatment from the MIMS study (94), expanding the 
population to also include patients treated with rituximab. The cohort included 38 
patients (19 women and 19 men); three had RRMS, 30 had SPMS, and five had 
PPMS. Fourteen patients had previously been treated with interferon beta and one 
with glatiramer acetate. At the pre-treatment assessment, the mean age was 49 years 
(range, 24-65 years), mean disease duration was 14 years (range, 2-29 years), and 
median EDSS was 6.0 (range, 3.0-8.0). After 12-24 months of immunosuppressive 
treatment (33 patients with mitoxantrone and 5 with rituximab), the median EDSS 
was 6.0 (range, 3.0-8.5). From this cohort, 20 mitoxantrone-treated patients (18 with 
SPMS and 2 with RRMS) were included in Paper III, and 10 of them (9 with SPMS, 
and 1 with RRMS) were re-examined post-treatment. In Paper IV, patients with 
RRMS (n = 3) were excluded, and Paper V included 22 mitoxantrone-treated pa-
tients (3 RRMS, 15 SPMS, 4 PPMS).
6.1.2.2 Second-line immunomodulatory treatment (Paper III)
Forty-one RRMS patients (14 men and 27 women) were assessed prior to natali-
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zumab treatment. Five patients were previously untreated, whereas 36 had break-
through disease with relapses or MRI activity while receiving other immunomo-
dulatory treatment (23 with interferon beta, 8 mitoxantrone, 4 glatiramer, and 1 
fingolimod). These patients comprised a subgroup of a previously described popu-
lation (264). They were all regarded as highly active, and were scheduled to start 
monthly intravenous treatment with 300 mg natalizumab according to Swedish gui-
delines (96) At first assessment, their mean age was 36 years (range, 13-60 years) 
and mean disease duration was 8.5 (range, 0.5-26 years). At both assessments, their 
median EDSS was 3.5 (range, 0-6.5).
6.2 Control subjects
This thesis includes three major control populations; 82 healthy controls (HC), 32 
spinal anaesthesia subjects (SAS), and 67 patients with systemic lupus erythema-
tosus (SLE). Informed consent was obtained from all control subjects, and studies 
were approved by the regional ethical boards of Gothenburg and Uppsala.
The first cohort consisted of HC and SAS who were included in a cross-sectional in-
vestigation of the sAPP-Aβ pathway in MS (Paper II). The majority were recruited 
at the Sahlgrenska University Hospital, Gothenburg, Sweden. HC were also recruit-
ed from the MS centre at Akershus University Hospital, Oslo, Norway. The second 
cohort was a sub-group of HC from the first cohort, who were further investigated 
in a long-term follow-up setting (Papers I-V). The third cohort consisted of patients 
with SLE (Paper II) recruited at the Department of Rheumatology, Sahlgrenska Uni-
versity Hospital, Sweden.
6.2.1 HC and SAS included in the cross-sectional study of the sAPP-
Aβ pathway (Paper II)
Our cross-sectional study included 114 HC and SAS (46 men and 68 women) with a 
mean age of 42 years (range, 18-82 years). The population consisted of 50 HC from 
the MS Centre, Gothenburg (208), 22 HC from the MS Centre, Oslo, and a mix of 
42 HC and SAS from other departments at the Sahlgrenska University Hospital. The 
subjects included blood donors, students (recruited by advertisement), spouses of 
patients, and a group of neurologically healthy individuals undergoing lower limb 
surgery, which was previously described (265).
6.2.2 HC population with long-term follow-up (Papers I-V)
Twenty-eight HC (20 men and 8 women) were included from a previously described 
control population of 50 healthy blood donors and students (208). Their mean age 
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was 33 years (range, 18-53 years). They were subjected to lumbar puncture twice 
with a median interval of 9 years.
6.2.3 Control population with systemic lupus erythematosus (Paper 
II)
Sixty-seven SLE patients (10 men and 57 women) were included. Their mean age 
was 42 years (range, 17-75 years). They were recruited at the Department of Rheu-
matology, Sahlgrenska University Hospital, and were diagnosed according to the 
revised SLE criteria of The American Rheumatism Association (266). Twenty-six 
of these subjects were considered to fulfill the criteria for cerebral SLE (267, 268).
Table 1. Overview of the number of patients and control subjects from Papers I-V.
MS patients Control subjects
Long-term 
follow-up
Cross-
sectional
Treated Long-term
follow-up
Cross-
sectional
HC/SAS
SLE
Mx or 
Rx*
Nz**
Paper I 25 0 0 0 28 0 0
Paper II 23 100 0 0 27 82/32 67
Paper III 26 0 20 41 28 0 0
Paper IV 0 0 35 0 14 0 0
Paper V 20 0 22 0 26 0 0
Mx, mitoxantrone; Rx, rituximab; Nz, natalizumab.
*Immunosuppressive therapies.
**Second-line immunomodulatory therapy.
Table 2. Demographics and clinical characteristics of the long-term follow-up cohort of patients 
(n = 25) and HC (n = 28) at baseline from Paper I.
Study group All MS RRMS SPMS Healthy 
controls
Subjects, n 25 15 10 28
Gender, F/M 18/7 14/1 4/6 8/20
Mean age (range), years 41 (21-59) 40 (21-59) 43 (27-52) 33 (18-53)
Median EDSS (range) 3.0 (1.0-8.0) 2.75 (1.0-4.5) 5.5 (2.0-8.0) NA
NA, not applicable.
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Table 3. Demographics and clinical characteristics of the long-term follow-up cohort of patients 
(n = 23) and HC (n = 27), and the cross-sectional cohort of patients (n = 100), HC/SAS (n = 114), 
and SLE (n = 67) at baseline from Paper II.
Group MS SLE Healthy controls
Subjects, n 100 67 114
Gender, F/M 33/67 10/57 46/68
Mean age (range), years 42 (17-65) 42 (17-75) 42 (18-82)
Median EDSS (range) 3.0 (0-8.0) NA NA
Some patients and HC were initially included in the cross-sectional study and thereafter inclu-
ded in the long-term follow-up cohort.
NA, not applicable.
Table 4. Demographics and clinical characteristics of the long-term follow-up cohort of patients 
(n = 26) and HC (n = 28), and patients of the treated cohort (natalizumab n = 41, mitoxantrone 
n = 20) at baseline from Paper III.
Group Subjects,
n
Gender 
F/M
Age,
Median (IQR),
years
Baseline EDSS
Median
(IQR)
Study population at baseline
RRMS 54 39/15 37 (32-46) 3.5 (2.0-4.5)
SPMS 33 17/16 53 (43-58) 6.0 (4.8-7.0)
Controls 28 7/21 40 (35-52) NA
Subpopulation of natalizumab and mitoxantrone treated patients
Natalizumab 29 RRMS 21/8 35 (30-39) 3.5 (2.0-6.0)
Mitoxantrone 9 SPMS
1 RRMS
3/7 45 (38-50) 6.0 (4.5-6.4)
Subpopulation analysed with immunoprecipitation and mass spectrometry 
RRMS 10 6/4 38 (32-47) 2.5 (0.0-6.0)
SPMS 11 6/5 54 (50-58) 6.5 (5.0-9.5)
Controls 10 2/8 41 (38-47) NA
IQR, interquartile range; NA, not applicable.
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Table 5. Demographics and clinical characteristics of the treated cohort (mitoxantrone or rituxi-
mab, n = 35) and 14 HC of the long-term cohort from Paper IV.
Group MS patients HC
Subjects, n 35 14
Gender, F/M 15/20 5/9
Mean age, (range), years 48 (22-65) 42 (31-61)
EDSS, median (range) 6.0 (3.0-8.0) NA
NA, not applicable.
Table 6. Demographics and clinical characteristics of the long-term follow-up cohort of patients 
(n = 20) and HC (n = 26), and patients of the treated cohort (mitoxantrone, n = 22) from Paper V.
Group 1 Subjects, 
n
Gender
F/M
Age* EDSS
Baseline**
All MS 20 15/5 41.5
(21-59)
3.0
(1.0-8.0)
RRMS 9 9/0 33.7
(21-48)
3.0
(0-8.0)
SPMS 7 3/4 46.7
(41-52)
7.5
(2.0-8.0)
Transitory 4 3/1 50
(44-59)
3.25
(2.0-4.0)
Group 2 n Gender
F/M
Age* EDSS
Baseline**
All MS 22 11/11 45.2
(22-60)
6.0
(3.0-8.0)
RRMS 3 3/0 42.6
(37-50)
6.0
(4.5-6.5)
SPMS 15 7/8 46.1
(22-60)
6.0
(3.0-8.0)
PPMS 4 1/3 43.5
(34-52)
6.5
(6.0-7.5)
Group
Controls
n Gender
F/M
Age* EDSS
Baseline**
HC 26 8/18 33.1
(18-60)
NA
*Data are mean (range), years.
**Data are median (range).
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6.3 Clinical assessments, MRI, and serum and CSF  
sampling
Disease activity was measured by annual relapse rate (Papers I-V) or presence of 
Gd+ T1-weighted images (Paper IV). A relapse was defined as patient-reported or 
objectively observed events typical of an acute inflammatory demyelinating event 
in the CNS, current or historical, with duration of at least 24 hours, in the absence 
of fever or infection (63). Neurological disability was determined by EDSS and its 
seven functional systems (152), and disease severity or progression was scored ac-
cording to progression index (158) or MSSS (156).
The MRI investigations (Paper IV) were performed according to the standard MS 
protocols of Sahlgrenska University Hospital, Örebro University Hospital, and 
Umeå University Hospital. The sequences used in the standard program are T1, 
T1 with standard-dose gadolinium contrast, T2, DWI, and Flair. MRI scans were 
performed with 1.5 or 3.0 Tesla machines, using 3-mm slice thickness, and took 
place no more than three months from clinical neurological examination and lumbar 
puncture. Serum samples were obtained by venepuncture and CSF samples were 
obtained by lumbar puncture; samples were handled and stored according to the 
recommendations of Bio MS (269). The clinical assessments and the serum and CSF 
sampling were performed once in the subjects of the cross-sectional cohorts, and 
twice in subjects of the long-term follow-up and the treated cohorts, with intervals 
of 8-10 years and 12-24 months, respectively.
6.4 Assays
All biochemical analyses in the studies of this thesis were run at the laboratory 
of neurochemistry, Sahlgrenska University Hospital, Mölndal, Sweden. They were 
performed by experienced and certified laboratory technicians who were blinded to 
the clinical and MRI data. To minimize variation, baseline and follow-up samples 
were analysed side by side on each assay plate, using one batch of reagents. All intra 
assay coefficients of variation were < 10%.
6.4.1 Polyclonal NFL assay (Paper I)
NFL was measured by an in-house-developed sandwich ELISA (205). Rabbit poly-
clonal anti-NFL IgG was used as the secondary antibody. Bound secondary antibo-
dy was detected using peroxidase-conjugated donkey anti-rabbit IgG. The standard 
curve ranged from 125 to 16 000 ng/L. The assay sensitivity was 125 ng/L.
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6.4.2 Monoclonal NFL assay (Paper IV)
NFL levels in CSF were determined by an enzyme-linked ELISA developed by the 
UMAN Diagnostics. CSF samples were incubated in pre-coated anti-NFL plates. As 
secondary antibodies, we used two monoclonal antibodies that are highly specific 
for NFL. Streptavidin horse radish peroxidase was used for detection. The assay 
sensitivity was 31 ng/L (209).
6.4.3 Glial fibrillary acidic protein assay (Papers I and IV)
GFAP was measured using an in-house developed ELISA, as previously described 
(270). Rabbit polyclonal anti-GFAP IgG was used as the secondary antibody. Cap-
tured secondary antibody was detected using peroxidase-conjugated donkey anti-
rabbit IgG. The procedure was performed at room temperature. The sensitivity of 
the GFAP assay was 32 ng/L. The standard curve ranged from 32 to 16 000 ng/L.
6.4.4 CXCL13 (Papers IV and V)
CXCL13 was measured by an ELISA Human CXCL13/BLC/BCA-1 Immunoassay 
(R&D Systems Inc., Abingdon, United Kingdom) according to the manufacturer’s 
instructions. In brief, this assay employs a sandwich enzyme immunoassay techni-
que. A monoclonal antibody specific for CXCL13 was precoated on a microplate. 
HRP-labelled CXCL13 monoclonal soluble detection antibody was used. The quan-
tification limit was 7.8 pg/mL, and CSF samples below that level were designated 
as 3.9 pg/mL.
6.4.5 Albumin ratio (Paper V)
Quantitative determinations of albumin in serum and CSF were performed by im-
munonephelometry on a Beckman Image Immunochemistry system (Beckman In-
struments, Beckman Coulter, Brea, CA, USA). Briefly, the nephelometer measured 
the increased light scattered as a result of particles created after addition of anti-
albumin antibodies to a solution. The albumin ratio was calculated as CSF albumin 
(mg/L)/serum albumin (g/L) × 1000.
6.4.6 IgG index, CSF-specific oligoclonal IgG bands (Paper V)
Quantitative determinations of IgG in serum and CSF were performed by immu-
nonephelometry on a Beckman Image Immunochemistry system (Beckman Instru-
ments, Beckman Coulter, Brea, CA, USA). The IgG index was calculated as CSF 
IgG (mg/L)/serum IgG (mg/L)/albumin ratio. OCB were visualized in CSF and 
serum by isoelectric focusing followed by silver staining, as previously described 
(271). Ocular quantification of CSF-specific OCB was performed independently by 
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two experienced researchers. Patients were divided into five different groups accor-
ding to the number of OCB: 0, 1, 2-4, 5-10, and >10.
6.4.7 BACE1 (β-Secretase ) activity (Paper II)
CSF BACE1 activity was measured using a highly sensitive and specific solution-
based assay, as previously described (272). Briefly, the assay consisted of an en-
zymatic reaction of CSF with a biotinylated 15-mer optimized BACE1 substrate 
(biotin-KTEEISEVNFEVEFR) and the use of pepstatin A to block non-specific pro-
tease activity, followed by cleavage product detection using a neoepitope-specific 
antibody. The extent of BACE1 activity was quantified using recombinant BACE1 
standards. The sensitivity of the assay was below 1.0 pM of recombinant BACE1.
6.4.8 α-sAPP and β-sAPP (Papers II and III)
The CSF α-sAPP and β-sAPP were determined using the sAPPα/sAPPβ Multiplex 
Assay for Meso Scale Discovery (MSD) platform (MSD, Gaithersburg, MD, USA), 
as described by the manufacturer. Briefly, this assay employed antibodies speci-
fic for the two fragments, run at the same time in two different electrodes coated 
with antibodies for 6E10 (an epitope within amino acids 3-8 of the Aβsequence) 
to capture α-sAPP, and a neoepitope-specific antibody on the C-terminal to capture 
β-sAPP. Both also had matching control electrodes. Both species were detected by 
the SULFO-TAG-labelled anti-APP antibody, p2-1. The sensitivity of this method 
was 120 pg/mL for α-sAPP, and 52 pg/mL for β-sAPP.
6.4.9 AβX-38, AβX-40, and AβX-42 (Papers II and III)
CSF AβX-38, AβX-40, and AβX-42 were determined using the MSD Aβ Triplex kit 
(Human Aβ peptide Ultra-Sensitive Kits), as described by the manufacturer. Briefly, 
this assay ran three samples at the same time on three attached electrodes. The N-
terminus included 4G8 antibodies (an epitope within amino acids 18-22 of the Aβ 
sequence) as capturing antibodies, while the C-terminus included SULFO-TAG-
labelled specific antibodies for detecting the different Aβ peptides. The method sen-
sitivity was 6 pg/mL for AβX-38, 2 pg/mL for AβX-40, and 7 pg/mL for AβX-42.
6.4.10 Aβ1-42 (Papers II and III)
CSF Aβ1-42 was determined using the INNO-BIA AlzBio3 kit (Innogenetics, 
Ghent, Belgium) on the xMAP Luminex platform, as described previously (273). 
Briefly, one monoclonal antibody (4D7A3) was attached to a capturing microsphere, 
and a second antibody (3D6) was attached to the opposite end. Both ends included 
antibodies for establishing the sequence 1-42. The flourochrome phycoerythrin was 
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coupled to streptavidin to measure the amount of Aβ1-42 on each microsphere. The 
method was flow cytometric, allowing microspheres with different antibodies to be 
run at the same time. Each microsphere was separated based on different signals 
after laser excitation. The sensitivity of the method was 25 ng/L.
6.4.11 Immunoprecipitation and mass spectrometry (Paper III)
This analysis used immunoprecipitation (IP) followed by matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry (MALDI-TOFMS) (274, 
275). Briefly, aliquots of the monoclonal antibodies 6E10 and 4G8 were separa-
tely added to magnetic beads coated with sheep anti-mouse IgG (Life Technolo-
gies, Carlsbad) and incubated. 6E10 + 4G8 antibody-bead solutions and Tween in 
phosphate-buffered saline (PBS) were added to CSF samples. The solution was then 
transferred to a magnetic particle processor (KingFisher Flex; Thermo Scientific, 
Waltham, MA, USA) for automatic washing and elution. The collected supernatant 
was dried by speed-vac and redissolved in formic acid (FA) in acetonitrile (ACN). 
The MALDI samples were prepared with the seed layer method, and analysed by 
MALDI-TOFMS (Bruker AutoFLEX (Bruker Daltonics). Each sample was analy-
sed in duplicate. The mass/charge ratio (m/z) used to identify the Aβ-peptide se-
quences represents the monoisotopic peak of the protonated molecule [M+ H+].
6.4.12 Liquid chromatography and tandem mass spectrometry  
(Paper III)
To confirm the identities of the Aβ species, the immunoprecipitates (IP) were ana-
lysed by liquid chromatography (LC) combined with high-resolution tandem mass 
spectrometry (MS-MS) (276). Briefly, LC-MS/MS analysis was performed on a ch-
romatographic system (GE Healthcare) using HotSep Kromasil C4 columns (G&T 
Septech) coupled to a mass spectrometer (Thermo Fisher Scientific). Collision-in-
duced dissociation (CID) was used to obtain fragment ion data.
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6.5 Statistics
Statistical inference was performed using SPSS software (several versions, updated 
over time), PASW Statistics 18 software (Paper IV), GraphPad Prism 5.00 (Graph-
Pad Software, San Diego, CA, USA) (Paper III), and Excel 2007 (Microsoft Corpo-
ration, Redmond, WA, USA) (Paper III).
Normally-distributed data were analysed by parametric tests. Between-group com-
parisons were made using Student´s t-test, ANOVA, and ANCOVA. Within-subject 
differences over time were analysed by paired t-test. Correlation analyses were per-
formed using Pearson correlation, linear regression analysis, partial correlation ana-
lysis, and one-way ANOVA. Data with skewed distributions were analysed using 
non-parametric tests. Between-group differences were analysed by Mann-Whitney 
U test, Kruskal-Wallis test, and non-parametric ANCOVA. The Wilcoxon ranked-
sign test was used for within-subject differences over time. The correlations bet-
ween variables were calculated using Spearman’s rank correlation.
6.5.1 Multivariate analyses
In Paper III, multivariate analysis was used to differentiate two groups based on 
their biomarker profiles. Each marker formed an orthogonal projection, which com-
bined to form an algorithm. This algorithm determines the direction (score vector) 
in the multivariate orthogonal space spanned by biomarkers that provides the best 
separation between the predefined groups. A stepwise variable reduction was perfor-
med until only the markers with positive contributions toward the separation were 
left, as judged by their relative contributions to the model. The calculations were 
implemented using the SIMCA P+ v. 12 software (Umetrics, Umea, Sweden).
Corrections for multiple comparisons were done using Bonferroni-correction. The 
data were reported as the mean when presumed to be normally distributed, other-
wise the median was given. P ≤ 0.05 indicated statistical significance and P ≤ 0.01 
highly significance.
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7. Results
7.1 Paper I
7.1.1 Increased CSF GFAP levels in MS patients
With adjustment for age, increased CSF GFAP levels were recorded in patients com-
pared to in HC (P < 0.05), whereas similar CSF NFL levels were observed in pa-
tients and HC. No significant differences were found between the RRMS and SPMS 
patients. GFAP and NFL levels were both correlated with age (both r = 0.50, P < 
0.01) (Figure 7).
Figure 7
Individual GFAP levels at two occasions for patients with relapsing-remitting multiple sclerosis 
(RRMS, n = 10), secondary progressive multiple sclerosis (SPMS, n = 10), patients converting 
from RRMS to SPMS (Transit, n = 5), and healthy controls (n = 28). The first examination is in-
dicated with circles and the second examination with squares. The mean annual GFAP increase 
is indicated for each group
7.1.2 CSF GFAP correlated with progression
When the data were corrected for age, CSF GFAP levels increased between the as-
sessments (P < 0.05). This increase was most prominent in the SPMS group. The 
mean annual GFAP increases were 6.5 ng/L for HC, 8.1 ng/L for RRMS patients, 
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12.8 ng/L for patients converting from RRMS to SPMS, and 18.9 ng/L for SPMS 
patients. However, this progressive trend was not accompanied by significant bet-
ween-group differences.
7.1.3 GFAP correlated with clinical disability and was closely related 
to neurological disability
GFAP levels correlated with neurological disability as measured by EDSS (r = 0.51, 
P < 0.05), and with disease severity or progression determined by MSSS (r = 0.47, P 
< 0.05). Dividing disability into the seven FS of EDSS revealed significant correla-
tions between GFAP and the FS scores of pyramidal (r = 0.51, P < 0.01), bowel and 
bladder (r = 0.51, P < 0.01), and brain stem (r = 0.53, P < 0.01). EDSS (P < 0.01) 
and progression index (P < 0.01) increased between assessments, mainly driven by 
increases in the scores of SPMS and patients changing course from RRMS to SPMS 
during long-term follow-up.
7.1.4 GFAP had predictive value
GFAP level at the first assessment had predictive value for neurological disability 
(EDSS) 8-10 years later (r = 0.45, P < 0.05). This was most pronounced in the SPMS 
group (r = 0.80, P < 0.01). However, GFAP level could not predict the increase of 
EDSS between the two assessments. The group with high GFAP levels (>350 ng/L) 
had a higher risk of achieving high EDSS (>5.5), with an OR of 4.5.
7.1.5 NFL was not elevated in clinically stable MS but some patients 
showed signs of subclinical disease activity
NFL levels were not increased in MS patients compared to in HC; they had no re-
lationship with disability or progression, and no prognostic value for disability de-
velopment. Two patients had increased NFL levels on only one occasion, and three 
patients showed high levels on multiple occasions, indicating acute axonal damage 
not associated with relapse.
7.2 Paper II
7.2.1 BACE1 distinguished MS from other inflammatory disease and 
controls
MS patients had lower CSF BACE1 activity than controls (P < 0.05) and patients 
with cerebral SLE (P < 0.01) (Figure 8). Patients with cerebral SLE had higher 
BACE1 activity than any other group (P < 0.05 for all comparisons). SPMS pa-
tients tended to have lower levels compared to other MS groups (P < 0.07). In MS, 
BACE1 activity correlated negatively with disease duration (r = −0.26, P = 0.01) 
and neurological disability as determined by EDSS (r = −0.25, P < 0.05).
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Figure 8
CSF BACE1 activity in patients with MS, patients with SLE with and without cerebral invol-
vement, and controls.
7.2.2 BACE1 activity correlated with APP metabolites that were  
altered in MS
In MS patients, BACE1 activity correlated weakly with levels of sAPP/Aβ markers 
(Aβ42, α-sAPP, and β-sAPP). Subgroup analysis revealed stronger correlations in 
SPMS patients (Aβ42: r = 0.40, P < 0.05; α-sAPP: r = 0.66, P < 0.01; β-sAPP: r = 
0.77, P < 0.01) than in RRMS patients (Aβ42: r = 0.38, P < 0.01; α-sAPP: r = 0.40, 
P < 0.01; β-sAPP: r = 0.26, P < 0.05). These correlations with Aβ42, α-sAPP, and 
β-sAPP, respectively, were also significant in non-cerebral (r = 0.54, r = 0.66, r = 
0.64, all P < 0.01) and cerebral (r = 0.75, r = 0.55, r = 0.54, all P < 0.01) SLE. In 
controls, only a weak correlation was found between BACE 1 and β-sAPP (r = 0.19, 
P < 0.05).
The CSF Aβ42, α-sAPP, and β-sAPP levels were significantly reduced in patients 
with MS compared to in controls (Table 7). However, the reductions in α-sAPP and 
β-sAPP were not specific to MS but were also seen in cerebral and non-cerebral 
SLE (Table 7). Compared with MS patients in remission, patients with on-going 
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or recent relapse (within one month) had lower levels of α-sAPP [respectively, 476 
ng/L (range, 265-1195 ng/L) and 711 ng/L (range, 186-1564 ng/L); P < 0.01] and 
β-sAPP [respectively, 239 ng/L (range, 146-559 ng/L) and 301 ng/L (range, 105-463 
ng/L); P < 0.01].
Table 7. Demographics and biomarker concentrations in MS, cerebral SLE, noncerebral SLE, 
and controls
7.2.3 BACE1 activity decreased towards progressive disease course
BACE1 activity decreased over time in MS patients (P < 0.05) who were assessed 
twice with an interval of 8-10 years. This decrease was most pronounced in RRMS 
patients, whereas SPMS patients had constantly low activity. None of the markers 
showed prognostic abilities or relation to clinical disability (EDSS).
7.3 Paper III
7.3.1 The APP metabolites were decreased in MS patients
RRMS and SPMS patients had lower baseline CSF levels of AβX-38, AβX-40, 
AβX-42, α-sAPP, and β-sAPP than control subjects, while only SPMS patients sho-
wed lower Aβ1-42 level (Figure 9). No significant differences were found between 
RRMS and SPMS patients. Since the study groups differed in age and gender dist-
ribution, these factors were corrected for in the analysis.
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Figure 9
Baseline levels of biomarkers, as measured by immunoassays.
* P<0.05, ** P<0.01 and *** P<0.001
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Figure 10
Changes in biomarkers after treatment.
Patients treated with natalizumab (Panel (a)) and mitoxantrone (Panel (b)). The number of pa-
tients analyzed varied between biomarkers, due to missing samples (Panel (a), N = 27–29; Panel 
(b), N = 8–10). The graphs show that follow-up concentrations normalized in relation to baseline 
levels (100%).
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7.3.2 Natalizumab normalized the APP metabolite levels
The APP metabolite levels were normalized in patients treated with natalizumab, 
with only two exceptions (Aβ x-42 and Aβ 1-42), while no changes in APP meta-
bolites were seen after treatment with mitoxantrone (Figure 10). However, patients 
treated with natalizumab were younger than those treated with mitoxantrone (P < 
0.05). Within the natalizumab-treated group, older patients had a lower absolute 
change in β-sAPP compared to younger patients (r = 0.43, P < 0.05). The age dif-
ferences seen between the groups may have influenced the β-sAPP trajectories in 
the two treatment groups; however, the overall dynamic biomarker response after 
natalizumab treatment did not seem to be confounded by age, and the correlation 
between age and β-sAPP was not significant after multiple comparisons.
7.3.3 Progressive MS patients exhibited altered sAPP/Aβ metabolism
The CSF was analysed with IP-MS and mass spectrometry, and 18 different Aβ 
species were isolated. Only small univariate differences in the relative levels of in-
dividual peptides were observed between the disease courses. Multivariate analysis 
revealed distinctly different patterns of sAPP/Aβ between SPMS and controls, with 
an intermediate pattern observed in RRMS.
7.4 Paper IV
7.4.1 NFL levels were reduced by immunosuppressive treatment in 
progressive MS patients
The mean NFL level in patients with progressive MS was reduced following 12-24 
months of mitoxantrone (n = 30) or rituximab treatment (n = 5), from 1780 ng/L 
(SD, 2018) to 870 ng/L (SD, 693) (P < 0.01). However, these reduced NFL levels in 
patients did not reach those found in HC [577 ng/L (SD, 326); P < 0.05] (Figure 11).
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Figure 11
Neurofilament light (NFL) in cerebrospinal fluid (CSF) before and following mitoxantrone 
(n=30) or rituximab (n=5) treatment. NFL levels in the CSF were compared to levels obtained 
in 14 healthy individuals. Box indicates interquartile range, bar indicates median, and whiskers 
indicating 95% CI.
7.4.2 First-line disease-modifying therapies seemed to influence the 
NFL levels in progressive MS
In previously untreated patients (n = 20), the pre-treatment mean NFL level (2462 
ng/L; SD, 2452) was significantly higher than in patients with on-going first-line 
disease-modifying therapies (DMT) (874 ng/L; SD, 434; n = 15; P < 0.05) (Figure 
12). Only the group of previously untreated patients showed significant NFL level 
reduction following 12-24 months of immunosuppressive treatment (P<0.01).
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Figure 12
Neurofilament light (NFL) in cerebrospinal fluid (CSF) before and following 12-24 months of 
mitoxantrone or rituximab treatment in previously untreated patients (n=20) or patients with 
ongoing disease modifying therapies (DMT, n=15) at study baseline. Box indicates interquartile 
range, bar indicates median, and whiskers indicating 95% CI.
7.4.3 NFL levels seemed to influence Gadolinium enhancement on 
MRI in progressive MS
Progressive MS patients with Gd+ lesions at study baseline (n = 12) presented with 
significantly higher pre-treatment NFL levels than patients without Gd+ lesions on 
MRI (n = 23) [2925 ng/L (SD, 2884) vs. 1184 ng/L (SD, 1024); P < 0.05] (Figure 
13). Only one patient with Gd+ lesions had been previously treated. Although pa-
tients with Gd+ lesions had the most marked NFL decrease [2925 ng/L (SD, 2884) 
vs. 889 (SD, 1041); P < 0.01], patients without signs of BBB damage on MRI also 
showed significantly reduced NFL levels following immunosuppressive treatment 
[1184 ng/L (SD, 1024) vs. 866 (SD, 449); P < 0.05].
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Figure 13
Neurofilament light (NFL) in cerebrospinal fluid (CSF) before and following 12-24 months of 
mitoxantrone or rituximab treatment in patients with (n=12) or without (n=23) pretreatment 
gadolinium enhancing lesions on MRI. Box indicates interquartile range, bar indicates median, 
and whiskers indicating 95% CI.
7.4.4 CXCL13 levels in CSF of progressive MS were normalized by 
immunosuppressive treatment
CXCL13 levels increased to above the ELISA detection limit were only found in 
11 of the 70 CSF samples obtained from progressive MS patients. The mean pre-
treatment CXCL13 level was significantly higher in MS patients (9.7 pg/mL) com-
pared to in HC subjects (<7.8 pg/mL; P < 0.05). Moreover, the mean CXCL13 level 
at treatment follow-up was significantly reduced (4.4 pg/mL; P < 0.01). With one 
exception, all of the CSF samples with detectable CXCL13 levels also had high 
NFL levels (>1200 ng/L, i.e. 2 SD above the mean NFL level of HC).
7.4.5 GFAP levels were increased in progressive MS patients but 
unaffected by immunosuppressive treatment
GFAP levels were higher in progressive MS patients compared to HC [650 ng/L 
(SD, 240) vs. 490 ng/L (SD, 170); P < 0.05). Immunosuppressive treatment had 
no significant effect on GFAP levels at follow-up. However, mean GFAP level was 
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significantly higher in patients with pre-treatment Gd+ compared to patients without 
signs of disease activity on MRI [803 ng/L (SD, 224) vs. 578 ng/L (SD, 216); P < 
0.01].
7.4.6 NFL were correlated with CXCL 13, and GFAP in progressive 
MS
Pre-treatment CSF NFL levels were correlated significantly with CXCL13 (r = 
0.527, P < 0.01) and GFAP levels (r = 0.471, P < 0.01). Following 12-24 months of 
immunosuppressive treatment, NFL levels were only correlated with GFAP levels (r 
= 0.440, P < 0.01). The pre- to post-treatment differences were significantly corre-
lated between NFL and CXCL13 (r = 0.475, P < 0.01) and between NFL and GFAP 
(r = 0.391, P < 0.05).
7.5 Paper V
7.5.1 The OCB pattern changed over 8-10 years of follow-up
Of 18 patients examined twice with an interval of 8-10 years, 16 had ≥2 OCB and 
two had one IgG band selectively produced in the CSF. Between the two examina-
tions, the OCB pattern changed in 15 patients. Without any isolated predisposing 
factor, the number of bands increased in four patients and decreased in six, three 
patients both gained and lost bands, and two had unchanged OCB number but with 
differences in intensity.
7.5.2 Immunosuppressive treatment did not affect the OCB
Of the 22 patients examined before and after 1-2 years of mitoxantrone treatment, 
the OCB counts or patterns changed in four patients (all with SPMS). Two exhibited 
increased OCB and two demonstrated both new and lost bands. OCB counts were 
not correlated with clinical course, EDSS, or MSSS.
7.5.3 CXCL13 levels were decreased following immunosuppressive 
treatment of progressive MS
CXCL13 was analysed at the second assessment in the long-term follow-up gro-
up, and at both pre- and post-treatment assessments, performed 24 months apart. 
Patients of the long-term follow-up group had CXCL13 levels similar to those of 
controls. Among progressive patients, the pre-treatment CXCL13 levels were signi-
ficantly higher than in HC [13.8 (SD, 1.22) vs. 4.6 (SD, 2.6); P < 0.01]. After 2 years 
of mitoxantrone treatment, the mean CXCL13 level was significantly reduced [4.3 
(SD, 1.9); P < 0.01] to the levels of HC.
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7.5.4 Correlations between OCB, IgG synthesis, CXCL13, and clinical 
parameters
In the long-term follow-up group, the IgG index was correlated with the numbers 
of OCB at both the first (r = 0.60, P < 0.01) and second assessments (r = 0.47, P 
< 0.01). No significant relationship was found between OCB and EDSS in SPMS. 
However, in RRMS patients (n = 9), EDSS correlated both with the OCB counts (r 
= 0.70, P < 0.05), and with the changed numbers of bands between the assessments 
(r = 0.68, P < 0.05).
In mitoxantrone-treated patients, the number of OCB correlated with the IgG index 
at both pre-treatment (r = 0.58, P < 0.01) and post-treatment (r = 0.45, P < 0.01) 
assessments.
CXCL13 level correlated with the IgG index in the long-term follow-up group (r = 
0.51, P < 0.05), as well as in the mitoxantrone-treated group (r = 0.61, P < 0.01). 
CXCL13 levels also correlated with the number of OCB (r = 0.49, P < 0.05) in 
mitoxantrone-treated patients. We found weak correlations of CXCL13 levels with 
EDSS (r = 0.32, P < 0.05) and with MSSS (P = 0.32, P < 0.05) in both investigated 
groups.
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8. Discussion
8.1 General considerations regarding biomarkers in MS
Recent years have seen the development of a growing number of therapeutic agents 
for MS, some of which have been introduced or are currently awaiting approval. 
There remains an obvious need for objective and reliable biomarkers to assess di-
sease activity, rate of progression, and therapeutic efficacy. Investigations of bio-
markers in MS may also reveal important information about pathophysiological 
processes. Currently available evidence indicates an indisputable role of inflam-
mation in the demyelination and axonal damage in early RRMS, whereas immune 
activity is less clearly involved in neurodegeneration in PMS. A set of biomarkers 
reflecting different aspects of MS immunopathogenesis could be useful for further 
exploring this subject.
MRI measurements are currently the dominant biomarkers in MS. Visualization of 
focal inflammation can be used to confirm clinical or detect sub-clinical disease 
activity (277). MRI is less useful in PMS; hence, there is a great need for new 
biomarkers reflecting the pathological processes of this stage. Unlike MRI, bio-
chemical biomarkers in CSF have the potential to specifically and directly mirror 
the immunopathological processes, indicating which inflammatory or degenerative 
pathway is activated. Additionally, our knowledge of the autoaggressive immune 
attack on the CNS in RRMS is strongly based on the animal model of experimental 
autoimmune encephalomyelitis (EAE), but no such reliable model exists for PMS. 
Therefore, investigations of CSF biomarkers may be of particular importance for 
resolving PMS pathophysiology. The present thesis discusses the value of biochem-
ical CSF biomarkers as a complement to clinical and MRI investigations in PMS, 
particularly regarding their potential for monitoring disease activity, disability pro-
gression, disease severity, prognosis, and therapeutic efficacy.
8.2 CSF biochemical biomarkers related to PMS disease 
activity
A biochemical biomarker of MS disease activity should reflect the occurrence of 
relapse or the appearance of new lesions. Accumulating numbers of inflammatory 
biomarkers, e.g. cytokines or chemokines (234, 278-281), and CNS parenchymal 
biomarkers (206, 207, 209, 236, 282-284) have been associated with increased dis-
ease activity in MS. However, only few studies have shown an association between 
on-going inflammation and signs of CNS damage (206, 285).
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8.2.1 Neurofilament light protein
Several studies have reported elevated CSF levels of neurofilament proteins during 
all stages of MS, with increased levels associated with relapse (207-209, 282, 286) 
and with Gd+ lesions on MRI (206). In the present study, we detected increased NFL 
levels in PMS patients with signs of increased activity on MRI (Paper IV). Increased 
NFL was also related to CXCL13, suggesting increased immune activity in these 
patients. In RRMS, the CSF NFL level increases 3- to 10-fold during relapse (208, 
209), then declines to low levels within 3 months (208, 286). In Paper IV, we found 
that PMS patients had increased NFL levels prior to immunosuppressive treatment, 
whereas the RRMS and SPMS patients from Paper I exhibited NFL levels similar to 
those observed in HC. These differences between studies may be partly due to the 
differences in patient selection. In Paper I, patients were included based on their low 
clinical disease activity, with no relapse documented within 3 months prior to study 
enrolment. In contrast, the PMS patients eligible for immunosuppressive treatment 
in Paper IV had obvious disability progression, with several of them showing sub-
clinical disease activity on MRI. Furthermore, the NFL immunoassay used in Paper 
I had lower sensitivity compared to the NFL ELISA used in Paper IV. Therefore, 
low-grade NFL changes that were detected in Paper IV may have been below the 
detection limit of the assay used in Paper I.
8.2.2 Glial fibrillary acidic protein
Previous studies have reported augmented CFS GFAP levels in RRMS, but these 
changes did not correlate with relapse rates (223). In Paper IV, we confirmed in-
creased GFAP levels in PMS patients compared to in HC (208). Interestingly, we 
also found that patients with Gd+ lesions on MRI prior to immunosuppressive treat-
ment had significantly higher GFAP levels compared to Gd-negative patients, indi-
cating that GFAP was partially influenced by disease activity.
8.2.3 CXCL13
Previous studies have shown elevated CXCL13 in MS, and that CXCL13 level 
correlates with disease activity in RRMS (234, 236). In Paper IV, we found in-
creased CXCL13 levels in PMS compared to in HC; however, only 11 of the 35 
PMS patients had CXCL13 levels above the detection limit of the assay. The highest 
CXCL13 levels were found in patients without previous DMT and with Gd+ lesions 
on MRI. The correlation between CXCL13 and disease activity reported for RRMS 
also seemed to be present in PMS. A clinically stable group of RRMS and SPMS pa-
tients without relapses occurring within 3 months prior to assessment (n = 20, Paper 
V) exhibited CXCL13 levels similar to those found in HC; again, only a minority (n 
= 3) of the 20 patients in this study had elevated CXCL13 levels. This finding is in 
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contrast with previous reports describing elevated CXCL13 levels in considerably 
higher proportions of patients (234, 236). This difference may be due to the lower 
proportion of immune active patients in our study populations, which comprised 
mainly progressive cases. The low frequency of CXCL13-positive CSF samples in 
our studies implies that the use of CXCL13 as a biomarker for PMS may be limited.
8.2.4 BACE1 activity and sAPP/Aβ metabolites
In the first study of these biomarkers, we showed significantly reduced CSF BACE1 
activity (Paper II) and lower CSF sAPP and Aβ metabolite levels (Papers II and 
III) in MS compared to in HC. The CSF concentrations of these biomarkers did not 
significantly differ between RRMS and SPMS. However, decreased levels of α- and 
β-sAPP were found in CSF of RRMS patients during relapse, compared to in stages 
of remission (Paper II), suggesting that clinical disease activity in RRMS seemed to 
reduce CSF levels of α- and β-sAPP.
8.3 Biochemical biomarkers in CSF reflecting disability  
development, progression, or severity of PMS
Ideally, biochemical biomarkers should predict and reflect disability progression 
and severity of MS. However, the search for suitable biomarkers is complicated 
by several unsolved questions regarding MS pathophysiology, as well as by the 
frequently weak reliability of clinical measurements of disability. Changes of MRI 
measurements are currently the dominant surrogate marker for MS progression. 
MRI can show correlations between T1 and T2 lesion volume (167), cerebral or cer-
vical spinal cord atrophy (184, 185), and disability development in MS. However, 
few biochemical biomarkers in CSF have been convincingly associated with dis-
ability progression (209, 211, 223, 287) or with signs of degeneration on MRI (210).
In the present studies (Papers I-V), disability was evaluated by EDSS, which is the 
most widely used scale but has low inter- and intra-rater sensitivity (153, 154). To 
reduce EDSS variability in the present studies, EDSS scoring was performed by 
only a few experienced neurologists (154). Other limitations of EDSS include its 
bimodal character and the relative lack of linearity, which particularly affects the 
scoring of PMS. Since EDSS scores above 3.5 mostly rely on ambulation, patients 
may progress in disability without influencing the EDSS score. This makes EDSS 
unreliable, especially in studies of shorter duration. To some extent, this limitation 
was overcome by the long-term follow-up of patients in Papers I, II, and V.
Disease severity and disability progression rate were determined by MSSS and pro-
gression index, respectively. These methods are derived directly from the EDSS, 
and provided temporal and prognostic information about the patient.
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8.3.1 Neurofilament light protein
We found no correlation between NFL and disability (EDSS) or progression (MSSS), 
and NFL showed no prognostic value (Papers I and IV). This was in contrast to the 
results of previous studies (209, 288), which obtained CSF for diagnostic reasons 
and found that NFL levels predicted disability assessed at 4 and 14 years later. How-
ever, the EDSS score from the diagnostic investigation was not reported, and hence 
the dependence of developed disease severity on early disability was not calculated. 
Nevertheless, these previous findings imply that the extent of early axonal damage 
predicts future disability. It should be noted that early disability is mainly depen-
dent on the location of individual lesions, while disability during progression results 
from accumulated lesion volumes and the development of cerebral and spinal cord 
atrophy. Moreover, the NFL level in CSF is also dependent on the interval between 
relapse onset and lumbar puncture (208, 286). The patients from Paper I were sub-
jected to long-term follow-up of 8-10 years; however, no predictive value of NFL 
was observed. As discussed in the previous section, this may have been due to the 
patient selection and the sensitivity of the NFL assay.
8.3.2 Glial fibrillary acidic protein
Our findings confirmed that patients with MS had increased GFAP levels compared 
to HC, and that the levels were particularly high in SPMS patients (208). Among 
MS patients, GFAP correlated to clinical disability (EDSS) and progression or se-
verity (MSSS) (Paper I). Similar results were previously reported in patients with 
high EDSS (>6.5) (289). Here, we also found that GFAP had prognostic value for 
future disability development. The risk for high EDSS (>5.5) was increased (OR = 
4.5) in patients with GFAP levels above 350 ng/L at the first assessment. However, 
this relationship was dependant on the EDSS found at the first assessment (Paper I).
In chronic neurological diseases, including PMS, sustained clinical disability is ex-
pected to be irreversible. High sustained EDSS can be achieved early in MS due 
to severe relapses, or can result from slow progression over several years. To com-
pensate for this imbalance, disease duration is included in the calculations of pro-
gression index and MSSS, which should result in more accurate measurements of 
progression rate or disease severity. We found that GFAP also correlated with pro-
gression index and MSSS, and that the annual GFAP increase was twice as high in 
SPMS compared to RRMS.
In the long-term follow-up setting (Paper I), GFAP seemed to have both prognostic 
value and to be a biomarker for progression; however, this was not true in PMS pa-
tients subjected to immunosuppressive treatment during 12-24 months (Paper IV).
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8.3.3 CXCL13
CXCL13 has been previously shown to exhibit a non-significant trend of correlating 
with clinical disability in RRMS (234). We found that CXCL13 weakly correlated 
with EDSS and MSSS in the long-term follow-up group and in patients about to 
start mitoxantrone treatment (Paper V). The prognostic value of CXCL13 was not 
measured because only a minority of the studied patients had detectable levels.
8.3.4 Intrathecal IgG synthesis
The clinical relevance of OCB and increased IgG index is unclear, apart from their 
diagnostic uses (290). In contrast to earlier studies (291), here we found that both 
the number of OCB and the change in OCB numbers were correlated with clinical 
disability (EDSS) in RRMS patients.
8.3.5 BACE1 activity and sAPP/Aβ metabolites
BACE1 activity and the sAPP/Aβ metabolites were found to be decreased in MS, 
and were negatively correlated with disability (EDSS) and severity (MSSS) in 
SPMS but not in RRMS. In RRMS, BACE1 activity decreased after 8-10 years of 
follow-up.
8.4 CSF biochemical biomarkers for discriminating between 
MS clinical courses
At some point, each of the investigated CSF biochemical biomarkers showed sig-
nificantly higher (NFL, GFAP, CXCL13, OCB, and IgG index) or lower (BACE1 
activity and sAPP/Aβ metabolites) levels in MS patients than in HC; however, none 
could differentiate between the clinical courses of MS. None of the studied biomark-
ers showed any distinct borders differentiating between RRMS and PMS, although 
some observations indicated a gradual change towards progressive course. GFAP 
levels tended to increase with disability progression, and the annual rate of GFAP 
increase seemed higher among SPMS patients than RRMS patients. Additionally, 
multivariate analysis revealed that the Aβ metabolite patterns were altered in MS pa-
tients, and that SPMS patients could be distinguished from HC based on the pattern 
of APP degradation products. RRMS patients seemed to constitute an intermediate 
group, but further discriminations were not possible with so few patients. These 
studies represent promising attempts to identify biomarkers that detect patients who 
are entering MS progression.
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8.5 Biomarkers for determining therapeutic efficacy in MS
In MS, therapeutic intervention with immunomodulatory or immunosuppressive 
therapies can change or inhibit immune activity and, if successful, reduce damage 
and degenerative processes of the CNS. MRI evidence of lesion formation, lesion 
load, and atrophy development are used as end-points in MS trials, and no biochem-
ical biomarkers have been accepted as surrogate markers for evaluating therapeutic 
efficacy in MS. Investigating biochemical biomarkers during therapeutic interven-
tion could increase our knowledge of the possible mechanism of action of the ap-
plied treatments, as well as of the pathophysiology of the disease. Such biomarkers 
may also be able to serve as objective measures in conjunction with clinical and 
MRI measures for monitoring therapy efficacy.
In the present thesis, we investigated the effects of natalizumab (Paper III), mitox-
antrone (Papers III, IV, and V) and rituximab (Paper IV) on a number of biomark-
ers. We also observed the treatment effects of first-line disease modifying treatment 
(DMT) (interferon beta and glatiramer acetate) in PMS (Paper IV).
8.5.1 Neurofilament light protein
In a previous study of relapsing MS (n = 83), 6-12 months of natalizumab treatment 
reduced NFL levels to those found in HC (264). Natalizumab treatment also af-
fected NFL levels in 9 SPMS patients with prior superimposed relapses. In Paper 
IV, we showed that 12-24 months of mitoxantrone or rituximab treatment reduced 
CSF NFL to levels approaching those observed in age-matched HC subjects. This 
effect was not confined to patients with Gd+ activity on MRI, but was also found 
in patients with increased NFL levels in the absence of Gd+ lesions at treatment 
onset. Pre-treatment NFL levels from patients who were previously treated with 
DMT were significantly lower than those from patients who were untreated at study 
baseline, suggesting that first-line DMT might influence NFL levels in PMS.
8.5.2 Glial fibrillary acidic protein
In patients with PMS, immunosuppressive treatment with mitoxantrone or rituxi-
mab had no significant impact on GFAP levels. However, PMS patients with Gd+ 
activity on MRI had increased GFAP levels prior to immunosuppressive treatment. 
Their GFAP levels were reduced post-treatment, indicating a treatment effect only 
in active PMS.
8.5.3 CXCL13 and intrathecal IgG synthesis
PMS patients in Paper IV and SPMS patients in Paper V showed reduced CXCL13 
levels after 12-24 months of immunosuppressive treatment; IgG production and 
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OCB were not affected (Paper V). To our knowledge, this result has not been pre-
viously shown.
We confirmed that the number and pattern of OCB were unchanged, even following 
potent immunosuppressive treatment (292, 293). Natalizumab treatment decreases 
IgG synthesis (294) and, to date, is the only treatment shown to reduce the propor-
tion of OCB-positive patients (294, 295).
8.5.4 sAPP/Aβ metabolites
In RRMS patients, natalizumab treatment increased sAPP/Aβ metabolites (except 
Aβ 1-42 and x-42) towards normal levels. On the other hand, after 12-24 months of 
mitoxantrone treatment, 9 SPMS patients and 1 RRMS patient exhibited no changes 
in Aβ and sAPP metabolites.
8.6 Biochemical biomarkers for exploring the pathophysio-
logy of progressive MS
8.6.1 Axonal degeneration
An early phenomenon in MS, axonal loss and degeneration is observed in all MS 
courses (112), and has been established as the major cause of cerebral and spinal 
cord atrophy and disability progression in MS (115, 296). The highest levels of neu-
rofilament protein occur during clinical or MRI signs of activity (206, 285). How-
ever, high neurofilament levels have also been observed in a plethora of diagnoses 
and pathological processes, such as ischemic stroke (297); CNS infections (201) 
and other autoimmune CNS diseases (268); and neurodegenerative diseases, such 
as ALS (205) and atypical Parkinson disorders (PSP, CBD, MSA-C, and MSA-P) 
(203).
We observed significantly increased NFL levels in PMS, with the highest levels in 
those with Gd+ lesions on MRI (Paper IV). Elevated NFL levels were associated 
with increased CXCL13 levels. Previous reports have shown similar associations 
between inflammatory biomarkers (CXCL13, osteopontin and MMP9) and NFL 
levels (207). In a previous study, we observed normalized NFL levels following 
6-12 months of natalizumab treatment of RRMS (264), and in Paper IV we showed 
that immunomodulation/suppression also reduced axonal damage in PMS. Overall, 
these findings indicate that the increased NFL release in CSF is largely mediated by 
the on-going CNS inflammation. However, it cannot be ruled out that other non-in-
flammatory degenerative mechanisms may also participate in PMS evolution.
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8.6.2 Astrogliosis
Astrocyte-mediated gliosis is a physiological reaction that is secondary to all forms 
of CNS damage (298). In MS, GFAP is considered the morphological basis of astro-
gliosis, and is the major constituent of chronic MS lesions (219). GFAP is consid-
ered a valuable astrogliosis biomarker and is elevated in MS, with the highest levels 
occurring during SPMS (208). Our results imply that astrogliosis increases with MS 
progression, but this process seemed to be essentially unresponsive to immunosup-
pressive treatment (Paper IV).
8.6.3 The role of the B cell lineage in PMS (CXCL13, IgG index, and OCB)
In recent years, evidence has accumulated indicating the importance of B cells in 
MS pathogenesis. One important finding is the reduction of MS disease activity 
achieved by anti-CD20 therapy (299-301), which results in B cell depletion. How-
ever, despite the B cell eradication in both the periphery and the CNS (101), IgG 
production in the CNS was not affected (293). Additionally, ectopic B cell follicles 
have been found in the meninges of PMS patients (129, 130, 302), which are report-
edly associated with a gradient of subpial cortical demyelination, neuronal loss, and 
cortical atrophy (130). These follicles are aggregates of B cells and plasma cells, 
and may explain the maintained CSF IgG production in OCB that is observed in 
PMS (1).
Increased intrathecal IgG synthesis, including presence of OCBs, is observed in 
>95% of MS patients and has diagnostic value (63, 228, 239, 290). In Paper V, we 
showed that the OCB patterns changed over the long-term follow-up, and were not 
related to disease course. This was in contrast to the widespread opinion that OCBs 
are stable over the course of MS, and represent an immunological “fingerprint” for 
each patient (290). This concept was based on a number of studies that have most-
ly been small, short in follow-up, and have used different methodologies for CSF 
OCB detection (247, 303-305). Our findings are consistent with the different OCB 
patterns found in different MS plaques from the same brain (306), and suggest a 
dynamic shift of clonally expanded cells of the B cell lineage over the course of MS. 
Another explanation could be the rearranged immunoglobulin genes with extensive 
mutations that have been observed in CSF B cells (307) and in the brains of MS pa-
tients (308). Such mutations may be antigen driven (309), and the exposure of new 
antigens following inflammation and degeneration might induce new mutations of 
immunoglobulin genes and possibly explain the altered OCB patterns.
We did not find that OCB or IgG production were influenced by immunosuppressive 
treatment (Paper V). This result was in line with reports from previous studies that 
OCB patterns were stable after potent immunomodulatory or immunosuppressive 
treatments, such as rituximab (293) and hematopoietic stem cell transplantation 
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(292). Only natalizumab treatment has been shown to induce OCB disappearance 
in MS (294, 295). Mitoxantrone did not alter IgG production, despite its powerful 
ability to depress both B and T cells. Mitoxantrone does not cross the BBB, which 
supports the suspicion that an autonomous and long-lived B cell/plasma cell popu-
lation is compartmentalized in the CNS.
CXCL13 is a chemokine that can attract and maintain B cells within the CSF/CNS. 
Here we confirmed previous findings that the CXCL13 level in the CSF was asso-
ciated with IgG synthesis (234). These results support a B cell dependence of IgG 
synthesis. Furthermore, the complexity of this system is illustrated by the fact that 
only CXCL13, and not IgG synthesis, was affected by mitoxantrone.
8.6.4 BACE1 activity and sAPP/Aβ metabolism
In Paper II, we illustrated for the first time that BACE1 activity and sAPP/Aβ me-
tabolites are involved in MS pathophysiology. The β-pathway has been considered 
to be of special interest in studies of MS, since animal studies demonstrated that 
BACE1 cleaves neuregulin 1 from its membrane-bound form to stimulate myelin-
ation by oligodendrocytes. Demyelination and defective remyelination is a domi-
nant feature in MS (148). Here we found reduced levels of BACE1 in MS patients 
compared to in controls and in patients with cerebral SLE used as inflammatory 
controls (Paper II); this difference was most pronounced in patients with long-term 
SPMS. While there is no clear direct parallel between myelination in mouse studies 
and remyelination in humans, these findings suggest one possible explanation for 
the altered oligodendrocyte function observed in late MS (250, 310). These results 
cannot be considered a general phenomenon due to CNS inflammation, since cere-
bral SLE demonstrated significantly increased CSF BACE1 levels.
We observed reduced levels of sAPP/Aβ in the CSF of MS patients (Papers II and 
III), which has also been recently confirmed by other groups (311, 312). Based on 
our findings and the available literature, we concluded that these reduced levels were 
a result of general neuroinflammation (258-261). Although it is unclear why these 
levels decrease during inflammation, possible explanations include decreased pro-
duction, increased aggregation, or increased clearance. However, amyloid plaques 
are uncommon in MS (313). Neuronal Aβ release is related to synaptic activity 
(314), and CSF Aβ levels correlate to CSF levels of granins (315), which are re-
leased during regulated neuronal secretion. Since oligodendrocytes initiate myelin-
ation preferentially on active axons, the decreased Aβ levels might represent parts of 
a vicious circle of axon inactivation (316) and disturbed remyelination. Our findings 
in Paper III are consistent with a reversible neuronal impairment early in the disease 
(reversible reductions of sAPP/Aβ peptides in RRMS) and irreversibility during the 
progressive course (irreversible reductions of sAPP/Aβ peptides in SPMS).
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9. Concluding remarks and future considerations
The pathophysiology of MS is complex, prominently featuring numerous active me-
chanisms, such as demyelination, astrogliosis, and axonal degeneration. It is obvious 
that no biomarker alone can describe this. The aim of this thesis was to investigate 
if biomarkers in the cerebrospinal fluid (CSF) of MS patients could provide new 
insights into the pathophysiology of MS progression, and if biomarker levels could 
reflect disease activity, disability progression, or therapeutic efficacy.
We found elevated levels of NFL, illustrated ongoing axonal damage, in PMS pa-
tients in fast progression; most pronounced in patients with Gd+ lesions on MRI 
without first line DMT (Paper IV). This was in contrast to findings in clinically 
stabile patients at long-term follow-up, who had levels as HC (Paper I). We found 
thus that the axonal damage was determined by the disease activity regardless of 
disease course.
In long-term follow-up (Paper I) GFAP was confirmed as a biomarker reflecting 
disability and disease severity in PMS. GFAP also showed a prognostic value for 
future disability. These findings were in line with accumulating astrogliosis in PMS.
The increased levels of NFL and CXCL13 in PMS were associated with disease 
activity and the levels decreased after immune suppressive and immune modulatory 
treatment. These biomarkers are potential tools for monitoring therapeutic efficacy.
We found signs of B-cell activity in all stages of MS (Paper IV and V). CXCL13 was 
associated to disease activity and axonal damage and also to the IgG production in 
CNS and OCB. We illustrated, in opposite to the general view, changed number and 
pattern of OCB in CSF over time (Paper V). These findings illustrated an on-going 
and a dynamic B-cell activation in all courses of MS and a B-cell dependence of 
intrathecal IgG synthesis.
We showed for the first time an alteration of the sAPP/Aβ metabolism in MS (Paper 
II and III). This was illustrated both by the reduced activity of BACE1 and by the 
reduced levels of sAPP/Aβ metabolites in CSF and are possible signs of impaired 
neuronal activity in the CNS. The reduction of the sAPP/Aβ metabolism was re-
versible in the RRMS after immune modulating treatment but irreversible in SPMS 
after immune suppressive treatment. We concluded this as a potential sign of irre-
versibility of neuronal impairment late in the disease. In PMS the levels of degrada-
tion products was not only reduced but the pattern of metabolites was also changed 
compared to HC. This was visualized by mass spectrometry.
All data in the present thesis illustrated a relationship between CNS inflammation and 
neurodegeneration in all courses of MS; however, it cannot be ruled out that other 
non-inflammatory degenerative mechanisms may also participate in PMS evolution.
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Investigated biomarkers in CSF provide important information about the pathop-
hysiology in PMS, and may serve as complement to clinical and MRI measures for 
assessment of disease activity, progression, severity and therapeutic efficacy.
NFL has previously been investigated in a number of studies and its relevance as 
a disease activity marker was confirmed in these studies also in PMS. NFL could 
be evaluated for use as a biomarker for monitoring treatment effect and could be 
suggested as an endpoint in phase II clinical trials. By combining NFL, CXCL13, 
GFAP and evaluation of disease activity and MRI a more complete evaluation of 
treatment effects could be achieved. Further investigations are needed to evaluate 
the correlation between CSF biomarkers and degeneration parameters on MRI, as 
T1 lesion volume and atrophy. The sAPP/Aβ metabolism are warranted to be further 
investigated for evaluation of the clinical usefulness of these markers and further 
investigate the mass spect profiles of the Aβ metabolites in CSF on larger patient po-
pulations. Access to these biomarkers also in blood should be of clinical importance 
but demands further development of more sensitive analysing methods.
77
Acknowledgements
Associate Professor Jan Lycke, my scientific supervisor and a clinical role 
 model. For introducing me to the MS field clinically and scientifically. Your sharp 
 reflections, conclusions and your brilliance in the art of writing are a huge inspira-
tion to me. Your energy and patience were essential for the completion of this pro-
ject. You have stood by me all the way with honesty and heartfelt sincerity. It is an 
honor to work with you. 
Professor Henrik Zetterberg, my inspiring co-supervisor. For making me un-
derstand some of the mysteries of laboratory medicine and for your enthusiasm for 
research. 
Clas Malmeström, my colleague, co-author, room mate and friend. You have been a 
source of endless help. I hope I will have you as a colleague for many years to come. 
Niklas Mattsson, my co-author and friend. Your brain works at double the speed of 
any normal person. You travel two times around the world in the time it takes me to 
get to work. I hope for more opportunities to work with you.
Professor Lars Rosengren, my co-author and former head of the Department of 
Neurology. Thank you for sharing your scientific knowledge. 
Mikael Edsbagge, Head of the Department of Neurology, for signing the right pa-
pers and giving me the conditions in which to practice this science. 
Martin Gunnarsson, my co-author and friend. Thank you for your support and 
your wonderful sense of humor.
To all my co-authors especially Anders Svenningsson, Kristin Augutis and Sara 
Haghighi who through energy and knowledge have contributed a lot to these studies. 
To all co-workers at the laboratory of neurochemistry especially Professor Kaj 
Blennow and Shirley Fridlund for support and knowhow in the lab.
Friends and colleagues at the department of Neurology in particular Marie Sjögren, 
Albert Hietala, Daniel Jons, Peter Vaghfeldt and Björn Runmarker for help and 
encouragement when so was needed. 
Snezana, Ulla, Birgitta, Ann, Anne, Ann-Christine, Ann-Helene, Belinda and 
all other former and present co-workers at the MS team for resolving challenges on 
the way and creating a pleasant atmosphere. To Sirpa for all your help and for the 
emptiness you left behind. 
Professor Oluf Andersen, for clinical and scientific inspiration and for knowing 
everything about neurology. 
78
The professors at the Institute of Clinical Neuroscience and Rehabilitation Lars 
Rönnbäck, Kristina Malmgren and Carsten Wikkelsö for your enthusiasm and 
encouragement. 
Head of the institute, Professor Agneta Holmäng,  for creating excellent working 
conditions at the Institute of Neuroscience and Physiology.
Oscar and Markus for excellent help with computers that did not work.
My lovely parents, Rolf and Ingela for your endless support through life. I hope I 
have made you proud of me for being me. 
My brothers Magnus, Hans and Lars for being just that and for making research 
something simple and accessible. We share blood and I love you.
My parents in-law Erling and Liv who, in spite of hard times, never hesitated to 
come to my support.
The Dahlberg and Ekenstråle families for understanding and supporting when the 
need arose.
Torunn, my wonderful wife, who has stood by and supported me through the years 
and helped me to my hold my course. I hope I will get the opportunity to show you 
my love and gratitude for the rest of my life.
Oscar, Anna, Carl and Ingrid, my amazing children who remind me of the mean-
ing of life everyday and for making me see myself without needing a mirror. Thank 
you for being understanding of me being away without understanding what I am 
doing. I love you.
The brave and kind people participating in these studies we called patients. Without 
you none of this would have been possible. This work I dedicate to you.
The works in this thesis were supported by grants from the NHR Foundation, the Edith Ja-
cobsson Foundation, Anna-Lisa and Bror Björnsson Foundation, the Swedish Association of 
Persons with Neurological Disabilities, the Swedish Research Council, the Göteborg Medical 
Society, the Västra Götaland Region, Alzheimerfonden, Stiftelsen för Gamla Tjänarinnor, Med-
Coast, Swedish Brain Power, the Åke Wiberg Foundation, Soderberg Foundation, Alzheimer’s 
Association, Swedish Brain Power, Swedish State Support for Clinical Research, Sahlgrenska 
Academy, Lundbeck Foundation, Stiftelsen Gamla Tjanarinnor, Uppsala Universitets Medicins-
ka Fakultet, Swedish Brain Fund, Goteborgs lakaresallskap, Thureus stiftelse, Pfannenstills stif-
telse, Demensfonden, the Research Foundation of the Multiple Sclerosis Society of Gothenburg 
and Biogen Idec
79
References
1. Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, et 
al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. 
Brain. 2009 May;132(Pt 5):1175-89. PubMed PMID: 19339255. Pubmed Central PM-
CID: 2677799. Epub 2009/04/03.
2. Kutzelnigg A, Lucchinetti CF, Stadelmann C, Bruck W, Rauschka H, Bergmann M, et al. 
Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain. 2005 
Nov;128(Pt 11):2705-12. PubMed PMID: 16230320. Epub 2005/10/19.
3. Prineas JW, Kwon EE, Cho ES, Sharer LR, Barnett MH, Oleszak EL, et al. Immunopat-
hology of secondary-progressive multiple sclerosis. Ann Neurol. 2001 Nov;50(5):646-57. 
PubMed PMID: 11706971. Epub 2001/11/15.
4. Semra YK, Seidi OA, Sharief MK. Heightened intrathecal release of axonal cytoskeletal 
proteins in multiple sclerosis is associated with progressive disease and clinical disability. 
J Neuroimmunol. 2002 Jan;122(1-2):132-9. PubMed PMID: 11777552. Epub 2002/01/05.
5. Prineas JW, Parratt JD. Oligodendrocytes and the early multiple sclerosis lesion. Ann 
Neurol. 2012 Jul;72(1):18-31. PubMed PMID: 22829266. Epub 2012/07/26.
6. Fawcett JW, Asher RA. The glial scar and central nervous system repair. Brain Res Bull. 
1999 Aug;49(6):377-91. PubMed PMID: 10483914. Epub 1999/09/14.
7. Dalton CM, Brex PA, Jenkins R, Fox NC, Miszkiel KA, Crum WR, et al. Progressive 
ventricular enlargement in patients with clinically isolated syndromes is associated 
with the early development of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2002 
Aug;73(2):141-7. PubMed PMID: 12122170. Pubmed Central PMCID: 1737988.
8. Schumacker GA, Beebe G, Kibler RF, Kurland LT, Kurtzke JF, McDowell F, et al. Pro-
blems of Experimental Trials of Therapy in Multiple Sclerosis: Report by the Panel on the 
Evaluation of Experimental Trials of Therapy in Multiple Sclerosis. Ann N Y Acad Sci. 
1965 Mar 31;122:552-68. PubMed PMID: 14313512. Epub 1965/03/31.
9. Tumani H, Hartung HP, Hemmer B, Teunissen C, Deisenhammer F, Giovannoni G, et al. 
Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol Dis. 2009 Aug;35(2):117-
27. PubMed PMID: 19426803.
10. Ahlgren C, Oden A, Lycke J. High nationwide prevalence of multiple sclerosis in Sweden. 
Mult Scler. 2011 Aug;17(8):901-8. PubMed PMID: 21459810. Epub 2011/04/05.
11. Sundstrom P, Nystrom L, Forsgren L. Incidence (1988-97) and prevalence (1997) of mul-
tiple sclerosis in Vasterbotten County in northern Sweden. J Neurol Neurosurg Psychiatry. 
2003 Jan;74(1):29-32. PubMed PMID: 12486262. Pubmed Central PMCID: 1738162.
12. Svenningsson A, Runmarker B, Lycke J, Andersen O. Incidence of MS during two 
fifteen-year periods in the Gothenburg region of Sweden. Acta Neurol Scand. 1990 
Sep;82(3):161-8. PubMed PMID: 2270743.
13. Hernan MA, Olek MJ, Ascherio A. Geographic variation of MS incidence in two pro-
spective studies of US women. Neurology. 1999 Nov 10;53(8):1711-8. PubMed PMID: 
10563617. Epub 1999/11/24.
14. Simpson S, Jr., Blizzard L, Otahal P, Van der Mei I, Taylor B. Latitude is significantly 
associated with the prevalence of multiple sclerosis: a meta-analysis. J Neurol Neurosurg 
Psychiatry. 2011 Oct;82(10):1132-41. PubMed PMID: 21478203. Epub 2011/04/12.
80
15. Midgard R. Incidence and prevalence of multiple sclerosis in Norway. Acta Neurol Scand 
Suppl. 2012 (195):36-42. PubMed PMID: 23278655.
16. Pugliatti M, Sotgiu S, Rosati G. The worldwide prevalence of multiple sclerosis. Clin 
Neurol Neurosurg. 2002 Jul;104(3):182-91. PubMed PMID: 12127652.
17. Wallin MT, Culpepper WJ, Coffman P, Pulaski S, Maloni H, Mahan CM, et al. The Gulf 
War era multiple sclerosis cohort: age and incidence rates by race, sex and service. Brain. 
2012 Jun;135(Pt 6):1778-85. PubMed PMID: 22628389.
18. Orton SM, Herrera BM, Yee IM, Valdar W, Ramagopalan SV, Sadovnick AD, et al. 
Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol. 2006 
Nov;5(11):932-6. PubMed PMID: 17052660. Epub 2006/10/21.
19. Trojano M, Lucchese G, Graziano G, Taylor BV, Simpson S, Jr., Lepore V, et al. Geo-
graphical Variations in Sex Ratio Trends over Time in Multiple Sclerosis. PLoS One. 
2012;7(10):e48078. PubMed PMID: 23133550. Pubmed Central PMCID: 3485003. Epub 
2012/11/08.
20. Kotzamani D, Panou T, Mastorodemos V, Tzagournissakis M, Nikolakaki H, Spanaki 
C, et al. Rising incidence of multiple sclerosis in females associated with urbanization. 
Neurology. 2012 May 29;78(22):1728-35. PubMed PMID: 22592376. Epub 2012/05/18.
21. Orton SM, Ramagopalan SV, Brocklebank D, Herrera BM, Dyment DA, Yee IM, et al. Ef-
fect of immigration on multiple sclerosis sex ratio in Canada: the Canadian Collaborative 
Study. J Neurol Neurosurg Psychiatry. 2010 Jan;81(1):31-6. PubMed PMID: 19710047. 
Epub 2009/08/28.
22. Willer CJ, Dyment DA, Risch NJ, Sadovnick AD, Ebers GC. Twin concordance and 
sibling recurrence rates in multiple sclerosis. Proc Natl Acad Sci U S A. 2003 Oct 
28;100(22):12877-82. PubMed PMID: 14569025. Pubmed Central PMCID: 240712. 
Epub 2003/10/22.
23. Compston A, Coles A. Multiple sclerosis. Lancet. 2008 Oct 25;372(9648):1502-17. Pub-
Med PMID: 18970977.
24. Gourraud PA, Harbo HF, Hauser SL, Baranzini SE. The genetics of multiple sclerosis: 
an up-to-date review. Immunol Rev. 2012 Jul;248(1):87-103. PubMed PMID: 22725956. 
Epub 2012/06/26.
25. International Multiple Sclerosis Genetics C, Wellcome Trust Case Control C, Sawcer S, 
Hellenthal G, Pirinen M, Spencer CC, et al. Genetic risk and a primary role for cell-med-
iated immune mechanisms in multiple sclerosis. Nature. 2011 Aug 11;476(7359):214-9. 
PubMed PMID: 21833088. Pubmed Central PMCID: 3182531.
26. Healy BC, Liguori M, Tran D, Chitnis T, Glanz B, Wolfish C, et al. HLA B*44: pro-
tective effects in MS susceptibility and MRI outcome measures. Neurology. 2010 Aug 
17;75(7):634-40. PubMed PMID: 20713950. Pubmed Central PMCID: 2931768.
27. Yeo TW, De Jager PL, Gregory SG, Barcellos LF, Walton A, Goris A, et al. A second 
major histocompatibility complex susceptibility locus for multiple sclerosis. Ann Neurol. 
2007 Mar;61(3):228-36. PubMed PMID: 17252545. Pubmed Central PMCID: 2737610.
28. Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, et al. 
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclero-
sis. Nature. 2011 Aug 11;476(7359):214-9. PubMed PMID: 21833088. Pubmed Central 
PMCID: 3182531. Epub 2011/08/13.
81
29. International Multiple Sclerosis Genetics C, Hafler DA, Compston A, Sawcer S, Lander 
ES, Daly MJ, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N 
Engl J Med. 2007 Aug 30;357(9):851-62. PubMed PMID: 17660530.
30. Cotsapas C, Voight BF, Rossin E, Lage K, Neale BM, Wallace C, et al. Pervasive sharing 
of genetic effects in autoimmune disease. PLoS Genet. 2011 Aug;7(8):e1002254. PubMed 
PMID: 21852963. Pubmed Central PMCID: 3154137.
31. Baranzini SE. The genetics of autoimmune diseases: a networked perspective. Curr Opin 
Immunol. 2009 Dec;21(6):596-605. PubMed PMID: 19896815.
32. Alter M, Leibowitz U, Speer J. Risk of multiple sclerosis related to age at immigration to 
Israel. Arch Neurol. 1966 Sep;15(3):234-7. PubMed PMID: 5912003. Epub 1966/09/01.
33. Gale CR, Martyn CN. Migrant studies in multiple sclerosis. Prog Neurobiol. 1995 Nov-
Dec;47(4-5):425-48. PubMed PMID: 8966212. Epub 1995/11/01.
34. Joensen P. Multiple sclerosis: variation of incidence of onset over time in the Faroe Is-
lands. Mult Scler. 2011 Feb;17(2):241-4. PubMed PMID: 20978036. Epub 2010/10/28.
35. Rosati G, Aiello I, Granieri E, Pirastru MI, Becciu S, Demontis G, et al. Incidence of 
multiple sclerosis in Macomer, Sardinia, 1912-1981: onset of the disease after 1950. Neu-
rology. 1986 Jan;36(1):14-9. PubMed PMID: 3510404. Epub 1986/01/01.
36. Kurtzke JF, Hyllested K. Validity of the epidemics of multiple sclerosis in the Faroe Is-
lands. Neuroepidemiology. 1988;7(4):190-227. PubMed PMID: 3264056.
37. Cohen JI. Epstein-Barr virus infection. N Engl J Med. 2000 Aug 17;343(7):481-92. Pub-
Med PMID: 10944566.
38. Lunemann JD. Epstein-Barr virus in multiple sclerosis: a continuing conundrum. Neuro-
logy. 2012 Jan 3;78(1):11-2. PubMed PMID: 22156986.
39. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the 
role of infection. Ann Neurol. 2007 Apr;61(4):288-99. PubMed PMID: 17444504. Epub 
2007/04/21.
40. Handel AE, Williamson AJ, Disanto G, Handunnetthi L, Giovannoni G, Ramagopalan SV. 
An updated meta-analysis of risk of multiple sclerosis following infectious mononucleo-
sis. PLoS One. 2010;5(9). PubMed PMID: 20824132. Pubmed Central PMCID: 2931696. 
Epub 2010/09/09.
41. Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, Cinque P, et al. Dysre-
gulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med. 2007 Nov 
26;204(12):2899-912. PubMed PMID: 17984305. Pubmed Central PMCID: 2118531. 
Epub 2007/11/07.
42. Hernan MA, Olek MJ, Ascherio A. Cigarette smoking and incidence of multiple sclerosis. 
Am J Epidemiol. 2001 Jul 1;154(1):69-74. PubMed PMID: 11427406. Epub 2001/06/28.
43. Mikaeloff Y, Caridade G, Tardieu M, Suissa S. Parental smoking at home and the risk 
of childhood-onset multiple sclerosis in children. Brain. 2007 Oct;130(Pt 10):2589-95. 
PubMed PMID: 17827175. Epub 2007/09/11.
44. Hedstrom AK, Baarnhielm M, Olsson T, Alfredsson L. Exposure to environmental to-
bacco smoke is associated with increased risk for multiple sclerosis. Mult Scler. 2011 
Jul;17(7):788-93. PubMed PMID: 21372120. Epub 2011/03/05.
45. Di Pauli F, Reindl M, Ehling R, Schautzer F, Gneiss C, Lutterotti A, et al. Smoking is a 
risk factor for early conversion to clinically definite multiple sclerosis. Mult Scler. 2008 
Sep;14(8):1026-30. PubMed PMID: 18632775. Epub 2008/07/18.
82
46. Zivadinov R, Weinstock-Guttman B, Hashmi K, Abdelrahman N, Stosic M, Dwyer M, 
et al. Smoking is associated with increased lesion volumes and brain atrophy in multiple 
sclerosis. Neurology. 2009 Aug 18;73(7):504-10. PubMed PMID: 19687451. Pubmed 
Central PMCID: 2833095. Epub 2009/08/19.
47. Ascherio A, Munger KL, Simon KC. Vitamin D and multiple sclerosis. Lancet Neurol. 
2010 Jun;9(6):599-612. PubMed PMID: 20494325. Epub 2010/05/25.
48. Lucas RM, Ponsonby AL. Considering the potential benefits as well as adverse effects of 
sun exposure: can all the potential benefits be provided by oral vitamin D supplementa-
tion? Prog Biophys Mol Biol. 2006 Sep;92(1):140-9. PubMed PMID: 16616326.
49. Becklund BR, Severson KS, Vang SV, DeLuca HF. UV radiation suppresses experimental 
autoimmune encephalomyelitis independent of vitamin D production. Proc Natl Acad Sci 
U S A. 2010 Apr 6;107(14):6418-23. PubMed PMID: 20308557. Pubmed Central PM-
CID: 2851981.
50. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin 
D levels and risk of multiple sclerosis. JAMA. 2006 Dec 20;296(23):2832-8. PubMed 
PMID: 17179460. Epub 2006/12/21.
51. Simpson S, Jr., Taylor B, Blizzard L, Ponsonby AL, Pittas F, Tremlett H, et al. Higher 
25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neu-
rol. 2010 Aug;68(2):193-203. PubMed PMID: 20695012. Epub 2010/08/10.
52. Burton JM, Kimball S, Vieth R, Bar-Or A, Dosch HM, Cheung R, et al. A phase I/II dose-
escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology. 2010 Jun 
8;74(23):1852-9. PubMed PMID: 20427749. Pubmed Central PMCID: 2882221. Epub 
2010/04/30.
53. Ramagopalan SV, Heger A, Berlanga AJ, Maugeri NJ, Lincoln MR, Burrell A, et al. A 
ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with di-
sease and evolution. Genome Res. 2010 Oct;20(10):1352-60. PubMed PMID: 20736230. 
Pubmed Central PMCID: 2945184.
54. Ramagopalan SV, Maugeri NJ, Handunnetthi L, Lincoln MR, Orton SM, Dyment DA, et 
al. Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1*1501 
is regulated by vitamin D. PLoS Genet. 2009 Feb;5(2):e1000369. PubMed PMID: 
19197344. Pubmed Central PMCID: 2627899.
55. Hedstrom AK, Sundqvist E, Baarnhielm M, Nordin N, Hillert J, Kockum I, et al. Smoking 
and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis. 
Brain. 2011 Mar;134(Pt 3):653-64. PubMed PMID: 21303861.
56. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort 
with twenty-five years of follow-up. Brain. 1993 Feb;116 ( Pt 1):117-34. PubMed PMID: 
8453453. Epub 1993/02/01.
57. Miller DH, Chard DT, Ciccarelli O. Clinically isolated syndromes. Lancet Neurol. 2012 
Feb;11(2):157-69. PubMed PMID: 22265211.
58. Glad SB, Aarseth JH, Nyland H, Riise T, Myhr KM. Benign multiple sclerosis: a need for 
a consensus. Acta Neurol Scand Suppl. 2010 (190):44-50. PubMed PMID: 20586735.
59. Correale J, Ysrraelit MC, Fiol MP. Benign multiple sclerosis: does it exist? Curr Neurol 
Neurosci Rep. 2012 Oct;12(5):601-9. PubMed PMID: 22777531.
60. Correale J, Peirano I, Romano L. Benign multiple sclerosis: a new definition of this entity 
is needed. Mult Scler. 2012 Feb;18(2):210-8. PubMed PMID: 21865415.
83
61. Confavreux C, Vukusic S. Age at disability milestones in multiple sclerosis. Brain. 2006 
Mar;129(Pt 3):595-605. PubMed PMID: 16415309. Epub 2006/01/18.
62. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diag-
nostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983 
Mar;13(3):227-31. PubMed PMID: 6847134. Epub 1983/03/01.
63. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic 
criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011 
Feb;69(2):292-302. PubMed PMID: 21387374. Pubmed Central PMCID: 3084507. Epub 
2011/03/10.
64. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an 
international survey. National Multiple Sclerosis Society (USA) Advisory Committee on 
Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996 Apr;46(4):907-11. 
PubMed PMID: 8780061. Epub 1996/04/01.
65. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond 
to interferons. Annu Rev Biochem. 1998;67:227-64. PubMed PMID: 9759489. Epub 
1998/10/06.
66. Prat A, Biernacki K, Antel JP. Th1 and Th2 lymphocyte migration across the human 
BBB is specifically regulated by interferon beta and copolymer-1. J Autoimmun. 2005 
Mar;24(2):119-24. PubMed PMID: 15829404. Epub 2005/04/15.
67. Kieseier BC. The mechanism of action of interferon-beta in relapsing multiple sclerosis. 
CNS Drugs. 2011 Jun 1;25(6):491-502. PubMed PMID: 21649449. Epub 2011/06/09.
68. Mirandola SR, Hallal DE, Farias AS, Oliveira EC, Brandao CO, Ruocco HH, et al. Inter-
feron-beta modifies the peripheral blood cell cytokine secretion in patients with multiple 
sclerosis. Int Immunopharmacol. 2009 Jul;9(7-8):824-30. PubMed PMID: 19289181. 
Epub 2009/03/18.
69. Graber JJ, McGraw CA, Kimbrough D, Dhib-Jalbut S. Overlapping and distinct me-
chanisms of action of multiple sclerosis therapies. Clin Neurol Neurosurg. 2010 
Sep;112(7):583-91. PubMed PMID: 20627553. Epub 2010/07/16.
70. Pittock SJ. Interferon beta in multiple sclerosis: how much BENEFIT? Lancet. 2007 Aug 
4;370(9585):363-4. PubMed PMID: 17678997. Epub 2007/08/07.
71. Li DK, Zhao GJ, Paty DW. Randomized controlled trial of interferon-beta-1a in secon-
dary progressive MS: MRI results. Neurology. 2001 Jun 12;56(11):1505-13. PubMed 
PMID: 11402107. Epub 2001/06/13.
72. Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF, et al. 
Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neuro-
logy. 2002 Sep 10;59(5):679-87. PubMed PMID: 12221157. Epub 2002/09/11.
73. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results 
of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple 
Sclerosis Study Group. Neurology. 1993 Apr;43(4):655-61. PubMed PMID: 8469318.
74. Panitch H, Miller A, Paty D, Weinshenker B, North American Study Group on Interferon 
beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: 
results from a 3-year controlled study. Neurology. 2004 Nov 23;63(10):1788-95. PubMed 
PMID: 15557491.
75. Giovannoni G, Southam E, Waubant E. Systematic review of disease-modifying therapies 
to assess unmet needs in multiple sclerosis: tolerability and adherence. Mult Scler. 2012 
Jul;18(7):932-46. PubMed PMID: 22249762. Epub 2012/01/18.
84
76. Hegen H, Schleiser M, Gneiss C, Di Pauli F, Ehling R, Kuenz B, et al. Persistency of 
neutralizing antibodies depends on titer and interferon-beta preparation. Mult Scler. 2012 
May;18(5):610-5. PubMed PMID: 22013146.
77. Killestein J, Polman CH. Determinants of interferon beta efficacy in patients with mul-
tiple sclerosis. Nat Rev Neurol. 2011 Apr;7(4):221-8. PubMed PMID: 21364522. Epub 
2011/03/03.
78. Carter NJ, Keating GM. Glatiramer acetate: a review of its use in relapsing-remitting 
multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis. Drugs. 
2010 Aug 20;70(12):1545-77. PubMed PMID: 20687620. Epub 2010/08/07.
79. Blanchette F, Neuhaus O. Glatiramer acetate: evidence for a dual mechanism of action. J 
Neurol. 2008 Mar;255 Suppl 1:26-36. PubMed PMID: 18317674. Epub 2008/04/09.
80. Hestvik AL, Skorstad G, Price DA, Vartdal F, Holmoy T. Multiple sclerosis: glatiramer 
acetate induces anti-inflammatory T cells in the cerebrospinal fluid. Mult Scler. 2008 
Jul;14(6):749-58. PubMed PMID: 18611988. Epub 2008/07/10.
81. Brenner T, Arnon R, Sela M, Abramsky O, Meiner Z, Riven-Kreitman R, et al. Humoral 
and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with 
Copaxone. J Neuroimmunol. 2001 Apr 2;115(1-2):152-60. PubMed PMID: 11282165. 
Epub 2001/04/03.
82. Teitelbaum D, Brenner T, Abramsky O, Aharoni R, Sela M, Arnon R. Antibodies to glati-
ramer acetate do not interfere with its biological functions and therapeutic efficacy. Mult 
Scler. 2003 Dec;9(6):592-9. PubMed PMID: 14664472. Epub 2003/12/11.
83. Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, et al. Comparison of 
subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple 
sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): 
a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008 Oct;7(10):903-
14. PubMed PMID: 18789766. Epub 2008/09/16.
84. Cadavid D, Wolansky LJ, Skurnick J, Lincoln J, Cheriyan J, Szczepanowski K, et al. Ef-
ficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in 
the BECOME study. Neurology. 2009 Jun 9;72(23):1976-83. PubMed PMID: 19279320. 
Epub 2009/03/13.
85. O’Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, et al. 250 microg or 
500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting 
multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009 
Oct;8(10):889-97. PubMed PMID: 19729344. Epub 2009/09/05.
86. Bornstein MB, Miller A, Slagle S, Weitzman M, Drexler E, Keilson M, et al. A placebo-
controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progres-
sive multiple sclerosis. Neurology. 1991 Apr;41(4):533-9. PubMed PMID: 2011253.
87. Wolinsky JS, Narayana PA, O’Connor P, Coyle PK, Ford C, Johnson K, et al. Glatiramer 
acetate in primary progressive multiple sclerosis: results of a multinational, multicen-
ter, double-blind, placebo-controlled trial. Ann Neurol. 2007 Jan;61(1):14-24. PubMed 
PMID: 17262850.
88. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 
1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: 
results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 
1 Multiple Sclerosis Study Group. Neurology. 1995 Jul;45(7):1268-76. PubMed PMID: 
7617181. Epub 1995/07/01.
85
89. Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A 
randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N 
Engl J Med. 2006 Mar 2;354(9):899-910. PubMed PMID: 16510744. Epub 2006/03/03.
90. Vermersch P, Kappos L, Gold R, Foley JF, Olsson T, Cadavid D, et al. Clinical outcomes 
of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology. 2011 
May 17;76(20):1697-704. PubMed PMID: 21576685. Epub 2011/05/18.
91. Chataway J, Miller DH. Natalizumab therapy for multiple sclerosis. Neurotherapeutics. 
2013 Jan;10(1):19-28. PubMed PMID: 23307290. Pubmed Central PMCID: 3557363. 
Epub 2013/01/12.
92. Scott LJ, Figgitt DP. Mitoxantrone: a review of its use in multiple sclerosis. CNS Drugs. 
2004;18(6):379-96. PubMed PMID: 15089110. Epub 2004/04/20.
93. Edan G, Miller D, Clanet M, Confavreux C, Lyon-Caen O, Lubetzki C, et al. Therapeutic 
effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a ran-
domised multicentre study of active disease using MRI and clinical criteria. J Neurol 
Neurosurg Psychiatry. 1997 Feb;62(2):112-8. PubMed PMID: 9048709. Pubmed Central 
PMCID: 486720. Epub 1997/02/01.
94. Hartung HP, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey SP, et al. Mi-
toxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, rando-
mised, multicentre trial. Lancet. 2002 Dec 21-28;360(9350):2018-25. PubMed PMID: 
12504397. Epub 2002/12/31.
95. Marriott JJ, Miyasaki JM, Gronseth G, O’Connor PW, Therapeutics, Technology Assess-
ment Subcommittee of the American Academy of N. Evidence Report: The efficacy and 
safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the 
Therapeutics and Technology Assessment Subcommittee of the American Academy of 
Neurology. Neurology. 2010 May 4;74(18):1463-70. PubMed PMID: 20439849. Pubmed 
Central PMCID: 2871006. Epub 2010/05/05.
96. MS-association. Ts. Criteria for MS-treatment hwms, 2012). aa.
97. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in 
vivo cytotoxicity against tumor targets. Nat Med. 2000 Apr;6(4):443-6. PubMed PMID: 
10742152. Epub 2000/03/31.
98. Browning JL. B cells move to centre stage: novel opportunities for autoimmune disease 
treatment. Nat Rev Drug Discov. 2006 Jul;5(7):564-76. PubMed PMID: 16816838. Epub 
2006/07/04.
99. Dalakas MC. B cells as therapeutic targets in autoimmune neurological disorders. Nat 
Clin Pract Neurol. 2008 Oct;4(10):557-67. PubMed PMID: 18813230. Epub 2008/09/25.
100. Shlomchik MJ, Craft JE, Mamula MJ. From T to B and back again: positive feedback 
in systemic autoimmune disease. Nat Rev Immunol. 2001 Nov;1(2):147-53. PubMed 
PMID: 11905822. Epub 2002/03/22.
101. Petereit HF, Rubbert-Roth A. Rituximab levels in cerebrospinal fluid of patients with 
neurological autoimmune disorders. Mult Scler. 2009 Feb;15(2):189-92. PubMed PMID: 
18971221. Epub 2008/10/31.
102. Kitsos DK, Tsiodras S, Stamboulis E, Voumvourakis KI. Rituximab and multiple sclero-
sis. Clin Neuropharmacol. 2012 Mar-Apr;35(2):90-6. PubMed PMID: 22421587. Epub 
2012/03/17.
86
103. Naismith RT, Piccio L, Lyons JA, Lauber J, Tutlam NT, Parks BJ, et al. Rituximab add-on 
therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neuro-
logy. 2010 Jun 8;74(23):1860-7. PubMed PMID: 20530322. Pubmed Central PMCID: 
2882224.
104. Hawker K, O’Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, et al. Rituximab 
in patients with primary progressive multiple sclerosis: results of a randomized double-
blind placebo-controlled multicenter trial. Ann Neurol. 2009 Oct;66(4):460-71. PubMed 
PMID: 19847908. Epub 2009/10/23.
105. Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: 
an overview. Brain Pathol. 2007 Apr;17(2):210-8. PubMed PMID: 17388952. Epub 
2007/03/29.
106. Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the 
newly forming lesion. Ann Neurol. 2004 Apr;55(4):458-68. PubMed PMID: 15048884.
107. Prineas JW, Wright RG. Macrophages, lymphocytes, and plasma cells in the perivascular 
compartment in chronic multiple sclerosis. Lab Invest. 1978 Apr;38(4):409-21. PubMed 
PMID: 205724.
108. Cannella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis 
lesions. Ann Neurol. 1995 Apr;37(4):424-35. PubMed PMID: 7536402. Epub 1995/04/01.
109. Huang D, Han Y, Rani MR, Glabinski A, Trebst C, Sorensen T, et al. Chemokines and 
chemokine receptors in inflammation of the nervous system: manifold roles and exqui-
site regulation. Immunol Rev. 2000 Oct;177:52-67. PubMed PMID: 11138785. Epub 
2001/01/04.
110. Hochmeister S, Grundtner R, Bauer J, Engelhardt B, Lyck R, Gordon G, et al. Dysferlin 
is a new marker for leaky brain blood vessels in multiple sclerosis. J Neuropathol Exp 
Neurol. 2006 Sep;65(9):855-65. PubMed PMID: 16957579. Epub 2006/09/08.
111. Kwon EE, Prineas JW. Blood-brain barrier abnormalities in longstanding multiple 
sclerosis lesions. An immunohistochemical study. J Neuropathol Exp Neurol. 1994 
Nov;53(6):625-36. PubMed PMID: 7964903. Epub 1994/11/01.
112. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the 
lesions of multiple sclerosis. N Engl J Med. 1998 Jan 29;338(5):278-85. PubMed PMID: 
9445407. Epub 1998/01/29.
113. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple 
sclerosis lesions. Brain. 1997 Mar;120 ( Pt 3):393-9. PubMed PMID: 9126051. Epub 
1997/03/01.
114. Allen IV, McQuaid S, Mirakhur M, Nevin G. Pathological abnormalities in the normal-
appearing white matter in multiple sclerosis. Neurol Sci. 2001 Apr;22(2):141-4. PubMed 
PMID: 11603615. Epub 2001/10/18.
115. Evangelou N, DeLuca GC, Owens T, Esiri MM. Pathological study of spinal cord atrophy 
in multiple sclerosis suggests limited role of local lesions. Brain. 2005 Jan;128(Pt 1):29-
34. PubMed PMID: 15548559.
116. Love S. Demyelinating diseases. J Clin Pathol. 2006 Nov;59(11):1151-9. PubMed PMID: 
17071802. Pubmed Central PMCID: 1860500.
117. Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010 
Jan;119(1):7-35. PubMed PMID: 20012068. Pubmed Central PMCID: 2799634.
87
118. Voskuhl RR, Peterson RS, Song B, Ao Y, Morales LB, Tiwari-Woodruff S, et al. Reac-
tive astrocytes form scar-like perivascular barriers to leukocytes during adaptive immune 
inflammation of the CNS. J Neurosci. 2009 Sep 16;29(37):11511-22. PubMed PMID: 
19759299. Pubmed Central PMCID: 2768309. Epub 2009/09/18.
119. Silver J, Miller JH. Regeneration beyond the glial scar. Nat Rev Neurosci. 2004 
Feb;5(2):146-56. PubMed PMID: 14735117.
120. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogen-
eity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann 
Neurol. 2000 Jun;47(6):707-17. PubMed PMID: 10852536. Epub 2000/06/14.
121. Leussink VI, Lehmann HC, Meyer zu Horste G, Hartung HP, Stuve O, Kieseier BC. 
Rituximab induces clinical stabilization in a patient with fulminant multiple sclero-
sis not responding to natalizumab. Evidence for disease heterogeneity. J Neurol. 2008 
Sep;255(9):1436-8. PubMed PMID: 18685916.
122. Gold R, Linington C. Devic’s disease: bridging the gap between laboratory and clinic. 
Brain. 2002 Jul;125(Pt 7):1425-7. PubMed PMID: 12076994.
123. Peterson JW, Bo L, Mork S, Chang A, Trapp BD. Transected neurites, apoptotic neu-
rons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol. 2001 
Sep;50(3):389-400. PubMed PMID: 11558796. Epub 2001/09/18.
124. Calabrese M, Gallo P. Magnetic resonance evidence of cortical onset of multiple sclerosis. 
Mult Scler. 2009 Aug;15(8):933-41. PubMed PMID: 19667021. Epub 2009/08/12.
125. Lucchinetti CF, Popescu BF, Bunyan RF, Moll NM, Roemer SF, Lassmann H, et al. In-
flammatory cortical demyelination in early multiple sclerosis. N Engl J Med. 2011 Dec 
8;365(23):2188-97. PubMed PMID: 22150037. Pubmed Central PMCID: 3282172. Epub 
2011/12/14.
126. Howell OW, Reeves CA, Nicholas R, Carassiti D, Radotra B, Gentleman SM, et al. Me-
ningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. 
Brain. 2011 Sep;134(Pt 9):2755-71. PubMed PMID: 21840891. Epub 2011/08/16.
127. Popescu BF, Lucchinetti CF. Meningeal and cortical grey matter pathology in multiple 
sclerosis. BMC Neurol. 2012;12:11. PubMed PMID: 22397318. Pubmed Central PM-
CID: 3315403. Epub 2012/03/09.
128. Wegner C, Esiri MM, Chance SA, Palace J, Matthews PM. Neocortical neuronal, synap-
tic, and glial loss in multiple sclerosis. Neurology. 2006 Sep 26;67(6):960-7. PubMed 
PMID: 17000961. Epub 2006/09/27.
129. Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. Detection of ectopic B-
cell follicles with germinal centers in the meninges of patients with secondary progres-
sive multiple sclerosis. Brain Pathol. 2004 Apr;14(2):164-74. PubMed PMID: 15193029. 
Epub 2004/06/15.
130. Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, et al. Meningeal B-
cell follicles in secondary progressive multiple sclerosis associate with early onset of di-
sease and severe cortical pathology. Brain. 2007 Apr;130(Pt 4):1089-104. PubMed PMID: 
17438020. Epub 2007/04/18.
131. Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and 
pathogenesis. Nat Rev Neurol. 2012 Nov 5;8(11):647-56. PubMed PMID: 23007702.
88
132. Bjartmar C, Wujek JR, Trapp BD. Axonal loss in the pathology of MS: consequences for 
understanding the progressive phase of the disease. J Neurol Sci. 2003 Feb 15;206(2):165-
71. PubMed PMID: 12559505.
133. Frohman EM, Filippi M, Stuve O, Waxman SG, Corboy J, Phillips JT, et al. Characteri-
zing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses 
for future directions. Arch Neurol. 2005 Sep;62(9):1345-56. PubMed PMID: 16157741.
134. De Groot CJ, Bergers E, Kamphorst W, Ravid R, Polman CH, Barkhof F, et al. Post-
mortem MRI-guided sampling of multiple sclerosis brain lesions: increased yield of ac-
tive demyelinating and (p)reactive lesions. Brain. 2001 Aug;124(Pt 8):1635-45. PubMed 
PMID: 11459754. Epub 2001/07/19.
135. Czeh M, Gressens P, Kaindl AM. The yin and yang of microglia. Dev Neurosci. 2011;33(3-
4):199-209. PubMed PMID: 21757877. Epub 2011/07/16.
136. Kornek B, Storch MK, Bauer J, Djamshidian A, Weissert R, Wallstroem E, et al. Distribu-
tion of a calcium channel subunit in dystrophic axons in multiple sclerosis and experimen-
tal autoimmune encephalomyelitis. Brain. 2001 Jun;124(Pt 6):1114-24. PubMed PMID: 
11353727.
137. Ouardouz M, Coderre E, Basak A, Chen A, Zamponi GW, Hameed S, et al. Glutamate 
receptors on myelinated spinal cord axons: I. GluR6 kainate receptors. Ann Neurol. 2009 
Feb;65(2):151-9. PubMed PMID: 19224535. Pubmed Central PMCID: 2902553.
138. Craner MJ, Newcombe J, Black JA, Hartle C, Cuzner ML, Waxman SG. Molecular chan-
ges in neurons in multiple sclerosis: altered axonal expression of Nav1.2 and Nav1.6 
sodium channels and Na+/Ca2+ exchanger. Proc Natl Acad Sci U S A. 2004 May 
25;101(21):8168-73. PubMed PMID: 15148385. Pubmed Central PMCID: 419575.
139. Black JA, Liu S, Hains BC, Saab CY, Waxman SG. Long-term protection of central ax-
ons with phenytoin in monophasic and chronic-relapsing EAE. Brain. 2006 Dec;129(Pt 
12):3196-208. PubMed PMID: 16931536.
140. Trapp BD, Stys PK. Virtual hypoxia and chronic necrosis of demyelinated axons in mul-
tiple sclerosis. Lancet Neurol. 2009 Mar;8(3):280-91. PubMed PMID: 19233038.
141. Witte ME, Geurts JJ, de Vries HE, van der Valk P, van Horssen J. Mitochondrial dysfun-
ction: a potential link between neuroinflammation and neurodegeneration? Mitochondri-
on. 2010 Aug;10(5):411-8. PubMed PMID: 20573557.
142. Zambonin JL, Zhao C, Ohno N, Campbell GR, Engeham S, Ziabreva I, et al. Increased 
mitochondrial content in remyelinated axons: implications for multiple sclerosis. Brain. 
2011 Jul;134(Pt 7):1901-13. PubMed PMID: 21705418. Pubmed Central PMCID: 
3122369.
143. Witte ME, Bo L, Rodenburg RJ, Belien JA, Musters R, Hazes T, et al. Enhanced number 
and activity of mitochondria in multiple sclerosis lesions. J Pathol. 2009 Oct;219(2):193-
204. PubMed PMID: 19591199.
144. Mahad DJ, Ziabreva I, Campbell G, Lax N, White K, Hanson PS, et al. Mitochondrial 
changes within axons in multiple sclerosis. Brain. 2009 May;132(Pt 5):1161-74. PubMed 
PMID: 19293237. Pubmed Central PMCID: 3605917.
145. Mahad D, Lassmann H, Turnbull D. Review: Mitochondria and disease progression in 
multiple sclerosis. Neuropathol Appl Neurobiol. 2008 Dec;34(6):577-89. PubMed PMID: 
19076696. Pubmed Central PMCID: 2981078.
89
146. Bolanos JP, Almeida A, Stewart V, Peuchen S, Land JM, Clark JB, et al. Nitric oxide-
mediated mitochondrial damage in the brain: mechanisms and implications for neurod-
egenerative diseases. J Neurochem. 1997 Jun;68(6):2227-40. PubMed PMID: 9166714.
147. Smith KJ, Kapoor R, Felts PA. Demyelination: the role of reactive oxygen and nitrogen 
species. Brain Pathol. 1999 Jan;9(1):69-92. PubMed PMID: 9989453.
148. Chang A, Tourtellotte WW, Rudick R, Trapp BD. Premyelinating oligodendrocytes in 
chronic lesions of multiple sclerosis. N Engl J Med. 2002 Jan 17;346(3):165-73. PubMed 
PMID: 11796850.
149. Veto S, Acs P, Bauer J, Lassmann H, Berente Z, Setalo G, Jr., et al. Inhibiting poly(ADP-
ribose) polymerase: a potential therapy against oligodendrocyte death. Brain. 2010 
Mar;133(Pt 3):822-34. PubMed PMID: 20157013. Pubmed Central PMCID: 2964508.
150. Lopes KO, Sparks DL, Streit WJ. Microglial dystrophy in the aged and Alzheimer’s di-
sease brain is associated with ferritin immunoreactivity. Glia. 2008 Aug 1;56(10):1048-
60. PubMed PMID: 18442088.
151. Zhang X, Haaf M, Todorich B, Grosstephan E, Schieremberg H, Surguladze N, et al. 
Cytokine toxicity to oligodendrocyte precursors is mediated by iron. Glia. 2005 Nov 
15;52(3):199-208. PubMed PMID: 15968631.
152. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability 
status scale (EDSS). Neurology. 1983 Nov;33(11):1444-52. PubMed PMID: 6685237. 
Epub 1983/11/01.
153. Amato MP, Fratiglioni L, Groppi C, Siracusa G, Amaducci L. Interrater reliability in as-
sessing functional systems and disability on the Kurtzke scale in multiple sclerosis. Arch 
Neurol. 1988 Jul;45(7):746-8. PubMed PMID: 3390030. Epub 1988/07/01.
154. Goodkin DE, Cookfair D, Wende K, Bourdette D, Pullicino P, Scherokman B, et al. Inter- 
and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disabi-
lity Status Scale (EDSS). Multiple Sclerosis Collaborative Research Group. Neurology. 
1992 Apr;42(4):859-63. PubMed PMID: 1565242. Epub 1992/04/01.
155. Noseworthy JH, Vandervoort MK, Wong CJ, Ebers GC. Interrater variability with the 
Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple 
sclerosis clinical trial. The Canadian Cooperation MS Study Group. Neurology. 1990 
Jun;40(6):971-5. PubMed PMID: 2189084. Epub 1990/06/01.
156. Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S, et al. Mul-
tiple Sclerosis Severity Score: using disability and disease duration to rate disease severi-
ty. Neurology. 2005 Apr 12;64(7):1144-51. PubMed PMID: 15824338. Epub 2005/04/13.
157. Poser S, Ritter G, Bauer HJ, Grosse-Wilde H, Kuwert EK, Raun NE. HLA-antigens 
and the prognosis of multiple sclerosis. J Neurol. 1981;225(3):219-21. PubMed PMID: 
6167687. Epub 1981/01/01.
158. Trojano M, Liguori M, Bosco Zimatore G, Bugarini R, Avolio C, Paolicelli D, et al. Age-
related disability in multiple sclerosis. Ann Neurol. 2002 Apr;51(4):475-80. PubMed 
PMID: 11921053. Epub 2002/03/29.
159. Fischer JS, Rudick RA, Cutter GR, Reingold SC. The Multiple Sclerosis Functional 
Composite Measure (MSFC): an integrated approach to MS clinical outcome assess-
ment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler. 1999 
Aug;5(4):244-50. PubMed PMID: 10467383. Epub 1999/09/01.
90
160. Cohen JA, Fischer JS, Bolibrush DM, Jak AJ, Kniker JE, Mertz LA, et al. Intrarater and 
interrater reliability of the MS functional composite outcome measure. Neurology. 2000 
Feb 22;54(4):802-6. PubMed PMID: 10690966. Epub 2000/02/26.
161. Bosma LV, Kragt JJ, Brieva L, Khaleeli Z, Montalban X, Polman CH, et al. The search for 
responsive clinical endpoints in primary progressive multiple sclerosis. Mult Scler. 2009 
Jun;15(6):715-20. PubMed PMID: 19383646. Epub 2009/04/23.
162. Bosma L, Kragt J, Polman C, Uitdehaag B. Walking speed, rather than Expanded Disa-
bility Status Scale, relates to long-term patient-reported impact in progressive MS. Mult 
Scler. 2012 Aug 20. PubMed PMID: 22907939. Epub 2012/08/22.
163. Kragt JJ, Thompson AJ, Montalban X, Tintore M, Rio J, Polman CH, et al. Responsive-
ness and predictive value of EDSS and MSFC in primary progressive MS. Neurology. 
2008 Mar 25;70(13 Pt 2):1084-91. PubMed PMID: 18184917. Epub 2008/01/11.
164. Bosma LV, Kragt JJ, Knol DL, Polman CH, Uitdehaag BM. Clinical scales in progressive 
MS: predicting long-term disability. Mult Scler. 2012 Mar;18(3):345-50. PubMed PMID: 
21868487. Epub 2011/08/27.
165. Polman CH, Rudick RA. The multiple sclerosis functional composite: a clinically mea-
ningful measure of disability. Neurology. 2010 Apr 27;74 Suppl 3:S8-15. PubMed PMID: 
20421572. Epub 2010/05/07.
166. van Walderveen MA, Kamphorst W, Scheltens P, van Waesberghe JH, Ravid R, Valk J, 
et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in 
multiple sclerosis. Neurology. 1998 May;50(5):1282-8. PubMed PMID: 9595975. Epub 
1998/05/22.
167. Rovaris M, Comi G, Rocca MA, Cercignani M, Colombo B, Santuccio G, et al. Rele-
vance of hypointense lesions on fast fluid-attenuated inversion recovery MR images as a 
marker of disease severity in cases of multiple sclerosis. AJNR Am J Neuroradiol. 1999 
May;20(5):813-20. PubMed PMID: 10369351. Epub 1999/06/16.
168. Bruck W, Bitsch A, Kolenda H, Bruck Y, Stiefel M, Lassmann H. Inflammatory central 
nervous system demyelination: correlation of magnetic resonance imaging findings with 
lesion pathology. Ann Neurol. 1997 Nov;42(5):783-93. PubMed PMID: 9392578. Epub 
1997/12/10.
169. Meier DS, Weiner HL, Guttmann CR. MR imaging intensity modeling of damage and 
repair in multiple sclerosis: relationship of short-term lesion recovery to progression and 
disability. AJNR Am J Neuroradiol. 2007 Nov-Dec;28(10):1956-63. PubMed PMID: 
17998417. Epub 2007/11/14.
170. Bitar R, Leung G, Perng R, Tadros S, Moody AR, Sarrazin J, et al. MR pulse sequences: 
what every radiologist wants to know but is afraid to ask. Radiographics. 2006 Mar-
Apr;26(2):513-37. PubMed PMID: 16549614. Epub 2006/03/22.
171. Minagar A, Gonzalez-Toledo E, Pinkston J, Jaffe SL. Neuroimaging in multiple sclerosis. 
Int Rev Neurobiol. 2005;67:165-201. PubMed PMID: 16291023. Epub 2005/11/18.
172. Filippi M, Yousry T, Baratti C, Horsfield MA, Mammi S, Becker C, et al. Quantitative 
assessment of MRI lesion load in multiple sclerosis. A comparison of conventional spin-
echo with fast fluid-attenuated inversion recovery. Brain. 1996 Aug;119 ( Pt 4):1349-55. 
PubMed PMID: 8813296. Epub 1996/08/01.
173. Zivadinov R, Cox JL. Neuroimaging in multiple sclerosis. Int Rev Neurobiol. 2007;79:449-
74. PubMed PMID: 17531854. Epub 2007/05/29.
91
174. Bilello M, Suri N, Krejza J, Woo JH, Bagley LJ, Mamourian AC, et al. An approach to 
comparing accuracies of two FLAIR MR sequences in the detection of multiple sclerosis 
lesions in the brain in the absence of gold standard. Acad Radiol. 2010 Jun;17(6):686-95. 
PubMed PMID: 20457413. Epub 2010/05/12.
175. Brex PA, O’Riordan JI, Miszkiel KA, Moseley IF, Thompson AJ, Plant GT, et al. Multi-
sequence MRI in clinically isolated syndromes and the early development of MS. Neuro-
logy. 1999 Oct 12;53(6):1184-90. PubMed PMID: 10522870. Epub 1999/10/16.
176. Brex PA, Ciccarelli O, O’Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal 
study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med. 2002 
Jan 17;346(3):158-64. PubMed PMID: 11796849. Epub 2002/01/18.
177. Miller DH, Barkhof F, Nauta JJ. Gadolinium enhancement increases the sensitivity of 
MRI in detecting disease activity in multiple sclerosis. Brain. 1993 Oct;116 ( Pt 5):1077-
94. PubMed PMID: 8221048.
178. Nauta JJ, Thompson AJ, Barkhof F, Miller DH. Magnetic resonance imaging in monito-
ring the treatment of multiple sclerosis patients: statistical power of parallel-groups and 
crossover designs. J Neurol Sci. 1994 Mar;122(1):6-14. PubMed PMID: 8195804.
179. Simon JH. Brain atrophy in multiple sclerosis: what we know and would like to know. 
Mult Scler. 2006 Dec;12(6):679-87. PubMed PMID: 17262994. Epub 2007/02/01.
180. Miller DH, Barkhof F, Frank JA, Parker GJ, Thompson AJ. Measurement of atrophy in 
multiple sclerosis: pathological basis, methodological aspects and clinical relevance. 
Brain. 2002 Aug;125(Pt 8):1676-95. PubMed PMID: 12135961. Epub 2002/07/24.
181. Enzinger C, Fazekas F, Matthews PM, Ropele S, Schmidt H, Smith S, et al. Risk factors 
for progression of brain atrophy in aging: six-year follow-up of normal subjects. Neuro-
logy. 2005 May 24;64(10):1704-11. PubMed PMID: 15911795.
182. Scahill RI, Frost C, Jenkins R, Whitwell JL, Rossor MN, Fox NC. A longitudinal study 
of brain volume changes in normal aging using serial registered magnetic resonance ima-
ging. Arch Neurol. 2003 Jul;60(7):989-94. PubMed PMID: 12873856.
183. De Stefano N, Giorgio A, Battaglini M, Rovaris M, Sormani MP, Barkhof F, et al. As-
sessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. 
Neurology. 2010 Jun 8;74(23):1868-76. PubMed PMID: 20530323. Epub 2010/06/10.
184. Fisniku LK, Chard DT, Jackson JS, Anderson VM, Altmann DR, Miszkiel KA, et al. Gray 
matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol. 2008 
Sep;64(3):247-54. PubMed PMID: 18570297. Epub 2008/06/24.
185. Lycklama G, Thompson A, Filippi M, Miller D, Polman C, Fazekas F, et al. Spinal-
cord MRI in multiple sclerosis. Lancet Neurol. 2003 Sep;2(9):555-62. PubMed PMID: 
12941578. Epub 2003/08/28.
186. Barkhof F, Calabresi PA, Miller DH, Reingold SC. Imaging outcomes for neuroprotection 
and repair in multiple sclerosis trials. Nat Rev Neurol. 2009 May;5(5):256-66. PubMed 
PMID: 19488083. Epub 2009/06/03.
187. Rieckmann P, Altenhofen B, Riegel A, Baudewig J, Felgenhauer K. Soluble adhesion 
molecules (sVCAM-1 and sICAM-1) in cerebrospinal fluid and serum correlate with 
MRI activity in multiple sclerosis. Ann Neurol. 1997 Mar;41(3):326-33. PubMed PMID: 
9066353.
188. Felgenhauer K. Evaluation of molecular size by gel electrophoretic techniques. Hoppe 
Seylers Z Physiol Chem. 1974 Oct;355(10):1281-90. PubMed PMID: 4461630.
92
189. Wen SR, Liu GJ, Feng RN, Gong FC, Zhong H, Duan SR, et al. Increased levels of IL-23 
and osteopontin in serum and cerebrospinal fluid of multiple sclerosis patients. J Neu-
roimmunol. 2012 Mar;244(1-2):94-6. PubMed PMID: 22329905.
190. Vogt MH, Floris S, Killestein J, Knol DL, Smits M, Barkhof F, et al. Osteopontin levels 
and increased disease activity in relapsing-remitting multiple sclerosis patients. J Neu-
roimmunol. 2004 Oct;155(1-2):155-60. PubMed PMID: 15342207.
191. Malmestrom C, Gillett A, Jernas M, Khademi M, Axelsson M, Kockum I, et al. Serum 
levels of LIGHT in MS. Mult Scler. 2012 Oct 4. PubMed PMID: 23037546.
192. Avolio C, Ruggieri M, Giuliani F, Liuzzi GM, Leante R, Riccio P, et al. Serum MMP-2 
and MMP-9 are elevated in different multiple sclerosis subtypes. J Neuroimmunol. 2003 
Mar;136(1-2):46-53. PubMed PMID: 12620642.
193. Eikelenboom MJ, Uitdehaag BM, Petzold A. Blood and CSF Biomarker Dynamics in Mul-
tiple Sclerosis: Implications for Data Interpretation. Mult Scler Int. 2011;2011:823176. 
PubMed PMID: 22096644. Pubmed Central PMCID: 3195856.
194. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spi-
nal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005 Aug 
15;202(4):473-7. PubMed PMID: 16087714. Pubmed Central PMCID: 2212860.
195. Racke MK. Multiple sclerosis: The potassium channel KIR4.1-a potential autoantigen in 
MS. Nat Rev Neurol. 2012 Sep 18. PubMed PMID: 22986435.
196. Lee MK, Cleveland DW. Neuronal intermediate filaments. Annu Rev Neurosci. 
1996;19:187-217. PubMed PMID: 8833441. Epub 1996/01/01.
197. Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degenera-
tion and loss. J Neurol Sci. 2005 Jun 15;233(1-2):183-98. PubMed PMID: 15896809. 
Epub 2005/05/18.
198. Fuchs E, Cleveland DW. A structural scaffolding of intermediate filaments in health 
and disease. Science. 1998 Jan 23;279(5350):514-9. PubMed PMID: 9438837. Epub 
1998/02/07.
199. Teunissen CE, Khalil M. Neurofilaments as biomarkers in multiple sclerosis. Mult Scler. 
2012 May;18(5):552-6. PubMed PMID: 22492131. Epub 2012/04/12.
200. Kim S, Chang R, Teunissen C, Gebremichael Y, Petzold A. Neurofilament stoichiome-
try simulations during neurodegeneration suggest a remarkable self-sufficient and stable 
in vivo protein structure. J Neurol Sci. 2011 Aug 15;307(1-2):132-8. PubMed PMID: 
21601889. Epub 2011/05/24.
201. Studahl M, Rosengren L, Gunther G, Hagberg L. Difference in pathogenesis between 
herpes simplex virus type 1 encephalitis and tick-borne encephalitis demonstrated by 
means of cerebrospinal fluid markers of glial and neuronal destruction. J Neurol. 2000 
Aug;247(8):636-42. PubMed PMID: 11041333. Epub 2000/10/21.
202. Nylen K, Karlsson JE, Blomstrand C, Tarkowski A, Trysberg E, Rosengren LE. Cere-
brospinal fluid neurofilament and glial fibrillary acidic protein in patients with cerebral 
vasculitis. J Neurosci Res. 2002 Mar 15;67(6):844-51. PubMed PMID: 11891800. Epub 
2002/03/14.
203. Constantinescu R, Rosengren L, Johnels B, Zetterberg H, Holmberg B. Consecutive ana-
lyses of cerebrospinal fluid axonal and glial markers in Parkinson’s disease and atypi-
cal Parkinsonian disorders. Parkinsonism Relat Disord. 2010 Feb;16(2):142-5. PubMed 
PMID: 19647470. Epub 2009/08/04.
93
204. Tortelli R, Ruggieri M, Cortese R, D’Errico E, Capozzo R, Leo A, et al. Elevated cere-
brospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a 
possible marker of disease severity and progression. Eur J Neurol. 2012 Dec;19(12):1561-
7. PubMed PMID: 22680408. Epub 2012/06/12.
205. Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C. Patients with amyo-
trophic lateral sclerosis and other neurodegenerative diseases have increased levels of 
neurofilament protein in CSF. J Neurochem. 1996 Nov;67(5):2013-8. PubMed PMID: 
8863508. Epub 1996/11/01.
206. Teunissen CE, Iacobaeus E, Khademi M, Brundin L, Norgren N, Koel-Simmelink MJ, 
et al. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. 
Neurology. 2009 Apr 14;72(15):1322-9. PubMed PMID: 19365053. Epub 2009/04/15.
207. Romme Christensen J, Bornsen L, Khademi M, Olsson T, Jensen PE, Sorensen PS, et al. 
CSF inflammation and axonal damage are increased and correlate in progressive multiple 
sclerosis. Mult Scler. 2012 Nov 24. PubMed PMID: 23178691.
208. Malmestrom C, Haghighi S, Rosengren L, Andersen O, Lycke J. Neurofilament light pro-
tein and glial fibrillary acidic protein as biological markers in MS. Neurology. 2003 Dec 
23;61(12):1720-5. PubMed PMID: 14694036. Epub 2003/12/25.
209. Norgren N, Sundstrom P, Svenningsson A, Rosengren L, Stigbrand T, Gunnarsson M. 
Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology. 2004 
Nov 9;63(9):1586-90. PubMed PMID: 15534240. Epub 2004/11/10.
210. Khalil M, Enzinger C, Langkammer C, Ropele S, Mader A, Trentini A, et al. CSF neuro-
filament and N-acetylaspartate related brain changes in clinically isolated syndrome. Mult 
Scler. 2012 Aug 23. PubMed PMID: 22917689.
211. Petzold A, Eikelenboom MI, Keir G, Polman CH, Uitdehaag BM, Thompson EJ, et al. 
The new global multiple sclerosis severity score (MSSS) correlates with axonal but not 
glial biomarkers. Mult Scler. 2006 Jun;12(3):325-8. PubMed PMID: 16764346.
212. Petzold A, Mondria T, Kuhle J, Rocca MA, Cornelissen J, te Boekhorst P, et al. Evidence 
for acute neurotoxicity after chemotherapy. Ann Neurol. 2010 Dec;68(6):806-15. Pub-
Med PMID: 21194151. Epub 2011/01/05.
213. Petzold A, Keir G, Green AJ, Giovannoni G, Thompson EJ. A specific ELISA for mea-
suring neurofilament heavy chain phosphoforms. J Immunol Methods. 2003 Jul;278(1-
2):179-90. PubMed PMID: 12957406. Epub 2003/09/06.
214. Karlsson JE, Rosengren LE, Haglid KG. Polyclonal antisera to the individual neurofila-
ment triplet proteins: a characterization using ELISA and immunoblotting. J Neurochem. 
1989 Sep;53(3):759-65. PubMed PMID: 2760619. Epub 1989/09/01.
215. Cullen DK, Simon CM, LaPlaca MC. Strain rate-dependent induction of reactive astrog-
liosis and cell death in three-dimensional neuronal-astrocytic co-cultures. Brain Res. 2007 
Jul 16;1158:103-15. PubMed PMID: 17555726. Pubmed Central PMCID: 3179863. Epub 
2007/06/09.
216. Kepes JJ, Perentes E. Glial fibrillary acidic protein in chondrocytes of elastic cartila-
ge in the human epiglottis: an immunohistochemical study with polyvalent and mono-
clonal antibodies. Anat Rec. 1988 Mar;220(3):296-9. PubMed PMID: 3364756. Epub 
1988/03/01.
217. Omary MB, Lugea A, Lowe AW, Pandol SJ. The pancreatic stellate cell: a star on the rise 
in pancreatic diseases. J Clin Invest. 2007 Jan;117(1):50-9. PubMed PMID: 17200706. 
Pubmed Central PMCID: 1716214.
94
218. Reeves SA, Helman LJ, Allison A, Israel MA. Molecular cloning and primary structure of 
human glial fibrillary acidic protein. Proc Natl Acad Sci U S A. 1989 Jul;86(13):5178-82. 
PubMed PMID: 2740350. Pubmed Central PMCID: 297581. Epub 1989/07/01.
219. Eng LF, Vanderhaeghen JJ, Bignami A, Gerstl B. An acidic protein isolated from fi-
brous astrocytes. Brain Res. 1971 May 7;28(2):351-4. PubMed PMID: 5113526. Epub 
1971/05/07.
220. Eng LF, Ghirnikar RS, Lee YL. Glial fibrillary acidic protein: GFAP-thirty-one years 
(1969-2000). Neurochem Res. 2000 Oct;25(9-10):1439-51. PubMed PMID: 11059815. 
Epub 2000/11/04.
221. Wallin A, Blennow K, Rosengren LE. Glial fibrillary acidic protein in the cerebrospinal 
fluid of patients with dementia. Dementia. 1996 Sep-Oct;7(5):267-72. PubMed PMID: 
8872418. Epub 1996/09/01.
222. Tullberg M, Rosengren L, Blomsterwall E, Karlsson JE, Wikkelso C. CSF neurofilament 
and glial fibrillary acidic protein in normal pressure hydrocephalus. Neurology. 1998 
Apr;50(4):1122-7. PubMed PMID: 9566405. Epub 1998/05/05.
223. Rosengren LE, Lycke J, Andersen O. Glial fibrillary acidic protein in CSF of multiple 
sclerosis patients: relation to neurological deficit. J Neurol Sci. 1995 Nov;133(1-2):61-5. 
PubMed PMID: 8583233. Epub 1995/11/01.
224. Nylen K, Ost M, Csajbok LZ, Nilsson I, Blennow K, Nellgard B, et al. Increased serum-
GFAP in patients with severe traumatic brain injury is related to outcome. J Neurol Sci. 
2006 Jan 15;240(1-2):85-91. PubMed PMID: 16266720. Epub 2005/11/04.
225. Nylen K, Csajbok LZ, Ost M, Rashid A, Blennow K, Nellgard B, et al. Serum glial fibril-
lary acidic protein is related to focal brain injury and outcome after aneurysmal subarach-
noid hemorrhage. Stroke. 2007 May;38(5):1489-94. PubMed PMID: 17395862. Epub 
2007/03/31.
226. Tibbling G, Link H, Ohman S. Principles of albumin and IgG analyses in neurological dis-
orders. I. Establishment of reference values. Scand J Clin Lab Invest. 1977 Sep;37(5):385-
90. PubMed PMID: 337459.
227. Reiber H. Cerebrospinal fluid--physiology, analysis and interpretation of protein patterns 
for diagnosis of neurological diseases. Mult Scler. 1998 Jun;4(3):99-107. PubMed PMID: 
9762655. Epub 1998/10/08.
228. Andersson M, Alvarez-Cermeno J, Bernardi G, Cogato I, Fredman P, Frederiksen J, et 
al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol 
Neurosurg Psychiatry. 1994 Aug;57(8):897-902. PubMed PMID: 8057110. Pubmed Cen-
tral PMCID: 1073070. Epub 1994/08/01.
229. Tourtellotte W. On cerebrospinal fluid immunoglobulin-G (IgG) quotients in multiple 
sclerosis and other diseases. A review and a new formula to estimate the amount of IgG 
synthesized per day by the central nervous system. J Neurol Sci. 1970 Mar;10(3):279-304. 
PubMed PMID: 4909729. Epub 1970/03/01.
230. Legler DF, Loetscher M, Roos RS, Clark-Lewis I, Baggiolini M, Moser B. B cell-attrac-
ting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively 
attracts B lymphocytes via BLR1/CXCR5. J Exp Med. 1998 Feb 16;187(4):655-60. Pub-
Med PMID: 9463416. Pubmed Central PMCID: 2212150. Epub 1998/03/28.
231. Ansel KM, Harris RB, Cyster JG. CXCL13 is required for B1 cell homing, natural anti-
body production, and body cavity immunity. Immunity. 2002 Jan;16(1):67-76. PubMed 
PMID: 11825566. Epub 2002/02/05.
95
232. de Leval L, Rickman DS, Thielen C, Reynies A, Huang YL, Delsol G, et al. The gene 
expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link bet-
ween angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. 
Blood. 2007 Jun 1;109(11):4952-63. PubMed PMID: 17284527. Epub 2007/02/08.
233. Ljostad U, Mygland A. CSF B--lymphocyte chemoattractant (CXCL13) in the early diag-
nosis of acute Lyme neuroborreliosis. J Neurol. 2008 May;255(5):732-7. PubMed PMID: 
18344056.
234. Khademi M, Kockum I, Andersson ML, Iacobaeus E, Brundin L, Sellebjerg F, et al. Ce-
rebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the 
disease course. Mult Scler. 2011 Mar;17(3):335-43. PubMed PMID: 21135023. Epub 
2010/12/08.
235. Brettschneider J, Czerwoniak A, Senel M, Fang L, Kassubek J, Pinkhardt E, et al. The 
chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS). PLoS 
One. 2010;5(8):e11986. PubMed PMID: 20700489. Pubmed Central PMCID: 2916843.
236. Sellebjerg F, Bornsen L, Khademi M, Krakauer M, Olsson T, Frederiksen JL, et al. In-
creased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neu-
rology. 2009 Dec 8;73(23):2003-10. PubMed PMID: 19996075. Epub 2009/12/10.
237. Link H. Immunoglobulin G and low molecular weight proteins in human cerebrospinal 
fluid. Chemical and immunological characterisation with special reference to multiple 
sclerosis. Acta Neurol Scand. 1967;43:Suppl 28:1-136. PubMed PMID: 4167871. Epub 
1967/01/01.
238. Olsson T, Kostulas V, Link H. Improved detection of oligoclonal IgG in cerebrospinal 
fluid by isoelectric focusing in agarose, double-antibody peroxidase labeling, and avidin-
biotin amplification. Clin Chem. 1984 Jul;30(7):1246-9. PubMed PMID: 6375900. Epub 
1984/07/01.
239. Kostulas VK, Link H, Lefvert AK. Oligoclonal IgG bands in cerebrospinal fluid. Princip-
les for demonstration and interpretation based on findings in 1114 neurological patients. 
Arch Neurol. 1987 Oct;44(10):1041-4. PubMed PMID: 3632376. Epub 1987/10/01.
240. Cepok S, Rosche B, Grummel V, Vogel F, Zhou D, Sayn J, et al. Short-lived plasma blasts 
are the main B cell effector subset during the course of multiple sclerosis. Brain. 2005 
Jul;128(Pt 7):1667-76. PubMed PMID: 15800022. Epub 2005/04/01.
241. Winges KM, Gilden DH, Bennett JL, Yu X, Ritchie AM, Owens GP. Analysis of multiple 
sclerosis cerebrospinal fluid reveals a continuum of clonally related antibody-secreting 
cells that are predominantly plasma blasts. J Neuroimmunol. 2007 Dec;192(1-2):226-34. 
PubMed PMID: 17997491. Epub 2007/11/13.
242. Kabat EA, Moore DH, Landow H. An Electrophoretic Study of the Protein Components 
in Cerebrospinal Fluid and Their Relationship to the Serum Proteins. J Clin Invest. 1942 
Sep;21(5):571-7. PubMed PMID: 16694947. Pubmed Central PMCID: 435175. Epub 
1942/09/01.
243. Reiber H, Ungefehr S, Jacobi C. The intrathecal, polyspecific and oligoclonal immune 
response in multiple sclerosis. Mult Scler. 1998 Jun;4(3):111-7. PubMed PMID: 9762657. 
Epub 1998/10/08.
244. McLean BN, Luxton RW, Thompson EJ. A study of immunoglobulin G in the cerebrospi-
nal fluid of 1007 patients with suspected neurological disease using isoelectric focusing 
and the Log IgG-Index. A comparison and diagnostic applications. Brain. 1990 Oct;113 ( 
Pt 5):1269-89. PubMed PMID: 2245296. Epub 1990/10/01.
96
245. Tourtellotte WW, Murthy K, Brandes D, Sajben N, Ma B, Comiso P, et al. Schemes to 
eradicate the multiple sclerosis central nervous system immune reaction. Neurology. 1976 
Jun;26(6 PT 2):59-61. PubMed PMID: 179031. Epub 1976/06/01.
246. Lourenco P, Shirani A, Saeedi J, Oger J, Schreiber WE, Tremlett H. Oligoclonal bands 
and cerebrospinal fluid markers in multiple sclerosis: associations with disease course and 
progression. Mult Scler. Sep 7. PubMed PMID: 22961214. Epub 2012/09/11.
247. Rudick RA, Cookfair DL, Simonian NA, Ransohoff RM, Richert JR, Jacobs LD, et al. 
Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing 
multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. J Neuroimmu-
nol. 1999 Jan 1;93(1-2):8-14. PubMed PMID: 10378864. Epub 1999/06/23.
248. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma bio-
markers in Alzheimer disease. Nat Rev Neurol. 2010 Mar;6(3):131-44. PubMed PMID: 
20157306. Epub 2010/02/17.
249. Andreasson U, Portelius E, Andersson ME, Blennow K, Zetterberg H. Aspects of beta-
amyloid as a biomarker for Alzheimer’s disease. Biomark Med. 2007 Jun;1(1):59-78. 
PubMed PMID: 20477461. Epub 2007/06/01.
250. Hu X, Hicks CW, He W, Wong P, Macklin WB, Trapp BD, et al. Bace1 modulates myeli-
nation in the central and peripheral nervous system. Nat Neurosci. 2006 Dec;9(12):1520-
5. PubMed PMID: 17099708. Epub 2006/11/14.
251. Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A, et al. Con-
trol of peripheral nerve myelination by the beta-secretase BACE1. Science. 2006 Oct 
27;314(5799):664-6. PubMed PMID: 16990514. Epub 2006/09/23.
252. Taveggia C, Thaker P, Petrylak A, Caporaso GL, Toews A, Falls DL, et al. Type III neu-
regulin-1 promotes oligodendrocyte myelination. Glia. 2008 Feb;56(3):284-93. PubMed 
PMID: 18080294. Epub 2007/12/15.
253. Zhong Z, Ewers M, Teipel S, Burger K, Wallin A, Blennow K, et al. Levels of beta-secre-
tase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. 
Arch Gen Psychiatry. 2007 Jun;64(6):718-26. PubMed PMID: 17548753.
254. Zetterberg H, Andreasson U, Hansson O, Wu G, Sankaranarayanan S, Andersson ME, 
et al. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch 
Neurol. 2008 Aug;65(8):1102-7. PubMed PMID: 18695061.
255. Guglielmotto M, Aragno M, Autelli R, Giliberto L, Novo E, Colombatto S, et al. The up-
regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress 
and HIF1alpha. J Neurochem. 2009 Feb;108(4):1045-56. PubMed PMID: 19196431.
256. Walker KR, Kang EL, Whalen MJ, Shen Y, Tesco G. Depletion of GGA1 and GGA3 
mediates postinjury elevation of BACE1. J Neurosci. 2012 Jul 25;32(30):10423-37. Pub-
Med PMID: 22836275. Pubmed Central PMCID: 3490187.
257. Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, et al. Biomarkers for 
Alzheimer’s disease: academic, industry and regulatory perspectives. Nat Rev Drug Dis-
cov. 2010 Jul;9(7):560-74. PubMed PMID: 20592748.
258. Mattsson N, Bremell D, Anckarsater R, Blennow K, Anckarsater H, Zetterberg H, et al. 
Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism. BMC Neu-
rol. 2010;10:51. PubMed PMID: 20569437. Pubmed Central PMCID: 2902447. Epub 
2010/06/24.
97
259. Gisslen M, Krut J, Andreasson U, Blennow K, Cinque P, Brew BJ, et al. Amyloid and 
tau cerebrospinal fluid biomarkers in HIV infection. BMC Neurol. 2009;9:63. PubMed 
PMID: 20028512. Pubmed Central PMCID: 2807422. Epub 2009/12/24.
260. Sjogren M, Gisslen M, Vanmechelen E, Blennow K. Low cerebrospinal fluid beta-amy-
loid 42 in patients with acute bacterial meningitis and normalization after treatment. Neu-
rosci Lett. 2001 Nov 13;314(1-2):33-6. PubMed PMID: 11698140. Epub 2001/11/08.
261. Trysberg E, Hoglund K, Svenungsson E, Blennow K, Tarkowski A. Decreased levels of 
soluble amyloid beta-protein precursor and beta-amyloid protein in cerebrospinal fluid 
of patients with systemic lupus erythematosus. Arthritis Res Ther. 2004;6(2):R129-36. 
PubMed PMID: 15059276. Pubmed Central PMCID: 400431. Epub 2004/04/03.
262. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recom-
mended diagnostic criteria for multiple sclerosis: guidelines from the International Panel 
on the diagnosis of multiple sclerosis. Ann Neurol. 2001 Jul;50(1):121-7. PubMed PMID: 
11456302. Epub 2001/07/18.
263. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic 
criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. 
2005 Dec;58(6):840-6. PubMed PMID: 16283615.
264. Gunnarsson M, Malmestrom C, Axelsson M, Sundstrom P, Dahle C, Vrethem M, et al. 
Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann 
Neurol. 2011 Jan;69(1):83-9. PubMed PMID: 21280078. Epub 2011/02/01.
265. Anckarsater R, Vasic N, Jideus L, Kristiansson M, Zetterberg H, Blennow K, et al. Ce-
rebrospinal fluid protein reactions during non-neurological surgery. Acta Neurol Scand. 
2007 Apr;115(4):254-9. PubMed PMID: 17376123.
266. Hochberg MC. Updating the American College of Rheumatology revised criteria for the 
classification of systemic lupus erythematosus. Arthritis Rheum. 1997 Sep;40(9):1725. 
PubMed PMID: 9324032.
267. Breitbach SA, Alexander RW, Daltroy LH, Liang MH, Boll TJ, Karlson EW, et al. Deter-
minants of cognitive performance in systemic lupus erythematosus. J Clin Exp Neuropsy-
chol. 1998 Apr;20(2):157-66. PubMed PMID: 9777469.
268. Trysberg E, Nylen K, Rosengren LE, Tarkowski A. Neuronal and astrocytic damage in 
systemic lupus erythematosus patients with central nervous system involvement. Arthritis 
Rheum. 2003 Oct;48(10):2881-7. PubMed PMID: 14558094.
269. Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, Comabella M, et al. A con-
sensus protocol for the standardization of cerebrospinal fluid collection and biobanking. 
Neurology. 2009 Dec 1;73(22):1914-22. PubMed PMID: 19949037. Pubmed Central 
PMCID: 2839806. Epub 2009/12/02.
270. Rosengren LE, Wikkelso C, Hagberg L. A sensitive ELISA for glial fibrillary acidic pro-
tein: application in CSF of adults. J Neurosci Methods. 1994 Mar;51(2):197-204. PubMed 
PMID: 8051950.
271. Blennow K, Wallin A, Fredman P, Gottfries CG, Karlsson I, Svennerholm L. Intrathecal 
synthesis of immunoglobulins in patients with Alzheimer’s disease. Eur Neuropsychop-
harmacol. 1990 Nov;1(1):79-81. PubMed PMID: 2136219.
272. Wu G, Sankaranarayanan S, Tugusheva K, Kahana J, Seabrook G, Shi XP, et al. Decrease 
in age-adjusted cerebrospinal fluid beta-secretase activity in Alzheimer’s subjects. Clin 
Biochem. 2008 Aug;41(12):986-96. PubMed PMID: 18489907. Epub 2008/05/21.
98
273. Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B, et al. 
Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau 
(Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem. 2005 Feb;51(2):336-
45. PubMed PMID: 15563479. Epub 2004/11/26.
274. Portelius E, Price E, Brinkmalm G, Stiteler M, Olsson M, Persson R, et al. A novel pat-
hway for amyloid precursor protein processing. Neurobiol Aging. 2011 Jun;32(6):1090-8. 
PubMed PMID: 19604603. Epub 2009/07/17.
275. Portelius E, Westman-Brinkmalm A, Zetterberg H, Blennow K. Determination of be-
ta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass 
spectrometry. J Proteome Res. 2006 Apr;5(4):1010-6. PubMed PMID: 16602710. Epub 
2006/04/11.
276. Portelius E, Tran AJ, Andreasson U, Persson R, Brinkmalm G, Zetterberg H, et al. Charac-
terization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipi-
tation procedure followed by mass spectrometry. J Proteome Res. 2007 Nov;6(11):4433-
9. PubMed PMID: 17927230. Epub 2007/10/12.
277. Rocca MA, Messina R, Filippi M. Multiple sclerosis imaging: recent advances. J Neurol. 
Dec 21. PubMed PMID: 23263475. Epub 2012/12/25.
278. Franciotta D, Martino G, Zardini E, Furlan R, Bergamaschi R, Andreoni L, et al. Serum 
and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable di-
sease and undergoing immunomodulatory therapies. J Neuroimmunol. 2001 Apr 2;115(1-
2):192-8. PubMed PMID: 11282170.
279. Malmestrom C, Andersson BA, Haghighi S, Lycke J. IL-6 and CCL2 levels in CSF are 
associated with the clinical course of MS: implications for their possible immunopathoge-
nic roles. J Neuroimmunol. 2006 Jun;175(1-2):176-82. PubMed PMID: 16626811. Epub 
2006/04/22.
280. Sindern E, Niederkinkhaus Y, Henschel M, Ossege LM, Patzold T, Malin JP. Differential 
release of beta-chemokines in serum and CSF of patients with relapsing-remitting multi-
ple sclerosis. Acta Neurol Scand. 2001 Aug;104(2):88-91. PubMed PMID: 11493224.
281. Uccelli A, Pedemonte E, Narciso E, Mancardi G. Biological markers of the inflammatory 
phase of multiple sclerosis. Neurol Sci. 2003 Dec;24 Suppl 5:S271-4. PubMed PMID: 
14652787.
282. Kuhle J, Leppert D, Petzold A, Regeniter A, Schindler C, Mehling M, et al. Neurofilament 
heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neuro-
logy. 2011 Apr 5;76(14):1206-13. PubMed PMID: 21346223.
283. Sellebjerg F, Christiansen M, Nielsen PM, Frederiksen JL. Cerebrospinal fluid measures 
of disease activity in patients with multiple sclerosis. Mult Scler. 1998 Dec;4(6):475-9. 
PubMed PMID: 9987755.
284. Lamers KJ, de Reus HP, Jongen PJ. Myelin basic protein in CSF as indicator of disease 
activity in multiple sclerosis. Mult Scler. 1998 Jun;4(3):124-6. PubMed PMID: 9762659.
285. Lim ET, Sellebjerg F, Jensen CV, Altmann DR, Grant D, Keir G, et al. Acute axonal 
damage predicts clinical outcome in patients with multiple sclerosis. Mult Scler. 2005 
Oct;11(5):532-6. PubMed PMID: 16193890.
286. Lycke JN, Karlsson JE, Andersen O, Rosengren LE. Neurofilament protein in cerebrospi-
nal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychia-
try. 1998 Mar;64(3):402-4. PubMed PMID: 9527161. Pubmed Central PMCID: 2170011. 
Epub 1998/04/04.
99
287. Petzold A, Eikelenboom MJ, Keir G, Grant D, Lazeron RH, Polman CH, et al. Axonal da-
mage accumulates in the progressive phase of multiple sclerosis: three year follow up stu-
dy. J Neurol Neurosurg Psychiatry. 2005 Feb;76(2):206-11. PubMed PMID: 15654034. 
Pubmed Central PMCID: 1739484.
288. Salzer J, Svenningsson A, Sundstrom P. Neurofilament light as a prognostic marker in 
multiple sclerosis. Mult Scler. 2010 Mar;16(3):287-92. PubMed PMID: 20086018. Epub 
2010/01/21.
289. Petzold A, Eikelenboom MJ, Gveric D, Keir G, Chapman M, Lazeron RH, et al. Markers 
for different glial cell responses in multiple sclerosis: clinical and pathological correla-
tions. Brain. 2002 Jul;125(Pt 7):1462-73. PubMed PMID: 12076997.
290. Link H, Huang YM. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an upda-
te on methodology and clinical usefulness. J Neuroimmunol. 2006 Nov;180(1-2):17-28. 
PubMed PMID: 16945427.
291. Koch M, Heersema D, Mostert J, Teelken A, De Keyser J. Cerebrospinal fluid oligoclonal 
bands and progression of disability in multiple sclerosis. Eur J Neurol. 2007 Jul;14(7):797-
800. PubMed PMID: 17594338.
292. Saiz A, Carreras E, Berenguer J, Yague J, Martinez C, Marin P, et al. MRI and CSF oligo-
clonal bands after autologous hematopoietic stem cell transplantation in MS. Neurology. 
2001 Apr 24;56(8):1084-9. PubMed PMID: 11320183.
293. Piccio L, Naismith RT, Trinkaus K, Klein RS, Parks BJ, Lyons JA, et al. Changes in B- 
and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. 
Arch Neurol. 2010 Jun;67(6):707-14. PubMed PMID: 20558389. Pubmed Central PM-
CID: 2918395.
294. Harrer A, Tumani H, Niendorf S, Lauda F, Geis C, Weishaupt A, et al. Cerebrospinal fluid 
parameters of B cell-related activity in patients with active disease during natalizumab 
therapy. Mult Scler. 2012 Oct 23. PubMed PMID: 23093485. Epub 2012/10/25.
295. von Glehn F, Farias AS, de Oliveira AC, Damasceno A, Longhini AL, Oliveira EC, et 
al. Disappearance of cerebrospinal fluid oligoclonal bands after natalizumab treatment 
of multiple sclerosis patients. Mult Scler. 2012 Jul;18(7):1038-41. PubMed PMID: 
22041091.
296. Losseff NA, Wang L, Lai HM, Yoo DS, Gawne-Cain ML, McDonald WI, et al. Progres-
sive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain. 1996 Dec;119 ( Pt 
6):2009-19. PubMed PMID: 9010005. Epub 1996/12/01.
297. Petzold A, Michel P, Stock M, Schluep M. Glial and axonal body fluid biomarkers are 
related to infarct volume, severity, and outcome. J Stroke Cerebrovasc Dis. 2008 Jul-
Aug;17(4):196-203. PubMed PMID: 18589339.
298. Pekny M, Nilsson M. Astrocyte activation and reactive gliosis. Glia. 2005 Jun;50(4):427-
34. PubMed PMID: 15846805.
299. Bar-Or A, Calabresi PA, Arnold D, Markowitz C, Shafer S, Kasper LH, et al. Rituximab 
in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol. 
2008 Mar;63(3):395-400. PubMed PMID: 18383069.
300. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell deple-
tion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008 Feb 
14;358(7):676-88. PubMed PMID: 18272891. Epub 2008/02/15.
100
301. Kappos L, Li D, Calabresi PA, O’Connor P, Bar-Or A, Barkhof F, et al. Ocrelizumab in 
relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multi-
centre trial. Lancet. 2011 Nov 19;378(9805):1779-87. PubMed PMID: 22047971.
302. Prineas JW. Multiple sclerosis: presence of lymphatic capillaries and lymphoid tissue 
in the brain and spinal cord. Science. 1979 Mar 16;203(4385):1123-5. PubMed PMID: 
424741.
303. Vandvik B. Oligoclonal IgG and free light chains in the cerebrospinal fluid of patients 
with multiple sclerosis and infectious diseases of the central nervous system. Scand J Im-
munol. 1977;6(9):913-22. PubMed PMID: 410092.
304. Olsson JE, Link H. Immunoglobulin abnormalities in multiple sclerosis. Relation to clini-
cal parameters: exacerbations and remissions. Arch Neurol. 1973 Jun;28(6):392-9. Pub-
Med PMID: 4121785.
305. Delmotte P, Gonsette R. Biochemical findings in multiple sclerosis IV. Isoelectric focu-
sing of the CSF gamma globulins in multiple sclerosis (262 cases) and other neurological 
diseases (272 cases). J Neurol. 1977 Apr 28;215(1):27-37. PubMed PMID: 67197.
306. Mattson DH, Roos RP, Arnason BG. Isoelectric focusing of IgG eluted from multiple scle-
rosis and subacute sclerosing panencephalitis brains. Nature. 1980 Sep 25;287(5780):335-
7. PubMed PMID: 7421992.
307. Cameron EM, Spencer S, Lazarini J, Harp CT, Ward ES, Burgoon M, et al. Potential of a 
unique antibody gene signature to predict conversion to clinically definite multiple sclero-
sis. J Neuroimmunol. 2009 Aug 18;213(1-2):123-30. PubMed PMID: 19631394. Pubmed 
Central PMCID: 2785005.
308. Ligocki AJ, Lovato L, Xiang D, Guidry P, Scheuermann RH, Willis SN, et al. A unique 
antibody gene signature is prevalent in the central nervous system of patients with multi-
ple sclerosis. J Neuroimmunol. 2010 Sep 14;226(1-2):192-3. PubMed PMID: 20655601. 
Pubmed Central PMCID: 2937103.
309. Meinl E, Krumbholz M, Hohlfeld R. B lineage cells in the inflammatory central nervous 
system environment: migration, maintenance, local antibody production, and therapeutic 
modulation. Ann Neurol. 2006 Jun;59(6):880-92. PubMed PMID: 16718690.
310. Franklin RJ, Ffrench-Constant C. Remyelination in the CNS: from biology to therapy. Nat 
Rev Neurosci. 2008 Nov;9(11):839-55. PubMed PMID: 18931697.
311. Mori F, Rossi S, Sancesario G, Codeca C, Mataluni G, Monteleone F, et al. Cognitive and 
cortical plasticity deficits correlate with altered amyloid-beta CSF levels in multiple scle-
rosis. Neuropsychopharmacology. 2011 Feb;36(3):559-68. PubMed PMID: 20944553. 
Pubmed Central PMCID: 3055691.
312. Mai W, Hu X, Lu Z, Peng F, Wang Y. Cerebrospinal fluid levels of soluble amyloid precur-
sor protein and beta-amyloid 42 in patients with multiple sclerosis, neuromyelitis optica 
and clinically isolated syndrome. J Int Med Res. 2011;39(6):2402-13. PubMed PMID: 
22289560.
313. Dal Bianco A, Bradl M, Frischer J, Kutzelnigg A, Jellinger K, Lassmann H. Multiple 
sclerosis and Alzheimer’s disease. Ann Neurol. 2008 Feb;63(2):174-83. PubMed PMID: 
17924575.
314. Cirrito JR, Kang JE, Lee J, Stewart FR, Verges DK, Silverio LM, et al. Endocytosis is 
required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron. 2008 
Apr 10;58(1):42-51. PubMed PMID: 18400162. Pubmed Central PMCID: 2390913.
101
315. Mattsson N, Johansson P, Hansson O, Wallin A, Johansson JO, Andreasson U, et al. Con-
verging pathways of chromogranin and amyloid metabolism in the brain. J Alzheimers 
Dis. 2010;20(4):1039-49. PubMed PMID: 20413871.
316. Wake H, Lee PR, Fields RD. Control of local protein synthesis and initial events in my-
elination by action potentials. Science. 2011 Sep 16;333(6049):1647-51. PubMed PMID: 
21817014. Pubmed Central PMCID: 3482340.

